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Bronchopulmonary dysplasia 
Neonatal respiratory distress syndrome (RDS; also called hyaline membrane disease) 
can develop within minutes after birth in prematurely born infants and is characterized by 
progressive pulmonary atelectasis and respiratory failure for which the infants are mechani-
cally ventilated (1-3). 
It is already known for a long time that the development ofRDS is associated with sur-
factant deficiency of the immature lung (4). Surfactant has important biophysical functions 
in lung biology. It reduces surface tension. thereby preventing the collapse of alveoli and 
lungs during expiration. it stabilizes and keeps the small airways open. and it prevents pul-
monary edema by balancing hydrostatic filtration forces (5). 
1n the 1960s. with the improvement of neonatal intensive care and the use of mechan-
ical ventilation, a steep increase in survival rate of infants with RDS was achieved. It was 
noted then! that some of the infants with more severe lung injury recovered spontaneously in 
the first week oflife while others did not and developed a chronic lung disease (6). 
Northway et al. described in 1967 a chronic lung disease that developed in prema-
turely born infants with RDS who where ventilated with warm. humidified 80 to 100% con-
centrations of oxygen. The disorder was named bronchopulmonary dysplasia (BPD). which 
was based on the observed progressive pathological changes in the immature lung that affect-
ed both the parenchyma and airways and interfered with normal lung development. It was 
speculated that RDS. ventilator-induced injury and supplemental oxygen (causing oxygen 
toxicity) were the most important factors contributing to BPD development (7). 
1n the decades following the initial description by Northway. the pathogenesis and eti-
ology of the disease were further examined, and improvements in treatment were established. 
Despite this progress, BPD is still a major clinical problem and its incidence seems to 
increase. This increase is due to the improved survival rates of extremely premature infants 
with a very low birth weight ( < 1000 gram). either with RDS or with initially minimal or no 
signs of RDS (8-15). The risk for BPD increases with decreasing gestational age and birth 
weight, and ranges from 50% in infants with birth weights of700-900 g to 5% in infants with 
birth weights of more than 1250 g (9). 
BPD is also called chronic lung disease of prematurity (CLD) and both terms are used 
interchangeably throughout the literature. BPD is a description of severe lung damage that is 
based on histological changes in the immature lungs of infants that died because of respira-
tory failure (7). BPD is clinically characterized by signs of respiratory distress, requirement 
for oxygen supplementation and chest x-ray abnormalities after 28 days of age in an infant 
who required mechanical ventilation in the first week of life for a minimum of three days 
(16). CLD can be regarded as the long-term clinical, less severe presentation of the disease 
and is defined as the requirement for oxygen supplementation at a postconceptional age of 36 
weeks (17). 1n CLD there is extensive variability in disease severity, ranging from mild to 
severe or fatal. The milder forms often occur in very low birth weight infants with mild or no 
initial RDS (13, 14). 1n these milder forms, a patent ductus arteriosus and nosocomial infec-
tions play an important role in the development of the disease (13). 
11 
Chapter 1 
1.1 Long term sequelae of BPD 
Respiratory morbidity is common in infants and young children who are born prema-
turely and developed BPD. Lower respiratory tract infections are a major complication in the 
first year of life in infants with BPD. Lung compliance has been shown to be decreased in 
infants with BPD. indicating decreased elastic properties of the lung, down to 80% of normal 
at an age of three years (18). Infants with BPD show increased airway resistance that may 
persist into young adulthood (18). Adolescents and young adults with former BPD may have 
respiratory problems such as wheezing and episodes of pneumonia (19). 
Radiographic abnormalities occur in up to 90% of adolescents and children with a his-
tory of BPD and correlate with pulmonary function abnormalities (19). Airway hyperrespon-
siveness has been reported to occur in long term BPD survivors. It is unclear, whether this 
increased responsiveness is due to a genetic predisposition. neonatal lung injury. or 
anatomically smaller airways (19). 
Barker et al. demonstrated that the prevalence of chronic obstructive pulmonary dis-
ease was associated both with a lower birth weight and respiratory illness during infancy (20). 
Therefore. it has been suggested that children with BPD are predisposed to chronic 
obstructive pulmonary disease later in life (18). 
Other complications such as growth retardation have also been shown to occur in 
infants with BPD. It has been suggested that this is related to factors such as birth weight and 
gestational age rather than to BPD (19). 
1.2. Risk factors for BPD 
BPD development depends on multiple risk factors. Respiratory failure. premature 
birth, lung immaturity with concomitant surfactant deficiency. oxygen supplementation. and 
ventilator-induced injury are generally considered as the major risk factors (21). BPD may 
also develop as a consequence of treatment of respiratory failure due to meconium aspiration, 
neonatal pneumonia, congestive heart failure and congenital diaphragmatic hernia (22-25). 
Even three cases of BPD have been described in adults following treatment with unusually 
high ventilatory pressures and high oxygen concentrations (26). More recently BPD has 
become a frequent sequel in very low birth weight infants with mild or no RDS at birth (13, 
14). 
Alveolar rnpture (interstitial emphysema. pneumothorax and pneumomediastinum). 
pulmonary edema, patent ductus arteriosus and pulmonary infection prolong the need for 
mechanical ventilation and supplemental oxygen. and increase the risk for BPD development 
(13, 27-29). However, none of these factors have been shown to be essential for BPD 
development. Recently, chorioamnionitis has been suggested to accelerate lung maturation 
but to predispose to BPD development as well (30) 
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Genetic factors may also predispose to RDS/BPD development. Several studies have 
reported an increased risk for BPD development in white preterm infants compared to black 
infants (9. 10. 12. 31). However, a study by Kraybill et al. did not confirm this (32). The 
prevalence of RDS is increased and the course is more severe in male than in female preterm 
infants (9, 10. 31. 32). resulting in a higher BPD incidence in male compared to female 
preterm infants (31. 32). Familial asthma has been reported to be associated with BPD 
development from RDS (33. 34). However, other studies did not confirm this finding (35. 36). 
Carriage of HLA-A3 and HLA-Bl4 were found to be associated with increased risk 
for RDS. This made the authors to suggest that RDS development probably depends on the 
presence of susceptibility gene(s) in linkage equilibrium with the HLA-A3 and HLA-Bl4 
genes (37). A polymorphism within the gene coding for surfactant protein-B. and certain sur-
factant protein-A variants and their corresponding haplotypes have been associated with RDS 
(38). 
1.3. Histopathological changes in the BPD lung 
The histopathology of BPD changed substantially since its recognition in 1967. 
Improvements in neonatal intensive care during the last decades may account largely for this 
change. BPD changed from a disease with marked airway abnormalities and alternating zones 
of severe fibrotic and emphysematous lesions to a disease with varying degrees of fibrosis 
and reduced numbers of alveoli. To illustrate this. the following part summarizes a number of 
relevant histopathological srudies that have been published during the last three decades. 
BPD was first described in premarurely born infants (mean gestational age (ga) 32 
weeks~ ranging from 23-39 weeks and mean birth weight (bw) 1893 grams; ranging from 
900-3204 grams) as a sequel from RDS and its treatment (7). The development of BPD was 
originally divided into four stages; Stage I (2-3 days after birth), Stage II (4-10 days after 
birth). Stage ill (10-20 days after birth) and Stage IV (beyond one month after birth) (7). 
Stage I reflected the histopathology of RDS. with the presence of hyaline membranes. atelec-
tasis. lymphatic dilatation. and patchy loss of epithelial cells with metaplasia and necrosis of 
the bronchial mucosa. Stage II showed necrosis and repair of alveolar epithelium, persisting 
hyaline membranes. and emphysematous coalescence of alveoli. Additionally, focal thicken-
ing of capillary basement membranes. increased patchy bronchiolar necrosis, and increased 
patchy squamous metaplasia were observed. During stage ill less hyaline membranes were 
present and there was widespread bronchial and bronchiolar mucosal metaplasia and hyper-
plasia. In addition, marked mucous secretion and alveolar coalescence forming groups of 
emphysematous alveoli surrounded by atelectatic alveoli were observed. Furthermore. focal 
thickening of the basement membrane and fine strands of interseptal collagen were present. 
Stage IV revealed hypertrophy of peribronchiolar smooth muscle cells and alternating 
emphysematous and atelectatic lesions. Additionally. thickened basement membranes that 
separated the capillaries from the alveolar septa. and fibrosis in the alveolar septal walls was 
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observed. Furthermore. early vascular lesions of the pulmonary hypertensive type were 
present (7). 
In 1975. Rosan proposed another classification, also with four phases. based on char-
acteristic histopathological features and the number of days after birth at which these features 
were observed (39). The first phase (acute phase; 2-4 days after birth) was. at the alveolar 
level. mainly characterized by hyaline membranes and epithelial necrosis. At the level of the 
airways, patchy bronchiolar necrosis. mucosal secretion and hyaline membranes were 
observed. The second phase (regenerative phase; 4-8 days after birth) was marked by fore-
going injury plus attempts to cellular repair. as reflected by the presence of focal regenerat-
ing alveolar epithelium. In addition. moderate numbers of intra-alveolar macrophages were 
present. The airways were characterized by peribronchiolar edema and mucosal abnormali-
ties. The third phase (transitional phase; 8-16 days after birth) was described as the transition 
towards chronic lung disease. At the alveolar level, fewer hyaline membranes, continuing 
necrosis. numerous intra-alveolar macrophages and interalveolar fibroplasia were observed. 
The airways were characterized by necrotizing bronchiolitis. patchy metaplasia, increased 
numbers of smooth muscle cells. mucosal abnormalities. and peribronchial edema. The fourth 
phase (chronic phase; > 16 days after birth) describes rare or absent hyaline membranes at the 
alveolar level, separation of epithelial and endothelial basal laminae, the presence of numer-
ous intra-alveolar macrophages and intersaccular and intrasaccular fibrosis. At the airway 
level. metaplastic and hyperplastic collagenizing bronchiolitis and focal mucosal hyperplasia 
and necrosis were observed (39). 
Bonikos et al. described a light and electron microscopical stndy that was carried out 
in 21 infants (ga = 33 weeks (range: 28-40 weeks); bw = 1638 gram (range: !l00-3487 gram) 
in whom the pathological diagnosis of BPD had been made after treatment with high oxygen 
concentrations and positive-pressure ventilation with positive end-expiratory pressure ( 40). 
In this stndy, all the examined infants survived at least one week. The histopathological 
changes were graded as mild. moderate, severe and very severe. The primary alterations 
observed in all infants were damage of the bronchial and bronchiolar ciliary system and 
mucosal membranes, severe necrotizing bronchiolitis, and marked bronchiolar and alveolar 
fibrosis. Additionally, alternating areas of alveolar fibrosis, atelectasis and emphysema were 
observed. The abnormalities were most pronounced in infants who survived the longest 
period of time and who had the longest exposure to supplemental oxygen (40). 
In a histopathological study by Taghizadeh and Reynolds, high peak airway pressure 
during ventilation was concluded to be the major risk for BPD development from RDS. 
Although they identified another factor as the main risk for BPD, the pathological changes 
they described in infants (median ga of 30 weeks (range, 26-39 weeks); bw of 1310 gram 
(range, 730-2910 gram); death at a median age of 41 hours (range, I 1/2 hour-13 months)) 
were in concordance with the earlier discussed stndies (41). 
Interstitial fibrosis and emphysema were reported to be the most pronounced compli-
cations in the longest survivors with BPD in a group of 73 infants (bw ranging from 500-7080 
gram) that lived for at least two days. These complications were associated with the progres-
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sion of an early reparative stage via a subacute fibroproliferative stage into a chronic fibro-
proliferative response (42). It was demonstrated that regenerating type-IT pneumocytes con-
tributed to the reparative and proliferative reactions by reepithelialization of damaged septal 
walls. Hereby, type-IT pneumocytes incorporated hyaline membranes into septal walls, which 
seemed to stimulate interstitial fibroblast proliferation with resultant interstitial fibrosis ( 42). 
In some of the above discussed histopathological studies also long term survivors were 
included (7, 40. 42). Stocker described the pathological features of long-standing "healed" 
BPD in infants (mean bw = 1249 gram (range. 740-1850 gram; age of death between 3 and 
40 months) (43). Alveolar septal fibrosis was found to be the main residual feature in the 
"healed" stage of BPD in infants who had moderate to severe BPD in the neonatal period 
(43). Furthermore, long-standing "healed" BPD was reported to be associated with mast cell 
hyperplasia, particularly around small airways and in more distal alveolar regions, especial-
ly those exhibiting prominent fibrosis (44). 
Erickson et al. reported the existence of three different histopathological patterns of 
BPD that occurred with increasing age and independent of birth weight in a total of 46 
patients (bw ranging from 460-3000 gram) (45). Group I was characterized by interstitial 
fibrosis, group 3 by enlargement of the distal airways and little or no interstitial fibrosis. and 
in group 2 both lesions coexisted. They suggested that early BPD is characterized by inter-
stitial fibrosis (group 1). With increased survival and continuing growth, the interstitial fibro-
sis disappeared, changing the histopathological pattern to one with enormously enlarged dis-
tal airways and reduced numbers of alveoli. Such a change in histopathological pattern sug-
gests that normal alveolar proliferation is impaired as a consequence of the original injury and 
its repair (45). 
Three different histopathological types of BPD were also recognized by van Lierde et 
al. in a group of infants with an interquartile range for gestational age between 25.5 and 29 
weeks and for birth weight between 820 and 1165 gram (46). One histopathological type was 
labelled "interstitial-type" and was characterized by moderate to severe interstitial fibrosis 
and little or no airway abnormalities. The other type, labelled "bronchiolar-type", was char-
acterized by marked airway lesions and alveolar emphysema and mild to moderate intersti-
tial fibrosis. A third group of patients revealed pathological characteristics of both types of 
histology (46). The existence of this "mixed histology group" made the authors to speculate 
that the "interstitial" and "bronchiolar" types are two extreme ends of the spectrum of a 
single disease and that a switch from one type to the other can occur ( 46). The authors noted 
that the patients with "interstitial-type" histology suffered less barotrauma and oxygen toxi-
city as their bronchiolar counterparts. Therefore, they speculated that "mild pulmonary 
aggression·• resulted in a different repair response characterized by interstitial fibrosis with-
out significant airway abnormalities (46). 
A morphometric study in infants with gestational ages between 24-30 weeks, that died 
between 2-28 months with BPD, revealed decreased total numbers of alveoli that had an 
increased diameter. In addition, mild to severe alveolar septal fibrosis was present. 
Furthermore, bronchial and bronchiolar smooth muscle hypertrophy and bronchial gland 
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hyperplasia were observed (47). Reduced alveolar development has been demonstrated to 
result from mechanical ventilation of the premature lung, especially when associated with 
RDS (48). 
Surfactant deficiency of the premature lung is regarded as the primary underlying 
cause of RDS (4, 49. 50). Surfactant replacement therapy was generally introduced in 1989 
and coincided with a decline in mortality. This decline was attributed primarily to fewer 
deaths from respiratory causes among preterm infants. However. the effect of surfactant treat-
ment on BPD incidence is unclear (51). Histopathologically it has been shown that surfac-
tant-treated RDS patients that fail to respond to therapy have continuing alveolar injury (52). 
Husain et al. assessed the effects of surfactant therapy in a group of BPD patients (mean ga 
of 27 weeks (range. 24-30 weeks)) on pulmonary histopathological changes (53). In the sur-
factant treated group. 5 out of 14 patients had mild to severe alveolar septal fibrosis, while in 
the non-surfactant treated group moderate to severe alveolar septal fibrosis occurred in 7 of 
the 8 patients. Surfactant treatment did not influence the disturbed alveolar development as 
observed in BPD (53). 
From these studies it is evident that. due to an increased survival of less mature 
infants, BPD nowadays develops mostly in infants with lower gestational ages and birth 
weights than in the 1960s-1970s. while the infants with gestational ages and birth weights 
comparable to the groups described in the 1960s-1970s nowadays are less prone to develop 
BPD. BPD can be considered as a repair stage of RDS, with ongoing lung damage due to 
mechanical ventilation and oxygen toxicity during ihe repair attempts of the initial injury. The 
histopathological appearance of BPD has changed over time from a disease with alternating 
zones of severe fibrosis and emphysematous lesions, and marked airway abnormalities to a 
disease with varying degrees of fibrosis, and reduced numbers of simplified alveoli. 
Recently the terms "old" BPD and "new" BPD have been introduced to distinguish the 
classical Northway BPD and the current milder form of the disease. The "new'' BPD is com-
mon in very low birth weight infants (VLBW; birth weight of less than 1 kg). Lung patholo-
gy of the "new" BPD is characterized by mild airway injury, dilated gas exchange structures, 
decreased alveolization and less prominent inflammation and fibrosis than seen in the "old'' 
BPD (54, 55). 
1.4. Inflammation in the pathogenesis of bronchopulmonary dysplasia 
The mechanism causing BPD is not fully understood. Numerous factors have been 
implicated. Studies have demonstrated that early and prolonged postnatal pulmonary inflam-
mation occurs during BPD development. Pulmonary fibrosis results as a consequence of 
many types of severe lung injury and usually follows an alveolar inflammatory reaction (56). 
It is assumed that inflammation. as the result of lung injury due to mechanical ventilation and 
supplemental oxygen (i.e. oxygen toxicity), plays a critical role in tissue injury, tissue remod-
elling and fibrosis when BPD develops (55. 57). 
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1.4.1. 1nflammaiory cells in the pathogenesis of BPD 
A variety of inflammatory cells are implicated in the pathogenesis of BPD. Hereafter 
the most prominent ones will be discussed in relation to this pathogenesis. 
Neutrophils 
Histopathologically it has been shown that infants with developing BPD have an 
evolving pattern of pulmonary inflammation that consists initially mainly of neutrophils (58). 
In the same study. neutrophils and macrophages were shown to be present in tracheo-
bronchial washings (58). This observation was confirmed by a number of other studies. 
showing an early predominance of neutrophils (from a postnatal age of 4 days) in tracheal 
aspirates. followed by the appearance of alveolar macrophages (from a postnatal age of 8 
days) later in the course of BPD development (59-61). 
In 1983. Merritt et al. demonstrated that preterm infants with RDS had increased num-
bers of inflammatory cells in their airways compared to control infants who were ventilated 
for non-pulmonary problems. From postnatal day three. infants with subsequent BPD had 
increased numbers of inflammatory cells in their airways compared to infants with resolving 
RDS (62). These investigators showed the neutrophil to be the predominant inflammatory 
cell type at the early stage of inflammation (62). These findings. and observations by others. 
have lead to the suggestion that persistent presence of neutrophils in the lungs is associated 
with BPD development (63-66). 
Neutrophils present in the lungs after injury originate from the peripheral blood. Adult 
respiratory distress syndrome (ARDS) shares many pathological features with neonatal RDS. 
Neutrophils are also abundant in the lungs from ARDS patients. and it has been shown that 
leukopenia frequently precedes the onset of ARDS (67. 68). Studies in preterm lambs with 
RDS demonstrated reduced numbers of circulating neutrophils within the first two hours after 
birth reaching normal values again within 6-8 hours. The decrease in circulating neutrophils 
related to the accumulation of neutrophils in the airspaces (69). Recently. a decrease in the 
number of circulating neutrophils within two hours after birth was found to be associated with 
BPD development in premature infants (70). 
In the pathogenesis of BPD the neutrophil may play an important role in causing 
injury to the pulmonary parenchyma. Activated neutrophils release reactive oxygen radicals 
that cause epithelial and endothelial cell death (71, 72). In addition, neutrophil elastase is the 
main proteolytic enzyme for pulmonary tissue elastin and has tissue destructive properties 
(73). The activity of neutrophil elastase is normally controlled by naturally occurring 
inhibitors such as a 1-proteinase inhibitor (a1-Pl) and secretory leukocyte protease inhibitor 
(SLPI). An imbalance between elastase and its main inhibitor a 1-PI within the lung. as result 
of either an increase in elastase or a decrease in a 1-PI, has been postulated to play an impor-
tant role in adult lung injury (74). 
Inactivation of a 1-PI occurs by oxidation, which renders it susceptible to proteolytic 
digestion. Inactivated oxidized cx1-PI and a proteolytic digestion product have been found in 
tracheal aspirates during the early stage ofBPD (62). In infants with RDS. the elastase/a1-PI 
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ratio in bronchoalveolar lavage (BAL) fluid was demonstrated to be comparable to control 
infants. In infants that subsequently developed BPD. this ratio was elevated from one through 
four weeks of life. suggesting that increased elastolytic damage may occur in the pathogene-
sis of BPD (63). A number of studies have detected free elastase in most or all of the lung 
fluid samples examined (62, 63. 75-77), while other studies detected free elastase in only a 
few of the examined infants (78. 79). In cases that free elastase activity was detected in a 
sample. it was due to unavailability of a 1 -PI (78. 79). In addition to a 1 -PI, BPD development 
has shown to be associated with relatively low levels of SLPI (79, 80). 
Increased urinary levels of desmosine (a elastine degradation product) were observed 
at the end of the first week of life in infants who subsequently developed BPD, compared to 
control infants. suggesting increased pulmonary elastin degradation (81). In addition, desmo-
sine has been shown to be present in tracheal aspirate fluid (76). 
Histopathological examination revealed pulmonary elastic fiber degradation in early 
BPD (76). Alveolar secondary septa formation is thought to be dependent on a framework of 
elastin fibers. around which the septa will develop (82). Increased elastolytic activity during 
BPD development could contribute to damaging of the elastin framework, resulting in 
impaired/dintinished alveolization. Indeed decreased numbers of alveoli have been observed 
in the BPD lung (47). Therefore, the control of pulmonary elastase activity may be a poten-
tial therapeutic target for preventing BPD development. However. treatment with a 1 -PI did 
not significantly reduce the risk of BPD development (83). 
It has been shown that neutrophil culture supernatants exhibit extracellular matrix 
(ECM) degradative activity (84). Neutrophil collagenase (matrix metalloproteinase 
(MMP)-8) and gelatinase may play a role in this ECM degradation process. BAL flnid from 
infants who subsequently develop BPD was demonstrated to contain increased MMP-8 
levels compared to infants with resolving RDS (85). 
Neutrophil elastase may play an important role in the pathogenesis of pulmonary 
fibrosis as well. Recent evidence indicates that neutrophil elastase-deficient ntice are resist-
ant to bleomycin-induced pulmonary fibrosis (86). In addition. MMP-9 (gelatinase-B) and 
MMP-8 expression by neutrophils has been suggested to play a role in lung damage and 
fibrosis in adults (87). Furthermore. via the production and release of cytokines such as tumor 
necrosis factor (TNF)-a. interleukin (IL)· I~. IL-8, macrophage inflanunatory protein (MIP)-
la. and transfornting growth factor (TGF)-~. neutrophils may influence the inflammatory 
process and the development of fibrosis (88). 
Macrophages 
Histopathological studies revealed increased numbers of alveolar macrophages during 
BPD development (7. 39-41). Murch et al. demonstrated a marked and rapid increase of inter-
stitial CD68+ macrophages which was already maximal by 72 hours after birth (89). 
Contradictory results on alveolar macrophages have been observed in lung effluent 
flnids. During BPD development, decreased numbers of alveolar macrophages have been 
found compared with self-resolving RDS (63, 64). However. another study demonstrated that 
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macrophages were already increased from birth onwards in patients that subsequently devel-
op BPD compared to those who recover from RDS (90). Others described increased numbers 
of alveolar macrophages from 3-5 days after birth when BPD developed (66. 91). 
Furthermore, it was shown that surfactant treaunent may increase the number of alveolar 
macrophages obtained by BAL during BPD development (64). 
Increased total cell numbers were found to be present in BAL fluid from BPD patients 
at 4 months of age compared to control infants. The cell population consisted for 93% of 
alveolar macrophages that produced increased amounts of hydrogen peroxide compared to 
controls. indicating an activated status of these cells (92). Increased numbers of HLA-DR 
positive macrophages, observed within pulmonary tissue from infants who died with BPD, 
also indicate the activated state of pulmonary macrophages in BPD (93). 
Activated macrophages release a variety of products that may cause tissue injury. par-
ticipate in the inflammatory process and play an important role in tissue remodelling after 
injury. They release oxygen radicals which may have deleterious effects on the alveolar 
epithelium and endothelium (72). In addition. via the release of proteolytic enzymes. alveo-
lar macrophages are able to degrade ECM components (72). Production and secretion of pro-
teolytic enzymes. such as MMP-2 and MMP-9, by alveolar macrophages is associated with 
hyperoxia induced lung injury with subsequent pulmonary fibrosis (94). Alveolar 
macrophages may also secrete chemoattractants for other inflammatory cells such as 
neutrophils (95). 
Alveolar macrophages produce a variety of growth factors for epithelial cells. 
endothelial cells and fibroblasts, which are important in the repair process of injured lungs 
(96). Severity of epithelial damage. ongoing injury. and delay in epithelial repair may lead to 
an overstimulation of the normal repair response. An overstimulation of the repair response 
with exaggerated production and secretion of growth factors/cytokines such as TGF-~. 
platelet-derived growth factor (PDGF). insulin like growth factor-! (IGF-1). TNF-a. and 
IL-l by alveolar macrophages results in excessive fibroblast proliferation and ECM deposi-
tion (56. 97). 
Eosinophils 
There is only scarce evidence for the participation of eosinophils and eosinophil 
derived products in pulmonary inflammation and lung injury in BPD. Peripheral eosinophil 
cell counts are increased in the first month of life when BPD develops compared to control 
infants who do not develop BPD (98). Increased eosinophilic cationic protein (ECP) concen-
trations have been found in tracheal aspirates within the first month of life when BPD devel-
oped (98. 99). 
The release of ECP by activated eosinophils can directly cause injury by altering func-
tion and integrity of resident lung cells (100). In addition. eosinophils produce reactive oxy-
gen radicals, lipid mediators such as leukotriene C4 (LTC4) and platelet-activating factor 
(PAF) as well as cytokines and growth factors such as TNF-a, MIP-la, TGF-~ and PDGF 
that may contribute to tissue injury. inflammation and the development of fibrosis (100-103). 
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However, convincing infiltration of the lungs from BPD patients by eosinophils has not been 
shown. 
Lymphocytes 
The role of lymphocytes in the pathogenesis of BPD is also uncertain. One study 
describes the presence of soluble IL-2 receptor (s!L-2R; signifying T-cell activation) in plas-
ma and tracheal aspirates from infants with or at risk for BPD and infants with resolving RDS 
(104). Infants with or at risk for BPD were found to have higher s!L-2R levels in plasma than 
infants with RDS and age matched controls. However, no differences were observed in tra-
cheal aspirate levels, and no information about the cell population in tracheal aspirates or 
lung tissue was given in this study (104). 
IL-2 mRNA (a cytokine produced by activated T-helper cells) was undetectable in 
BAL cells from infants with RDS or BPD, indicating the absence of activated T-helper cells 
(105, 106). Furthermore, the lack of BAL cells immunoreactive for the T-lymphocyte 
markers CD3, CD4, and CDS supports the absence ofT-lymphocytes (106). 
L4.2. Chemotactic factors in the pathogenesis of BPD 
Tracheal aspirate fluid from infants with RDS was shown to be chemotactic for neu-
trophils. This chemotactic activity was increased from a postnatal age of five days in infants 
who subsequently developed BPD compared to those who did not (65). Increased levels of 
the neutrophil chemoattractants complement component C5-derived anaphylotoxin (C5a) and 
leukotriene-B4 (LTB4) were present in tracheal aspirates obtained in the first week of life in 
infants who later acquired BPD (65). Furthermore, the neutrophil chemoattractants LTB4, 
5-hydroxyeicosatetraenoic acid (5-HETE) and PAF were present in BAL fluid from BPD 
patients at postnatal ages over 30 days (I 07). Additionally. PAF levels in tracheal aspirates 
from 3 to 5 days after birth correlated with BPD severity (108). 
IL-8 is considered to be the major neutrophil chemotactic factor in the lung, and 
increased levels have been shown to persist for a prolonged period of time in lung effluents 
from infants who develop BPD (65, 109-115). In addition, increased pulmonary IL-8 levels 
have been shown to precede neutrophil influx and to correlate with the number of neutrophils 
and the myeloperoxidase activity (a marker for neutrophil activation) (Ill, 112, 115). 
Jones et al. demonstrated the presence of IL-8 protein in BAL fluid in early RDS, and 
furthermore demonstrated that the lavage cells (neutrophils and macrophages) probably add 
to IL-8 production as IL-8 mRNA could be detected in these cells (105). 
lmmunohistocheruically it was demonstrated that lung autopsy specimens from infants with 
early RDS expressed IL-8 in neutrophils and bronchial epithelial cells. In addition, if there 
was evidence of sepsis, IL-8 was also expressed by alveolar epithelial cells. endothelial cells, 
fibroblasts and smooth muscle cells of vessels as well as chondrocytes (116). The above indi-
cates that both inflanunatory cells and resident lung cells presumably contribute to IL-8 pro-
duction during RDS and subsequent BPD development. 
Growth-related protein-a (GRO-a) is another chemotactic factor for neutrophils and 
20 
Bronchopulmonary dysplasia 
has been shown to be present in BAL fluid obtained in the first week of life during BPD 
development (117). 
MIP-1 o:. RANTES (a factor called: regulated upon activation. normal T cell expressed 
and secreted). and monocyte chemoattractant protein (MCP)-1 are chemotactic factors for 
monocytes and macrophages (ll8). Increased levels of MIP-lo:. RANTES. and MCP-1 in 
BAL fluid and tracheal aspirates are associated with BPD development (90. 119). In addition. 
MIP-1 o; correlated with the later development of pulmonary fibrosis in premature infants 
ventilated due to RDS (90). 
Granulocyte colony-stimulating factor (G-CSF) and granulocyte macrophage colony-
stimulating factor (GM-CSF). are of potential importance in the recruitment and function of 
granulocytes and macrophages in the lung. These factors have recently been described to 
increase in BAL fluid during BPD development (120). Furthermore. the levels of G-CSF and 
GM-CSF correlated with the number of neutrophils and alveolar macrophages in BAL fluid 
(120). This may be related to the observation that G-CSF and GM-CSF delay apoptosis of 
these cells (121, 122). A summary of chemoattractants implicated in the pathogenesis of 
RDS/BPD is given in table I. 
Table 1. Chemoattractants implicated in the patho~enesis of RDS and BPD 
chemoattractants for neutrophils references 
LTB4 65. 107 
5-HETE 107 
PAF 107. 108 
C5a 65 
IL-8 65. 105. 110-113. 115. 119 
GRO-a 117 
G(M)-CSF 120 
chemoattractants for monocytes/macrophages references 
90 
RANTES 90 
MCP-1 117. 119 
G(M)-CSF 120 
1.4.3. Adhesion molecules in the pathogenesis of BPD 
Adhesion of neutrophils to endothelial cells is a critical event for migration from the 
vasculature into the lung parenchyma. Adhesion molecules. both on neutrophils and endothe-
21 
Chapter 1 
lial cells. play an important role in this process. Neutrophils express cell surface molecules 
such as ~,-integrins (lymphocyte function-associated antigen (LFA)-1. macrophage (Mac)-!) 
and L-selectin (123). LFA-1 binds intercellular adhesion molecule (!CAM)-! and ICAM-2 on 
endothelial cells. whereas Mac-! binds to !CAM-I (123). In addition. endothelial cells 
express E-selectin and P-selectin which are adhesion molecules for neutrophils (123). 
IL-8 and PAF upregulate the expression of LFA-1 and Mac-! on neutrophils. increas-
ing the adhesiveness of these cells (123). Neutrophil migration through the endothelial barri-
er results in shedding of adhesion molecules from both neutrophils and endothelial cells. 
resulting in soluble forms of these molecules. 
Increased levels of soluble ICAM-1 have been described in BAL fluid and tracheal 
aspirates from infants with BPD when compared to controls (112, 124). Furthermore. 
increased levels of soluble !CAM-I and soluble E-selectin in plasma and serum have been 
found to be associated with BPD (111. 125). However. other studies did not report differences 
in soluble !CAM-I concentrations in serum from infants that did and did not develop BPD as 
a consequence of RDS (124). 
1.4.4. Cytokines in the pathogenesis of BPD 
Besides IL-8. other proinflammatory cytokines such as IL-l. IL-6 and TNF-a seem to 
be important mediators in the inflammatory process associated with the development ofBPD. 
The association of these cytokines with the pathogenesis of BPD is described below. 
Interleukin- I 
Different isoforms of IL-l exist and are known to be associated with inflammatory 
diseases (126). Two members of the IL-l gene family. namely IL-l~ and IL-l receptor 
antagonist (!L-IRa). have been associated with BPD development (90. 91). 
IL-l~ increases in lung effluent fluids when BPD develops and is increased compared 
to infants with resolving RDS (90. 91. 114. 127). !L-IRa is known to block most IL-1~­
induced inflammatory actions and may limit the inflammatory response to IL-l (128. 129). 
Rindfleish et al. demonstrated that the BAL fluid IL-l~ concentration and IL-l activ-
ity increased during the first week of life when BPD developed. However. !L-IRa remained 
relatively unchanged during the first month of life (91). Therefore. a relative imbalance 
between IL-l~ and !L-IRa may contribute to prolonged inflammation in BPD (91). 
Kotecha et al. showed increased IL-l~ levels in BAL fluid from BPD patients com-
pared to patients with resolving RDS (127). Furthermore. BAL cells obtained from both RDS 
and BPD infants expressed similar amounts of IL-l~ mRNA. Immunocytochemistry revealed 
that IL-l~ protein was predominantly expressed by alveolar macrophages. although IL-l~ 
immunoreactivity was also observed in epithelial cells and neutrophils (127). This suggests 
that a variety of resident lung cells. which are not sampled by BAL. also synthesize and 
secrete IL-l~ during BPD development. 
IL-l~ is a known inducer of IL-8 synthesis and secretion by resident lung cells such 
as alveolar macrophages. endothelial cells. epithelial cells and fibroblasts (109. 123, 130. 
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131 ). IL-8 expression has been shown in both resident lung cells and inflammatory cells from 
RDS and BPD patients (116. 127). It is therefore likely that IL-l~ plays a role in the induc-
tion of IL-8 expression in the lung during the development of BPD. Indeed. it has been 
demonstrated that inflammatory cells in the lungs from preterm infants with RDS produce 
and secrete IL-8 and that IL-l~ contributes to this IL-8 production (106). IL-8 expression by 
inflammatory cells and resident lung cells may be important in the pathogenesis of BPD. as 
the synthesis of IL-8 by such cells may perpetuate the recruitment of neutrophils into the site 
of inflammation (109). 
IL-l~ also induces expression of cytokines such as IL-6. TNF-a and MIP-la and 
upregulates the expression of adhesion molecules such as !CAM-I (126). 
Altogether these data indicate that IL-l~ may play a role in the recruitment of inflam-
matory cells and the maintenance of the inflammatory process in the pathogenesis of BPD. 
Tumor necrosis factor 
TNF-a levels were found to be increased in BAL fluids and tracheal aspirates obtained 
on postnatal day 3 when BPD developed compared to resolving RDS and remained increased 
until postnatal day 40 (114. 132). Another study demonstrated that in BAL fluid of infants 
who later acquired BPD. TNF-a activity was not increased compared to relevant control 
infants on the first postnatal days. but subsequently increased reaching peak activity on post-
natal day 14 (133). This was accompanied by a significant increase ofTNF-a concentrations 
on postnatal days 14 and 28 (133). 
Immunohistochentically, Murch et al. have demonstrated the presence of TNF-a 
immunoreactive cells whose number was maximal in infants dying after 72 hours (89). 
TNF-a immunoreactivity was not confined to cells and could be detected through the whole 
interstitium (89). Increased numbers of TNF-<X immunoreactive BAL cells were reported 
from birth to a postnatal age of 22 days when BPD developed. These TNF-a immunoreac-
tive BAL cells in BPD were accompanied by increased concentrations of TNF-a compared 
to self-resolving RDS (90). 
TNF-<X exerts sintilar actions as IL-l~. such as induction of IL-8 expression (109). 
Therefore. TNF-a. sintilar to IL-l~. may play an important role in the induction of IL-8 
expression during BPD development. Indeed, it has been demonstrated that TNF-a con-
tributes to IL-8 production by lung inflammatory cells from infants with RDS (106). 
Interleukin 6 
IL-6 has a wide range of proinflammatory activities including the stimulation of acute 
phase proteins and the activation of B-and T-lymphocytes (57. 134). Bagchi et al. demon-
strated that there were no differences in IL-6 protein concentration in BAL fluid between 
BPD. RDS and controls on the first day of life (133). However. increased IL-6 activity did 
occur on the first day of life in BPD compared to RDS and controls (133). It was suggested 
that the IL-6 activity in the lungs of infants with resolving RDS and control infants is inacti-
vated or iultibited. but that such regulatory activity may be deficient in infants who develop 
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BPD (133). IL-6 activity remained elevated in BAL fluid from BPD infants in the first two 
weeks of life. and declined to low levels by 4 weeks (133). The Jack of concordance between 
IL-6 protein concentration and functional activity of IL-6 in this study stresses the importance 
of measuring cytokine activity in biological fluids. 
Another study demonstrated a gradual increase of IL-6 protein concentration in BAL 
fluid when BPD developed. In this study the IL-6 concentration peaked at ten days after birth 
and was significantly increased compared to RDS and control infants and declined thereafter 
(127). In addition. the alveolar macrophage was identified as the major source of IL-6. It was 
suggested that increased IL-6 levels in BPD derived from airway luminal and alveolar cells 
that can be recovered by BAL (127). 
In tracheal aspirates. increased IL-6 concentrations were observed at two and five days 
after birth in BPD compared to RDS. Furthermore. IL-6 remained detectable for at least two 
weeks after birth in BPD samples (114. 115). 
Although IL-6 is often regarded as a proinflammatory cytokine. it also exerts anti-
inflammatory activities. IL-6 inhibits the production of the proinflammatory cytokines IL-l 
and TNF with minimal effects on the synthesis of anti-inflammatory cytokines such as IL-10. 
Additionally. IL-6 induces the synthesis of glucocorticoids and promotes the synthesis of 
IL-lRa and soluble TNF receptor p55 (135). 
Interleukin I 0 
IL-10 is an anti-inflammatory cytokine that inhibits the production of cytokines such 
as TNF-a. IL-Ia. IL-l~. IL-6 and IL-8 by macrophages and monocytes (136. 137). IL-10 
rnRNA was found to be absent in BAL cells from preterm infants at risk of BPD in contrast 
to term ventilated infants with acute respiratory failure (105). Additionally. IL-10 was unde-
tectable in BAL fluid from infants with and at risk of BPD (105. 138). 
It has been suggested that the different maturational stage between preterm and term 
infants accounts for the inability of the preterm infants to express IL-10. Furthermore. it was 
speculated that the absence of IL-10 in preterm infants with RDS may account for the 
inability to downregulate inflammation and predispose to BPD development (105). 
Kwong eta!. demonstrated that IL-10 inhibited IL-l~ and IL-8 expression by lung 
inflammatory cells from preterm infants with RDS. They suggested recombinant IL-l 0 as a 
potential anti-inflammatory treatment for RDS (138). A recent study described the presence 
of IL-l 0 in BAL fluid from ventilated preterm infants without a clear association with BPD 
development (139). 
The different time-points at which certain cytokines were found to be elevated in the 
studies discussed above may be due to different sample techniques used. different popula-
tions of patients examined and differences in neonatal intensive care between the different 
centers. Despite these differences it is clear that an early and prolonged inflammatory 
response occurs in the pathogenesis of BPD. A summary of the cytokines likely to be 
involved in the pathogenesis of BPD is given in table 2. 
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Table 2. Cytokines in lung effiuent fluid likely involved in the pathogenesis of BPD 
cytokine 
IL-l~ 
!L-IRa 
JL.6 
TNF-a 
IL-10 
+increased 
-decreased 
= no difference 
level during BPD development 
compared to RDS or control infants 
+ 
+ 
+ 
-I= 
references 
90. 91. 114. 127 
91 
114. 115. 127. 133 
90, 114, 132, 133 
105. 138. 139 
Cytokine mRNA expression by lung inflammatory cells in the pathogenesis of BPD 
In the pathogenesis of RDS and BPD the inflammatory cells in the lungs are regarded 
as major sources of the inflammatory cytokines in lung effluent fluids. Besides immunocyto-
chemical analyses of lung inflammatory cells. also rnRNA analyses (reverse transcriptase 
polymerase chain reaction; RT-PCR) identified these cells as an important source of inflam-
matory cytokines. Several studies detected rnRNA for IL-l a. IL-l~. TNF-a. IL-6 and IL-8 
in BAL cells (105. 106, 127, 140). IL-2 rnRNA was undetectable. indicating the absence of 
T-lymphocytes (105). 
Cytokine rnRNA expression profiles of cells from tracheal aspirates and BAL from the 
same patient have been examined and found to be different (140). This may be due to differ-
ences in the composition of the cell population in tracheal aspirate and in BAL (140). This 
indicates that care has to be taken when comparing data on cell differentials and cytokine 
expression profiles between tracheal aspirates and BAL. 
A summary of cytokines likely to contribute to the pathogenesis of BPD and presum-
ably produced by lung inflammatory cells is given in table 3. 
IL-l and TNF-a are able to induce acute lung injury and subsequent fibrosis in animal models 
As stated before, the pathogenesis of BPD is characterized by initial acute lung injury 
that is followed by a repair process with subsequent fibrosis development. IL-l and TNF-a 
contribute to, or even cause, features of acute lung injury such as neutrophil accumulation, 
increased pulmonary vascular permeability. edema and fibrosis. The next part describes data 
obtained from animal models that support a possible central role for IL-l and TNF-a in the 
pathogenesis of BPD. A detailed introduction on the concept of pulmonary fibrosis and fibre-
genic mediators will be given in chapter 2 of this thesis. 
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Table 3. Cytokines likely produced by (inflammatory) BAL cells in the pathogenesis of BPD 
cytokine 
ILM1cx 
IL-l~ 
IL-6 
IL-8 
TNFMcx 
IL-10 
+present 
-absent 
n.d. not determined 
immunocytochemistry 
n.d. 
+ 
+ 
+ 
+ 
n.d. 
mRNA references 
+ 140 
+ 106. 127. !38. 140 
+ 127, 140 
+ 106. 127. 138. 140 
+ 90. 106. 138. 140 
105. 138 
Intratracheal instillation of IL-l (IL-l a and IL-l~) in rodents induces acute lung 
injury characterized by neutrophil influx, generation of oxygen metabolites. increased lung 
lavage protein and hemoglobin concentrations, and increased lung-wet-weight to body-
weight ratios (141. 142). Recent evidence suggests that PAF contributes to the lung neu-
trophil recruitment and lung leakage that occurs when IL-l is administered intratracheally 
into rats (143). 
In a rabbit model of acute ventilator-induced lung injury. administration of !L-IRa 
resulted in a significant reduction of pulmonary vascular leakage as well as reduction of elas-
tase and neutrophil numbers in lavage fluid (144). Other studies confirm that administration 
of IL-lRa or transgenic expression of IL-lRa in rat or mouse lungs inhibits the acute lung 
injury and neutrophil influx induced by intratracheal administration of!L-1 (141. 145. 146). 
Transgenic expression of human IL-lRa in mice resulted in decreased mRNA induc-
tion of the chemokines MIP-la and MIP-2 after intratracheal administration of IL-Ia. This 
suggests that the inflammatory response to intratracheal IL-l is partly mediated by the 
expression of chemokines (146). 
Pulmonary fibrosis can occur as the consequence of many types of severe lung injury 
and usually follows an alveolar inflammatory reaction (56). Pigue! et al. demonstrated that 
administration of !L-IRa via continuous abdominal perfusion was able to prevent silica or 
bleomycin-induced pulmonary fibrosis in mice (147). In addition, !L-IRa was able to reverse 
established pulmonary fibrosis induced by either silica or bleomycin (147). 
Recently. it was shown that transient overexpression of IL-l~ in the epithelial cells of 
rat lungs, using adenovirus mediated gene transfer. induced acute inflammation (148). This 
inflammation was characterized by infiltration of neutrophils and macrophages, increased 
levels of IL-6 and TNF-a, and alveolar tissue destruction (148). The initial inflammatory 
response was followed by progressive interstitial fibrosis which occurred coincident with 
sustained induction of the profibrotic mediator TGF-~ 1 (148). 
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Together these data demonstrate that IL-l is able to induce acute lung injury and sub-
sequent pulmonary fibrosis. Recently. however, also a role for IL-l~ was suggested in 
alveolar epithelial repair (149). 
Intravenous injection of TNF-a in guinea pigs caused lung inflammation and 
increased pulmonary vascular permeability with resultant edema (150). This could be pre-
vented by granulocyte depletion (151). Intratracheal injection of TNF-a has been shown to 
increase pulmonary vascular permeability and neutrophil accumulation in the alveolar septa 
and to cause an acute intra-alveolar neutrophil exudate (152). Other studies in rats, however, 
did not show such effects of TNF-a (153). Furthermore. intratracheal instillation of TNF-a. 
comparable to IL-l, has been shown to induce the expression of cytokine-induced neutrophil 
chemoattractant (CINC), which is often considered to be the rat equivalent of human IL-8 
(154). 
A central role for TNF-a in the development of pulmonary fibrosis was suggested by 
the experiments from Pigue! et al. They demonstrated that anti-TNF-antibodies or recombi-
nant soluble TNF-receptor inhibited the development of bleomycin or silica-induced pul-
monary fibrosis in mice (155-157). 
Recently. it was demonstrated that transient overexpression of TNF-a in rat lungs, 
using adenovirus mediated gene transfer. induced acute inflammation. This inflammation was 
characterized by increased infiltration of neutrophils, macrophages and lymphocytes, and 
eventually resulted in pulmonary fibrosis (158). It was suggested that in this model the fibre-
genesis was due to secondary upregulation ofTGF-~ 1 and the subsequent appearance of pul-
monary myofibroblasts (158). 
The use of TNF-a receptor knockout mice confirmed that TNF-a is essential for the 
development of pulmonary fibrosis in an asbestos model. It was postulated that TNF-a medi-
ated its effects through the activation of other growth factors such as PDGF and TGF-a (159). 
These data imply that TNF-a. like IL- I, is able to induce or participate in the patho-
logical features that are observed in BPD development. Therefore, both IL-l and TNF-a may 
be key inflammatory cytokines in the initiation and/or augmentation of the inflammatory 
response in the pathogenesis of BPD (Fig. 1). 
1.4.5. Other factors influencing pulmonary inflammation in the pathogenesis of BPD 
Adrenal insufficiency 
Early adrenal insufficiency, reflected by decreased cortisol production, may also play 
a role in the pathogenesis of BPD (160). The normal physiological response to stress includes 
increased secretion of cortisol by the adrenal glands (161). Watterberg et al. described lower 
serum cortisol levels in the first week of life in infants who developed BPD compared to 
infants who did not (160). Infants with lower serum cortisol levels had increased lung inflam-
mation (increased total protein, albumin. a 1-PI and IL-6 in tracheal aspirates) and increased 
incidence of patent ductus arteriosus (160). In addition. infants who developed BPD had 
lower cortisol levels after intravenous adrenal corticotropic hormone (ACTH) administration 
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repair 
fibrosis 
Figure 1 
/ 
IL-1 
TNF-« 
resident lung cells 
oxygen radicals proteolytic enzymes e.g. elastase, MMPs 
Processes that occur in the pathogenesis of BPD and may be induced and/or augmented by IL-1 and TNF-a. 
Stimulation of resident lung cells such as epithelial cells. endothelial cells. fibroblasts and alveolar macrophages by 
IL-1 and TNF-a may lead to the production and release of chemokines. cytoldnes and growth factors. Furthermore, 
IL-l and TNF-a can upregulate the expression of adhesion molecules on endothelial cells and leukocytes. This facil-
itates the migration of inflammatory cells into the lung. These inflammatory cells produce cytokines. oxygen radi-
cals and proteolytic enzymes that may cause pulmonary damage. Other cytoldnes, in concert with growth factors. 
participate in the repair and fibrotic response after pulmonary injury. 
N<j> = neutrophils, M<j> = monocytes/macrophages. 
than infants who did not develop BPD (162). However, another study described a weak asso-
ciation between plasma cortisol and BPD development. and after adjustment for gestational 
age and clinical risk index for babies. the predicted probability for BPD was only minimally 
influenced by the cortisol concentration (163). 
Recent pilot studies demonstrated that early low-dose hydrocortisone treatment 
increased the likelihood of survival without BPD and increased the plasma cortisol levels 
(164. 165). 
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Pulmonary infection 
Most individual studies and meta-analyses support an assocJaUon between 
Ureaplasma urealyticum colonization of the respiratory tract and subsequent development of 
BPD in preterm infants. The suggestion that this association is independent of prematurity or 
low birth weight is controversial (166). 
Airway colonization with U. urealyticum or bacteria at birth has been shown to be 
associated with an increased inflanJmatory response on the first day after birth in infants with 
RDS (167). Compared with non-colonized infants, tracheal aspirate chemotactic activity. 
neutrophil count. and concentrations of IL-l. LTB4 and elastase-a1-PI are significantly 
higher in the colonized group. Also concentrations of IL-8 tend to be increased in colonized 
infants (167). Levels of C5a and albumin in tracheal aspirates have been found comparable 
between colonized and non-colonized infants (167). 
Increased levels of proinflanJmatory cytokines such as IL-l~ and TNF-a in tracheal 
aspirates from U. urealyticum colonized preterm infants have been confirmed in other 
studies (168). However. U. urealyticum colonization did not influence the concentration of 
IL-l~. IL-8 and TNF-a in BAL fluid (169). Furthermore. nosocomial pneumonia in combi-
nation with BPD increases elastase activity in BAL fluid compared to non-infected BPD 
infants and may therefore result in increased elastolytic damage to the lung parenchyma 
(170). It has been suggested that such additional inflanJmatory responses in the lungs due to 
infection with micro-organisms results in an increased incidence of BPD in children with 
RDS (171) 
1.4.6. Strategies to modulate pulmonary inflammation in infants with RDS!BPD 
Corticosteroid treatment 
Corticosteroids are effective regulators of inflammation. Corticosteroids exert their 
anti-inflanJmatory effects via glucocorticoid receptors (GR) that are present in the cytoplasm 
of the cell. The corticosteroid binds the GR after which the steroid/GR complex translocates 
from the cytoplasm to the nucleus where it binds to glucocorticoid responsive elements 
(GRE) in the promoter region of the target genes. The activated GR may bind to a GRE 
resulting in upregulation of transcription of the target gene. Alternatively, the activated GR 
binds to a negative GRE (nGRE) resulting in downregulation of the transcription of the 
corresponding gene. The susceptibility of cytokine genes to the inhibitory effects of 
corticosteroids is influenced by the number of nGRE's in the promoter region (172). 
Corticosteroids are known to inhibit the transcription of inflammatory cytokines, 
including IL-l, TNF-a, IL-6, IL-8. MCP-1, MIP-la and GM-CSF (173). These effects of 
corticosteroids can be mediated by interaction of GR with an nGRE in the promoter region 
of the genes. A number of cytokine genes. including IL-8. MCP-1 and RANTES, are nega-
tively regulated by corticosteroids but do not have a GRE in their promoter region. IL-8 and 
MCP-1 are predominantly regulated via the transcription factor nuclear factor-kappa B 
(NF-KB). RANTES is regulated by the transcription factors activating protein (AP)-1 and 
NF-KB. The activated GR may directly interact with AP-1 or NF-KB and in such a way pre-
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vent cytokine gene transcription. Corticosteroids may also modulate mRNA stability via 
increased breakdown of mRNA and thereby reduce synthesis of cytokines such as IL-l~- IL-
3. IL-6 and GM-CSF (173). 
Corticosteroids not only block the synthesis of cytokines but may also block their 
effects. Several cytokines exert their cellular effects via activation of the transcription factors 
AP-1 and NF-KB that subsequently activate or repress target genes and can therefore be reg-
nlated in a opposing manner by corticosteroids (172). 
In addition to the downregulatory effects on inflammatory cytokines. corticosteroids 
may modulate inflammation by upregulating the expression and release of the IL-l "decoy .. 
receptor. Furthermore. corticosteroids may downregulate adhesion molecules including 
ICAM-1. which may be due to inhibition of cytokine synthesis or a direct effect of 
corticosteroids on adhesion molecule gene transcription. Additionally. corticosteroids may 
increase the synthesis of SLPI by increasing the transcription of the coding gene (173). 
The corticosteroid dexamethasone (Dex) is commonly used in the treatment of infants 
with or at risk of BPD development. It has been shown that Dex treatment improves lung 
function and compliance and facilitates weaning from the ventilator. The long-term outcome 
of Dex treatment is still uncertain (174. 175). Furthermore. Dex treatment is associated 
with a number of adverse side effects including hyperglycemia. growth impairment. 
neuro-developmental impairment and gastrointestinal perforation (174. 176. 177). 
The pulmonary inflammation in BPD development may be modulated by Dex treat-
ment. It has been demonstrated that the number of inflammatory cells. especially neutrophils. 
significantly decreased in lung fluids from infants with or at risk of BPD after Dex treatment 
(178-180). The decreased neutrophil number was accompauied by a decrease in elastase level 
(75. 178). Additionally. a decrease in albumin levels occurred in lung fluid after Dex. indi-
cating decreased pulmonary vascnlar permeability (178. 179. 181). 
Inflammatory cytokines and chemokines including TNF-a. IL-l~ and MIP-la 
decreased in lung fluids from infants with or at risk of BPD after Dex treatment (90. 132. 
179). Other markers of inflammation such as LTB4 and 6-keto prostaglandin decreased also 
after Dex (179. 180). Furthermore. Dex treatment resulted in a significant reduction of the 
chemotactic activity of tracheal aspirates for neutrophils (179). Waisman et al. have demon-
strated that Dex treatment of infants with or at risk of BPD caused a decreased expression of 
the adhesion molecule L-selectin on circulating polymorphonuclear leukocytes and mono-
cytes. The authors speculated that downregulation of L-selectin would result in reduced 
ntigration of leukocytes into the lungs (182). Altogether these data indicate that the clinical 
improvement observed in infants with or at risk of BPD after Dex treatment may be 
mediated by suppression of the pulmonary inflammation. 
Opposite to its downregulatory effect on inflammatory cytokines. Dex treatment has 
been shown to increase the concentration of vascular endothelial growth factor (VEGF) in 
BAL flnid from infants at risk of BPD. It was suggested that this Dex associated increase in 
VEGF may affect the disturbed pulmonary angiogenesis in infants developing BPD (183). 
Besides a modulating effect on inflammation, corticosteroids are known to exert a 
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number of effects on lung development and maturation such as the stimulation of surfactant 
and antioxidant enzyme synthesis. The effects of corticosteroids on lung development have 
recently been reviewed (175) and will therefore not be discussed. 
Influence of mechanical ventilation on inflammation in BPD 
Although mechanical ventilation optimizes gas exchange, it may also induce second-
ary lung damage often referred to as ventilator-induced lung injury (VILI). Inflammatory 
cytokines such as IL-l~- IL-6. and TNF-a have been shown to influence the course of VILI 
(184). As it is generally assumed that pulmonary inflammation plays an important role in the 
pathogenesis of BPD (57). lung protective ventilation strategies that attenuate the inflamma-
tory response may be helpful in preventing BPD development. 
In an immature baboon model for BPD development it has been shown that high-fre-
quency oscillatory ventilation (HFOV) resulted in less pulmonary inflammation than low vol-
ume positive pressure ventilation (LV-PPV) (185). After LV-PPV increased total inflamma-
tory cell counts and increased numbers of monocytes/macrophages were found in tracheal 
aspirate fluids. Furthermore. increased tracheal aspirate concentrations of ll..-8 were detected 
compared to HFOV (185). HFOV treated baboons appeared to have better inflated and less 
tltick-walled distal lung parenchyma compared to the LV-PPV group. Additionally. a trend to 
improved alveolization was observed in the HFOV group (185). 
A study by Thome et al. in preterm infants. revealed no beneficial effect of HFOV on 
inflammatory parameters such as albuntin. IL-8 and LTB4 in tracheal aspirates (186). 
Methodological differences between tltis study and the earlier mentioned baboon study may 
account for the discordant observations. 
Recently, we demonstrated that applying the open lung concept to positive pressure 
ventilation (PPV OLe) in surfactant-depleted newborn piglets resulted in a sintilar reduction of 
pulmonary inflammation as HFOV OLC compared to conventional PPV (PPV coN) (187). BAL 
fluid from PPV CON contained increased numbers of total inflammatory cells. neutrophils. IL-
8 and thrombin activity compared to both other ventilation strategies (187). These data indi-
cate that application of ntild ventilation strategies may result in less pulmonary inflammation 
and therefore may be helpful in preventing BPD development. 
1.5. Concluding remarks 
With the improvements in neonatal intensive care. prematurely born infants with RDS 
were found to be at risk of BPD development. characterized by extensive remodelling of the 
lung parenchyma with decreased alveolar development and fibrosis as hallmarks. 
During the last three decades extensive research has been performed on the pathogen-
esis of BPD. It has become clear that factors such as ventilator-induced lung injury and oxy-
gen toxicity contribute to the pathogenesis of BPD by inducing and/or augmenting an exces-
sive and prolonged pulmonary inflammation. It is generally accepted that this inflammation 
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contributes to the lung injury. tissue remodelling and subsequent fibrosis in the pathogenesis 
of BPD. Therefore. much effort is put into the development of strategies that can reduce the 
pulmonary inflanunation and subsequent BPD development in these infants. 
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Pulmonary fibrosis and bronchopulmonary dysplasia 
Processes leading to the development of fibrosis are comparable to those in normal 
wound healing. Normal tissue repair follows a series of events that are tightly regulated over 
time. Cell recruitment and replication as well as extracellular matrix (ECM) synthesis and 
degradation are critical events in tissue repair and are regulated by a host of mediators derived 
from inflarumatory and resident cells as well as from the blood (!). Fibrosis can be defined 
as an excessive deposition of ECM components. resulting in loss of normal tissue architec-
ture and function. 
In general. fibrosis develops after an insult followed by tissue injury. subsequent 
inflarumation and a repair attempt (!). However. the control of cell function that occurs in 
proper wound healing is lost. presumably due to overproduction of mediators involved in the 
healing process. Additionally. the cells responding to these mediators may become more 
susceptible to these mediators due to an upregulation of mediator specific receptors(!). 
It has been suggested that a fibrotic response is driven by three factors: I) a continu-
ous insult with resultant injury or a continuous stimulus: 2) excessive synthesis of ECM pro-
teins. especially collagen: and 3) decreased degradation of deposited ECM proteins by 
degradative enzymes (1). Fibrosis can occur in many different organs. such as heart, liver. 
kidney or lung. The pathogenetic mechanisms involved appear largely the same (2-5). 
The ECM is built by a large number of different components. such as collagens. 
elastin. Iantinin. entactin. fibronectin. tenascin. thrombospondins. hyaluronan and decorin (I. 
6. 7). The collagen fantily consists of at least 19 closely related but structurally and metabol-
ically distinct proteins. Collagens represent 60-65% of the connective tissue in adult lung (6). 
The interstitial fibrillar types I and III. which exist in a ratio of 2: I. comprise about 90% of 
the collagens in the adult lung (8). In fibrosis there is a loss of homeostasis that results in 
excessive accumulation of ECM components. especially collagen. elastin. fibronectin and 
proteoglycans (6). although the term fibrosis is generally associated with excessive collagen 
deposition. 
2.1. Pathogenesis of pulmonary fibrosis 
Pulmonary fibrosis may result from a broad range of insults such as infection, alveo-
lar cell carcinoma. radiation, drugs. organic/inorganic dust inhalation, and hyperoxia (oxygen 
toxicity) (5. 9-12). Despite the wide variety of insults associated with pulmonary fibrosis. the 
mechanisms involved appear largely the same (13). One of the first and persistent histologi-
cal features observed in the pathogenesis of pulmonary fibrosis is epithelial and endothelial 
cell injury leading to denuded basement membranes and the regeneration of these cells (14-
18). Such injury destroys the permeability barrier with resultant proteinaceous oedema, hya-
line membranes and influx of inflarumatory cells. This is followed by the development of pul-
monary fibrosis, characterized by excessive fibroblast proliferation and collagen deposition. 
Severity of epithelial damage. ongoing injury. and delay in epithelial repair appear to be key 
factors for overstimulation of the normal repair response leading to pulmonary fibrosis (19). 
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Nowadays it is generally assumed that mediators produced by pulmonary inflamma-
tory cells, such as alveolar macrophages. and resident lung cells, such as epithelial cells, 
endothelial cells, and fibroblasts. and blood born mediators. induce fibroblasts to migrate, 
proliferate and to produce excess collagen (20-32). Figure I depicts the mechanisms involved 
in the pathogenesis of pulmonary fibrosis. 
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Figure 1 
Mechanisms involved in the pathogenesis of pulmonary fibrosis. Epithelial and endothelial cell injury elicits the 
movement of inflammatory cells between capillary. alveolar, and interstitial compartments with the release of fibro· 
genic mediators. These mediators activate fibroblasts which migrate to the lesion. proliferate and produce and 
deposit increased amounts of extracellular matrix proteins. resulting in fibrosis. (Adapted with permission from: 
McAnulty RJ and Laurent GJ 1995, Exp Nephrol3: 96·107). 
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2.1.1. Collagen in pulmonary fibrosis 
Increased collagen deposition is clearly observed upon histologic examination of 
fibrotic lung tissue and has been confirmed by biochemical analysis (15. 16. 18. 33-40). Both 
biochemical and immunohistochemical studies have provided evidence that the early stages 
of pulmonary fibrosis are characterized by an increase of type-Ill collagen relative to type-! 
collagen while in established fibrosis an increase of type-! collagen is observed (8. 37. 41-
43). Increased levels of N-terminal and C-terminal pro-peptides of collagen type-! and III, 
which are extracellular products of collagen synthesis. have been detected in BAL fluid and 
serum from adult patients with fibrosing lung disease ( 44-50). Broekelmann et al. demon-
strated by in situ hybridization that foci of fibroblasts in organizing fibrotic lesions (early 
stage fibrosis) expressed type-! procollagen mRNA. In established dense fibrotic areas (late 
stage fibrosis). however. no type-! procollagen mRNA was expressed (51). This is in con-
cordance with immunohistochemical analysis of type-! procollagen expression by fibroblasts 
in fibrosing lung disease (52). The presence of type-! procollagen in fibroblasts in fibrotic 
lung and its absence in fibroblasts of normal lung tissue supports the hypothesis that fibrosis 
is associated with an altered collagen-synthesizing phenotype of tissue fibroblasts (52. 53). 
In vitro studies on collagen synthesis by fibroblasts obtained from fibrotic lung are 
conflicting. A number of studies did not show increased collagen synthesis by fibroblasts 
from fibrotic lung compared to fibroblasts from normal lung (54. 55). while others studies did 
demonstrate increased collagen synthesis by fibroblasts from fibrotic lungs (56. 57). 
Recently. Ramos et al. described increased a! (I) collagen mRNA expression and collagen 
synthesis by fibroblasts from fibrotic lung tissue (58). In these studies large variation in col-
lagen synthesis for the different fibroblast lines was observed. On the other hand, fibroblasts 
from areas of active organizing fibrosis express procollagen mRNA and protein. while 
fibroblasts in established dense fibrotic areas express less or not at all (51. 52). Therefore. the 
site from which the fibroblasts are isolated from the lung tissue may influence the capacity to 
synthesize collagen in vitro. 
It has been demonstrated that normal lung tissue contains different subsets of 
fibroblasts. based on the ability of these cells to bind Clq (the large subunit of the first com-
ponent of complement). Under basal conditions. fibroblasts with high C!q binding capacity 
synthesize more collagen than fibroblasts with low Clq binding capacity. Therefore, fibrob-
lasts with high Clq binding capacity may be responsible for the collagen synthesis necessary 
during healing. Persistence of such collagen-synthesizing cells in healing tissue may lead to 
the collagen accumulation characteristic for fibrotic lesions (59, 60). 
In the field of pulmonary fibrosis there has been a lot of emphasis on increased colla-
gen synthesis. However. decreased degradation of collagen by proteolytic enzymes such as 
matrix metalloproteinases (MMPs) may also contribute to excessive ECM accumulation. 
Loss of the highly regulated balance between MMPs and tissue inhibitors of metallopro-
teinases (TIMPs) may contribute to collagen accumulation (61-63). A detailed description of 
the role for MMPs and TIMPs in pulmonary fibrosis will be given in chapter 2.1 .4.4. 
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2.1.2. The role of fibroblasts in pulmonary fibrosis 
The fibroblast is the major collagen synthesizing cell-type in the lung parenchyma. 
Current concepts on the mechanisms leading to excessive ECM deposition in pulmonary 
fibrosis suggest that fibroblast proliferation may play an important role (13. 20). Histological 
examination of tissue taken from lungs undergoing episodes of active or end-stage pulmonary 
fibrosis shows evidence of increased fibroblast numbers (14-16. 34. 36. 64, 65). 
In vitro studies on the proliferative characteristics of fibroblasts obtained from 
fibrotic lungs are inconclusive. It has been demonstrated that fibroblasts obtained from fibrot-
ic tissues proliferate with a higher rate than fibroblast from normal lung tissue (66. 67). 
Raghu et al. demonstrated that fibroblasts obtained from early inflammatory fibrotic lesions 
had higher proliferation rates than fibroblasts from normal lung tissue. while fibroblasts 
obtained from established dense fibrotic regions proliferated with a lower rate than fibrob-
lasts from normal lung tissue (68). Recently. a study described decreased proliferation rates 
in fibroblasts obtained from fibrotic lung tissue compared to fibroblasts obtained from nor-
mal lung tissue (58). In this study it was suggested that the high percentage of a-smooth mus-
cle (tx-SM) actin positive fibroblasts (myofibroblasts) in the fibrotic cell population account-
ed for the observed lower proliferative activity as these cell have been shown to grow slow-
ly in vitro (58. 69). The slower growth rate of fibrotic fibroblasts. however. may also be 
explained by increased apoptosis of these cells compared to fibroblasts from normal lung tis-
sue (58). 
Mia et al. did not find differences in the basal growth rate of fibroblasts obtained from 
early fibrotic lesions. higher-intensity fibrotic lesions. and fibroblasts obtained from normal 
lung tissue. Fibroblasts from end-stage fibrotic lesions were not analyzed in this study (70). 
Furthermore. the proliferative response to the fibroblast mitogen platelet-derived growth fac-
tor (PDGF) was comparable between fibroblasts obtained from normal lung and from early 
and higher-intensity fibrotic lesions. which is in concordance with data described by Raghu 
et al. (68. 70). 
Prostaglandin E2 (PG~) is a potent inhibitor of fibroblast proliferation and collagen 
synthesis (71-73). TGF-~1 • which is a profibrotic mediator. has been shown to downregulate 
proliferation of normal lung fibroblasts at high concentrations by the induction of PG~ syn-
thesis. However. TGF-~1 was unable to downregulate the proliferation of lung fibroblasts 
obtained from fibrotic lung tissue (57). The reduced capacity of fibroblasts from fibrotic tis-
sue to synthesize PGE2• both basally and in response to TGF-~ 1 • was found to be due to an 
inability to upregulate cyclooxygenase-2 (COX-2) enzyme. which is the rate limiting enzyme 
in prostanoid biosynthesis (57. 74). Moreover, it was shown that the proliferation of 
fibroblasts from fibrotic lungs was less inhibited by PGE2 than the proliferation of fibroblasts 
from normal lung tissue (70). 
Suganuma et al. described that fibroblasts from fibrotic lung had enhanced migratory 
capacity. both under basal conditions and towards PDGF. compared to fibroblasts from nor-
mal lung tissue (75). Fibroblasts from tissues with dense fibrosis had a greater capacity to 
migrate than those from an earlier stage of fibrosis (75). Interestingly. bronchoalveolar (BAL) 
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fluid from patients with fibrosing lung disease is highly chemotactic for fibroblasts (76). 
Indeed fibroblasts have been cultured out of BAL fluid (77). In vitro studies have demon-
strated that such migrating fibroblasts were enriched for a-SM actin (78). 
Together these data suggest that different phenotypes of fibroblasts with regard to pro-
liferative and migratory capacity occur within fibrotic lungs. These fibroblasts differ from 
normal lung fibroblasts. A change in phenotype of the pulmonary fibroblasts may play an 
important role in the pathogenesis of pulmonary fibrosis. 
2.1.3. The role of myofibroblasts in pulmonary fibrosis 
It has become evident over the last few years that there is phenotypic heterogeneity 
among fibroblasts with regard to proliferation rate. collagen synthesis rate. and surface mark-
er expression (54. 57. 59. 66-68. 79). Myofibroblasts are a unique subpopulation of activat-
ed fibroblasts that express a-SM actin. which is a feature of smooth muscle differentiation 
(80). 
Myofibroblasts play a central role in wound healing. presumably as an extension of 
their role in normal growth and differentiation. During wound healing. the myofibroblast 
appears to be involved in the formation and repair of the ECM. as well as the proliferation 
and differentiation of epithelial. vascular and neurogenic elements. Due to the expression of 
a-SM actin the myofibroblast is contractile and therefore can reduce the denuded surface area 
of wounded tissue (80). 
Myofibroblast hyperplasia has been demonstrated in areas of active pulmonary fibro-
sis in humans and in animal models for pulmonary fibrosis. The myofibroblasts appear to be 
the main subset responsible for collagen accumulation (64, 81-87). Successful tissue repair 
after injury was characterized by a gradual disappearance of the myofibroblast as described 
in a rodent model of bleomycin-induced lung injury with self-limiting pulmonary fibrosis. In 
this model. active fibrosis was characterized by increased numbers of myofibroblasts and col-
lagen expression. When fibrosis subsided. decreased numbers of myofibroblasts and collagen 
expression were observed (87 -89). 
Several cell types present in the lung are potential precursors of the myofibroblasts 
associated with pulmonary fibrosis. These include airway or vascular smooth muscle cells. 
pericytes. contractile interstitial cells, and septal tip cells. The fibroblast. however. is 
regarded as the main precursor cell for the myofibroblast (90). 
Cytokines and growth factors are likely to play a role in inducing the transformation 
of fibroblasts into a-SM actin expressing myofibroblasts. It has been suggested that TGF-
~1 and TNF-a. which were expressed in excess by hyperplastic type-II epithelial cells in pul-
monary fibrosis, stimulate the expression of a-SM actin by pulmonary myofibroblasts (85). 
In bleomycin-induced pulmonary fibrosis in rats, it was demonstrated that increased TGF-~1 
expression preceded the differentiation of alveolar fibroblasts into a-SM actin expressing 
myofibroblasts (23). Furthermore, adenoviral gene transfer of GM-CSF in the alveolus 
resulted in local accumulation of TGF-~ 1 • followed by a-SM actin and collagen synthesis by 
pulmonary myofibroblasts. and eventually pulmonary fibrosis (91). Among the mediators 
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implicated in myofibroblast modulation, TGF-~ 1 can be considered as a direct inducer of the 
myofibroblastic phenotype as in vitro studies have demonstrated that TGF-~ 1 induced o:-SM 
actin expression as well as collagen synthesis by fibroblasts (92-94). 
2.1.4. Mediators of pulmonary fibrosis 
Pulmonary fibrosis can be the consequence of a variety of insults and is characterized 
by increased deposition of ECM proteins within the pulmonary interstitium. Changes in col-
lagen deposition can result from attraction of fibroblasts to the active site of injury to increase 
their number. replication of fibroblasts. clonal selection of sub-populations of fibroblasts with 
a specific phenotype such as rapid replication or high collagen production, or changes in the 
collagen synthesis and degradation. Many mediators (produced by inflammatory or resident 
lung cells or derived from the blood) affecting these fibroblast functions have been identified 
and have been linked to pulmonary fibrosis both in human and in experimental animal 
studies. The "balance" between mediators that positively or negatively regulate fibroblast 
activity in the context of collagen synthesis and/or degradation and fibroblast proliferation 
and/or chemotaxis is thought to play a central role in the pathogenesis of pulmonary fibrosis 
(95). A summary of mediators having direct effect on fibroblast functions and known to be 
involved in pulmonary fibrosis in both humans and animal models is given in table I. 
TGF-~1 is the most potent stimulator of collagen synthesis. Therefore its role in pul-
monary fibrosis will be discussed in more detail. In addition to this, the role of PDGE the 
coagulation cascade (especially thrombin) and the role of matrix metalloproteinases will be 
discussed as they are of special interest for this thesis. 
2.1.4.1. Transforming growthfactor-{3 
TGF-~ is a dimeric protein of which three isoforms exist in mammals. These isoforms 
have been designated as TFG-~1 , TFG-~2 and TFG-~3 (165). All these isoforms are initially 
translated as large precursor molecules. TGF-~ is secreted in a small or large latent complex 
that is inactive (166). The precise mechanism of TGF-~ activation in vivo is still unknown. 
However, a number of candidate molecules including plasmin, MMP-2 and MMP-9, a cell 
surface MMP-9/CD44 complex, the ECM protein thrombospondin-1 and the o:,~6-integrin 
have been found to activate latent TGF-~ (166-169). TGF-~1 is the predominant and most 
studied isoform and often just implicated as TGF-~ (165). 
TGF-~ 1 is a well known inducer of collagen synthesis (96, 170-172). It influences col-
lagen production in a number of ways. It stimulates the transcription of the procollagen gene 
and increases the stability ofprocollagen mRNA (171. 173, 174). 
Besides increased collagen synthesis, decreased breakdown may also result in exces-
sive collagen accumulation. TGF-~ has been demonstrated to decrease intracellular collagen 
degradation, to reduce the production of collagenase (MMP-1) and to increase the production 
of the collagenase inhibitor tissue inhibitor of metalloproteinase (TIMP) (94, I 00). In such a 
way TGF-~ can promote collagen deposition by fibroblasts. 
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Table 1. Mediators involved in pulmonary fibrosis that modulate fibroblast activity directly 
Mediator 
PDGF 
CTGF 
TNF-o: 
IGF-1 
ET-1 
Fn 
PGE2 
IFN-y 
IL-l 
Effect on fibroblast 
Collagen i 
Collagen degradation J, 
Proliferation 1' J, 
Chemotaxis 1' 
Collagenase J.. 
Metalloprotein::J.Se 
inhibitors 1' 
Proliferation 1' 
Chemotaxis 1' 
Collagen:l.<;e 1' J, 
Collagen i 
Proliferation i 
Chemotaxis i 
Collagen J, 
Proliferation i 
Chemotaxis 1' 
Collagenase i 
Collagen 1' 
Proliferation 1' 
Collagenase J, 
Collagen 1' 
Collagen degradation J, 
Proliferation 1' 
Chemotaxis 1' 
Collagen:J.Se J, 
Source 
edc. epc. eos. 
fib. smc. mac. 
meso. plat 
edc. epc, fib. smc. 
meso. man. mac. plat 
epc. fib 
cdc. fib. lym. 
man. mac 
blood born. 
fib. mac. smc 
edc. epc. fib. 
mac 
Proliferation 1' blood born. edc. 
Chemotaxis 1' epc. fib. mac 
CoHagen J, blood born. 
Proliferation J, edc. epc. fib. 
Chemotaxis J, smc. mon. mac 
Collagen::J.Se J, J 1' 
Metalloproteinase inhibitors J, 
Collagen J, lym. mac 
Proliferation 1' 
Collagenase J, 
Collagen 1' fib. man. mac 
Proliferation 1' 
Collagen::J.Se 1' 
Metalloproteinase inhibitors 1' 
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Reference 
27. 72. 94. 96-101 
25, 102-107 
108-110 
lll-119 
125-129 
!30-133 
57, 72. 73. 134-138 
139-146 
119. 147-153 
to be continued on the next page 
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Table 1. (continued) 
Mediator Effect on fibroblast Source Reference 
MCP-1 Collagen 1' edc. epc, fib. 154-158 
Collagenase 1' smc. mon. 
Metalloproteinase inhibitors i mac. cos 
Thr Collagen 1' blood born 32, 159-161 
Proliferation 1' 
Chemotaxis 1' 
Fxa Proliferation i blood born 162-164 
cdc - endothelial cells. cos - eosinophils. epc = epithelial cells. fib - fibroblasts. Jym - lymphocytes. mac -
macrophages. meso = mesothelial cells. mon = monocytes. plat = platelets. smc = smooth muscle cells 
TGF-~ 1 =transforming growth factor~~ 1 
PDGF =platelet-derived growth factor 
CTGF =connective tissue growth factor 
TNF-cx. = tumor necrosis factor-a 
IGF-1 =insulin like growth factor-1 
ET-1 = endothelin-1 
Fn = fibronectin 
i = increased 
t = decreased 
it = biphasic 
i;t =increased I decreased 
PG~ = prostaglandin ~ 
IFN-y= interferon-)' 
IL-l = interleukin-1 
MCP-1 =monocyte chemotactic protein-! 
Thr = thrombin 
FXa =factor Xa (activated factor X) 
Furthermore. TGF-~ has been shown to be chemotactic for fibroblasts. to influence 
fibroblast proliferation in a biphasic manner and to induce o:-SM actin expression (72. 93, 
99). 
TGF-[3 in pulmonary fibrosis 
In animal models of pulmonary fibrosis increased TGF-~ 1 mRNA expression levels 
were detected before type-! and type-III procollagen mRNA expression levels increased (175, 
176). Besides TGF-~1 • increased TGF-~2 and TGF-~3 mRNA levels have also been demon-
strated in bleomycin-induced pulmonary fibrosis (177). Numerous cellular constituents of the 
lung. such as alveolar macrophages. bronchial and alveolar epithelial cells. endothelial cells. 
mesothelial cells fibroblasts and smooth muscle cells have been identified as a potential 
source for all three isoforms of TGF-~ (177.178). A study by Coker eta!. demonstrated that 
both TGF-~2 and- ~3 share the ability of TGF-~ 1 to promote collagen deposition by stimu-
lating fibroblast procollagen synthesis in vitro (178). However. using in situ hybridization, 
they identified TGF-~1 as the predominant isoform in bleomycin-induced pulmonary fibro-
sis. which is in concordance with earlier published PCR analysis data in bleomycin treated 
mice (178. 179). Increased TGF-~ protein levels have been described in lung tissue after 
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intratracheal instillation of bleomycin and was temporally related to enhanced synthesis of 
collagen by pulmonary fibroblasts (23). Increased TGF-~ protein expression preceded myofi-
broblast hyperplasia and was detected in macrophages. bronchiolar epithelium and subep-
ithelial matrix. and ECM associated with areas of repair and fibrosis (23. 87. 101). 
Furthermore. after bleomycin-induced injury alveolar macrophages not only produced TGF-
~ but also secreted large quantities of biologically active TGF-~. Also. in BAL fluid 
increased levels ofTGF-~ have been detected after bleomycin-induced lung injury (180-183). 
In vitro studies have demonstrated that bleomycin not only stimulates TGF-~ production by 
alveolar macrophages. but also by endothelial cells (28. 184). 
The importance ofTGF-~1 in pulmonary fibrosis was nicely shown in a study in which 
active TGF-~ 1 was transiently overexpressed in rat lung. This overexpression resulted in 
severe pulmonary fibrosis characterized by excessive deposition of collagen and the appear-
ance of myofibroblast like cells (185). Furthermore. inhibition studies stress the importance 
of TGF-~ in the pathogenesis of pulmonary fibrosis. Administration of TGF-~ antibodies or 
recombinant soluble TGF-~ receptor-IT resulted in dintinished collagen accumulation after 
intratracheal instillation of bleomycin or immune-induced (intranasal exposure to heat-killed 
Bacillus Calmette-Guerin) pulmonary fibrosis ( 186-188). 
Decorin is a proteoglycan with two binding sites for all TGF-~ isoforms and is an 
important negative regulator of this growth factor. Adenoviral transfer of decorin into the 
lungs has been demonstrated to inhibit bleomycin-induced pulmonary fibrosis. and this effect 
was probably mediated at the level of TGF-~ activity ( 183). Furthermore. addition of taurine 
and niacin. which are known protectors of tissue injury. to the diet three days before intratra-
cheal instillation of bleomycin and continuing thereafter. reduced pulmonary fibrosis at least 
partly via the inhibition ofTGF-~ 1 mRNA expression (189). IFN-yhas been shown to down-
regulate bleomycin-induced pulmonary fibrosis via a reduction in the overexpression of 
TGF-~ mRNA. and consequently a reduced production ofprocollagen mRNA (190). 
TGF-~ mediates signals from the membrane to the nucleus via the SMAD proteins. 
SMAD7, however. functions as an inhibitor of TGF-~ signaling (191). Transient expression 
of SMAD7 in the lungs inhibited bleomycin-induced pulmonary fibrosis without affecting 
the amount of TGF-~1 present ( 192). 
A novel mechanism for the activation of latent TGF-~1 has recently been suggested. 
In this mechanism the C<y~6 integrin expressed on epithelial cells binds latent TGF-~ 1 and is 
involved in its activation (169). It was demonstrated that ~6 knockout ntice were protected 
from bleomycin-induced pulmonary fibrosis. and that bleomycin induced C<y~6 expression on 
airway and alveolar epithelial cells throughout the lungs (169). 
In patients with pulmonary fibrosis. in situ hybridization revealed that in areas of early 
active fibrosis TGF-~ 1 mRNA was expressed by macrophages close to fibroblasts actively 
expressing type-! procollagen mRNA (51). Additionally. immunohistochentistry revealed 
intense staining for TGF-~1 around fibroblastic foci. which was co-distributed with procolla-
gen type-! expression by fibroblasts (51). Other immunohistochentical studies detected TGF-
~1 protein in regenerating and hyperplastic alveolar type-II epithelial cells as well as in the 
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fibrous tissue located beneath the hyperplastic epithelial cells (27. 85). 
Recently it was shown that TGF-~1 and TGF-~3 mRNA localized to alveolar 
macrophages and bronchiolar epithelium in normal human lung. In addition to this. mes-
enchymal and endothelial cells only expressed TGF-~ 1 mRNA (193). In fibrotic lung tissue. 
both isoforms of TGF were also detected in alveolar type-IJ epithelial cells, and it was 
demonstrated that TGF-~1 mRNA expression was enhanced in fibrotic lung while TGF-~3 
was not consistently altered (193). This indicates that TGF-~1 .like in bleomycin-induced pul-
monary fibrosis in mice. is the predominant TGF-~ isoform in the pathogenesis of pulmonary 
fibrosis ( 193). 
Increased TGF-~ 1 levels have been detected in BAL fluid from patients with fibros-
ing lung disease. In vitro studies identified the alveolar macrophage as an important source 
ofTGF-~ production in the pathogenesis of pulmonary fibrosis (194-196). 
Taken together. these observations suggest an important role for TGF-~ in the 
development of pulmonary fibrosis. 
2.1.4.2. Platelet-derived growth factor 
PDGF is a family of growth stimulating polypeptides. The PDGFs are dimers consist-
ing of two polypeptide chains. referred to as the A- and B-chains. These chains may assem-
ble to form three different isoforms of PDGE referred to as PDGF-AA. PDGF-AB. and 
PDGF-BB ( 197). The PDGF isoforms exert their effects via two receptor tyrosine kinases. 
denoted PDGFR-a and PDGFR-~ (197). Ligand binding induces dimerization of the recep-
tor. The PDGFR-a binds both PDGF-A and B chains while PDGFR-~ only binds the 
PDGF-B chain (198). Therefore. dependent on the PDGF isoform. different types of recep-
tor homo- or heterodimers (a-a. a-~ or ~-~) are formed. with the a-a receptor binding all 
three PDGF isoforrns. the a-~ receptor binding PDGF-AB and PDGF-BB. and the~-~ recep-
tor binding PDGF-BB only (199). Recently. two new PDGF-chains have been described and 
denoted PDGF-C and PDGF-D. Both chains form homodimers resulting in PDGF-CC and 
PDGF-DD (200-202). In addition. it was shown that PDGF-C is a ligand for PDGFR-a while 
PDGF-D is a ligand for PDGFR-~ (200. 201). As little is know yet about PDGF-C and 
PDGF-D. only the "classic" PDGF isoforms will be discussed here. 
Among the different fibroblast mitogens. PDGF is regarded as the most potent one. In 
vitro studies have demonstrated that all three isoforms of PDGF stimulate lung fibroblast pro-
liferation. However. fibroblasts from different species may differ in their responsiveness to 
PDGF isoforms (102. 103). In addition to its effect on replication. in vitro studies have iden-
tified PDGF as a chemoattractant for fibroblasts (104. 203). 
Several in vitro studies on the effect of PDGF on collagen mRNA expression and col-
lagen synthesis by fibroblasts are inconclusive. It has been described that the different PDGF 
isoforms did not affect type-! and -ill procollagen mRNA expression and collagen synthesis 
by fibroblasts (103. 105). However. if fibroblasts were cultured on dishes coated with 
2-hydroxyethyl methacrylate (poly (HEMA)) or in three dimensional collagen gels, 
PDGF-BB increased collagen synthesis with or without mediating type-! procollagen 
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mRNA. respectively (204). Furthermore. PDGF may influence the accumulation of collagen 
as it has been demonstrated that PDGF-BB influences collagenase expression by fibroblasts 
in a biphasic manner (106). Additionally. PDGF-BB may upregulate TIMP expression by 
fibroblasts in a synergistic manner with other factors (105. 106). 
PDGF in pulmonary fibrosis 
A potential role for PDGF in pulmonary fibrosis has become evident from a number 
of animal studies. In rats. intratracheal instillation of an expression vector containing the 
human PDGF-B gene resulted in pulmonary overexpression of this gene and caused signifi-
cant fibroproliferation and collagen synthesis (205). Overexpression of the PDGF-B gene 
under control of the surfactant protein-C promoter in mice resulted in alternating areas of 
emphysema and fibrosis (206). Intratracheal injection of PDGF-BB in rats resulted in 
increased incorporation of bromodeoxyuridine (BrdU) into peribronchial and perivascular 
stromal cells and spindle-shaped mesenchymal cells in the alveolar parenchyma and 
increased collagen deposition (207). 
Asbestos exposure may also lead to pulmonary fibrosis. It has been demonstrated that 
in lungs from rats exposed to chryostile asbestos. mRNA encoding PDGF-A and -B increased 
as soon as 5 hours after exposure and remained elevated for at least 30 days (26). 
Additionally. it was shown that PDGF-A and -B chains were produced by bronchiolar-
alveolar epithelial cells. macrophages and interstitial cells (26). Increased levels of PDGF-A 
and -B mRNA and protein have also been demonstrated in BAL cells and fluid. and lung tis-
sue from animals with bleomycin-induced pulmonary fibrosis. and have been shown to con-
tribute to BAL fluid-induced fibroblast proliferation (107. 124. 181. 208). 
The tyrphostin AG1296 is a tyrosine kinase inhibitor that specifically inhibits 
autophosphorylation of the PDGFR. AG1296 has been shown to inhibit vanadium pentoxide 
(V 20s) induced pulmonary mesenchymal cell proliferation and collagen deposition (209). 
Yoshida et al. demonstrated that transgenic overexpression of the extracellular domain of the 
PDGFR-~ in the lung inhibited bleomycin-induced fibrosis (210). Pirefenidone (PD) is a drug 
that inhibits bleomycin-induced lung injury in hamsters when added to the diet (2ll). 
Additionally. it has been demonstrated that PD decreased the levels of PDGF isoforms in 
BAL fluid after bleomycin and reduced BAL fluid ntitogenicity for fibroblasts (208). 
In human patients with pulmonary fibrosis. increased expression of PDGF-A and - B 
mRNA and protein has been demonstrated in alveolar macrophages. and PDGF-B appeared 
to be the most abundantly expressed (25. 212. 213). Alveolar macrophages from adult 
patients with pulmonary fibrosis were found to secrete increased amounts of PDGF. and 
increased concentrations of PDGF have been described in BAL fluid (21. 194. 195. 213. 
214). Culture medium. conditioned by alveolar macrophages from patients with pulmonary 
fibrosis. was found to be ntitogenic for fibroblasts. and PDGF largely accounted for this uti to-
genic activity (21. 213). 
Increased PDGF-B mRNA and protein were also detected in fibrotic lung tissue. and 
in situ hybridization revealed localization to alveolar epithelial cells. capillary endothelial 
53 
Chapter 2 
cells. alveolar and interstitial macrophages and pleural mesothelial cells (24. 215). Increased 
protein expression of PDGF-A. PDGF-B. PDGFR-a and PDGFR-~ in endothelial cells. vas-
cular smooth muscle cells and fibroblasts was demonstrated to occur only in early fibrotic 
lesions. Macrophages. however. expressed these proteins in both early and established fibro-
sis (25). Furthermore. rnRNA expression for PDGF-B and PDGFR-~ was present in alveolar 
type-II cells of lung tissues from early fibrotic lesions and not established fibrosis. while 
rnRNAs for PDGF-A and PDGFR-a were never detected (25). 
Altogether these data suggest an important role for PDGF in the pathogenesis of pul-
monary fibrosis. 
2.1.4.3. Coagulation cascade 
Tissue injury associated with vascular damage results in activation of the coagulation 
cascade (216). The main function of the coagulation cascade is preventing the loss of blood. 
and it does so via the formation of a provisional clot (consisting of platelets and fibrin). 
Stepwise activation of coagulation serine proteases present in the plasma results in the con-
version of prothrombin into active thrombin. Thrombin plays a central role in the coagulation 
cascade by converting soluble plasma fibrinogen into an insoluble fibrin clot and stimulates 
aggregation and degranulation of platelets (216. 217). Two pathways. referred to as the 
extrinsic and intrinsic pathways. are involved in the generation of active thrombin. It is 
thought that the extrinsic pathway is critical in the initiation of fibrin formation. while the 
intrinsic pathway plays an important role in the maintenance of fibrin formation (216). 
Dramatic activation of the coagulation cascade has been documented in cases of acute 
lung injury and pulmonary fibrosis (164. 218-221). In pulmonary fibrosis and diffuse alveo-
lar damage increased coagulant activity has been shown to be associated with increased pul-
monary fibrin deposition (164. 219). 
The next part will shortly discuss the coagulation pathways resulting in thrombin acti-
vation. Thereafter. cellular effects elicited by thrombin and evidence for thrombin as an active 
mediator in pulmonary fibrosis will be discussed. Although not discussed. one should realize 
that thrombin can also influence lung pathology via coagulation (fibrin deposition and 
fibrinogen derivatives) itself (29-31. 222-224). 
The extrinsic pathway 
The initiation of the coagulation cascade occurs following vascular injury and the 
exposure of tissue factor (TF; expressed on the surface of several different cell types) to the 
blood. TF forms a complex with factor VII which circulates in the blood, and activates this 
factor VII (leading to factor Vlla). The complex VIla-TF converts factor X towards factor 
Xa. The newly generated factor Xa forms a complex with factor Va (prothrombinase) which 
is capable of converting prothrombin to thrombin. which then acts directly on fibrinogen 
(216). 
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The intrinsic pathway 
The intrinsic pathway is an alternative coagulation pathway which is triggered by the 
contact system of coagulation when blood comes in contact with negatively charged compo-
nents of the subendothelial connective tissue. such as collagen (217. 225). The contact sys-
tem involves factor XII. prekallikrein. high-molecular-weight kininogen and factor XI (225). 
It results in the activation of factor XI which then activates factor IX of the intrinsic pathway 
(216. 225). Factor !Xa associates with factor VIlla and then activates factor X at the point 
where the intrinsic and extrinsic pathways of coagulation converge (216). 
Thrombin not only converts fibrinogen into fibrin. but also amplifies the coagulation 
cascade by converting factor v into its active form. In addition thrombin activates factor xrn. 
Activated factor XIII stabilizes the fibrin clot by covalent cross-linking of fibrin. 
Additionally. thrombin activates factor XI. which results in amplification of the intrinsic path-
way (216. 225). A simplified scheme of both coagulation pathways is depicted in figure 2. 
Under normal conditions the coagulation cascade is tightly controlled by anticoagu-
lant pathways. The main inhibitor of the extrinsic pathway of coagulation is tissue-factor-
pathway-inhibitor (TFPI). TFPI forms an inactive complex with factor Vlla!TF/factor Xa 
thereby inhibiting fibrin formation (216). Another important inhibitor of coagulation is 
antithrombin Ill (ATlll). ATlll is capable of inhibiting thrombin as well as the factors !Xa. 
Xa. and XIa (216). The complex formation of ATIII with different coagulation factors is 
greatly enhanced by heparin. Additionally. heparin cofactor II. <X:;-macroglobulin. activated 
protein C inhibitor and a 1-PI may also play an important role in the regulation of the coagu-
lation cascade (216). Blood coagulation may also be regulated by protein-C. Thrombin can 
bind to thrombomodulin on endothelial cells. Thrombomodulin stimulates the activation of 
Coagulation cascade 
vascular injury 
~ 
extrinsic 
pathway 
Figure2 
contact system 
XI a factor XI 
- TF-VII- TF-VIIa ~ 
factoriX~ ~ factoriX 
factor X Xa factor X 
~ 
prothrombin thrombin 
~
fibrinogen fibrin 
Simplified scheme of the coagulation cascade, involving the stepwise activation of serine proteases by the extrinsic 
and the intrinsic pathways. At the point of convergence of these two pathways. factor Xa converts prothrombin into 
active thrombin. Thrombin convert.'\ soluble fibrinogen into insoluble fibrin. 
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protein-C by thrombin. In this case thrombin loses its activity toward its substrates while acti-
vated protein-C inactivates factor Va and factor VII!a (216). 
Thrombin 
Besides its central role in blood coagulation, thrombin mediates other cellular effects 
that may play an important role in inflammatory, tissue repair. and fibrotic responses. 
Thrombin has been shown to directly increase endothelial permeability. in addition to its 
effects on permeability secondary to intravascular coagulation (226). Furthermore, thrombin 
acts as a chemoattractant for inflammatory cells and fibroblasts and as a mitogen for 
fibroblasts and vascular smooth muscle cells (160. 227-229). The mitogenic effect is likely 
to be due to autocrine release of PDGF-AA and an upregulation of the PDGFR-0: (162. 229. 
230). Thrombin has also been shown to increase procollagen type-! mRNA expression, as 
well as procollagen production by fibroblasts (159). Additionally. thrombin has been demon-
strated to induce connective tissue growth factor (CTGF) mRNA expression by fibroblasts. 
CTGF is known to be a potent mitogen and chemoattractant for fibroblasts. as well as a stim-
ulator ofprocollagen production by these cells (231). Furthermore. thrombin upregulates the 
production of inflammation. repair and fibrosis associated mediators, such as IL-6, IL-8. IL-
l~- fibronectin. endothelin-1 and -2. and PDGF-AA by fibroblasts, epithelial and endothelial 
cells. smooth muscle cells and alveolar macrophages (162. 232-239). 
Thrombin in pulmonary fibrosis 
Increased levels of active thrombin have shown to be present in BAL fluid from rats 
with bleomycin-induced acute lung injury with subsequent pulmonary fibrosis. Thrombin 
activity contributed siguificantly to BAL fluid-induced fibroblast proliferation (161. 240). 
Immunohistochemical staining for thrombin was found to be associated with alveolar 
macrophages within inflammatory and fibroproliferative foci. and fibroblast-like interstitial 
cells (161). 
Studies using inhibitors of the coagulation cascade have clearly demonstrated a role 
for coagulation and thrombin in acute lung injury. Exogenous delivery of hirudin and ATIII 
have shown to be protective and to result in decreased pulmonary fibrinogen deposition and 
BAL fluid procoagulant activity in animal models of acute lung injury (241, 242). 
Additionally, it has been shown that heparin improved gas exchange in a model of acute lung 
injury in newborn piglets (243). Heparin has also been shown to inhibit bleomycin-induced 
pulmonary fibrosis in mice, without reducing the number of inflammatory cells (244). BAL 
fluid from mice treated with bleomycin contained decreased levels of activated protein-C 
(245). It was demonstrated that intratracheal administration of activated protein-C to 
bleomycin-treated mice reduced thrombin activity in BAL fluid as well as collagen deposi-
tion in the lung (245). Direct inhibition of thrombin activity (using the compound 
UK-156406) reduced collagen accumulation and type-! procollagen and CTGF mRNA 
expression levels in the lungs from bleomycin-treated rats without modulation of the inflam-
matory cell influx (161). 
In adult patients with pulmonary fibrosis increased levels of active thrombin have 
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been detected in BAL fluid and contributed significantly to BAL fluid-induced fibroblast pro-
liferation (32, 230). Increased levels of the thrombin-ATIII complex (TATUI). a sensitive 
marker of thrombin generation. and decreased pulmonary protein-C activation have also been 
demonstrated in BAL fluid from patients with pulmonary fibrosis (246, 247). 
Altogether. these data suggest an important role for thrombin in the pathogenesis of 
pulmonary fibrosis. 
2.1.4.4. Matrix metalloproteinases and their involvement in pulmonary fibrosis 
l\11\IIPs play a role in many normal biological processes such as development. bone 
remodelling, wound healing. angiogenesis and apoptosis (248). Inadequate MMP production 
or regulation of activity has been implicated in a variety of pathological processes such as 
tumour invasion. SjOgren's syndrome, rheumatoid arthritis. lung disease and organ fibrosis 
(62. 249-256). 
MMPs comprise a large family of zinc endoproteases that share structural domains 
and are collectively capable of degrading all ECM components. The enzymes have both a 
descriptive name and an MMP number. MMPs can be divided into different families based 
on substrate specificity. which is summarized in table 2 (248, 249, 257. 258). All MMPs are 
synthesized as prepro-enzymes. The "pre''region targets for secretion and the "pro"region 
contains a sequence which ligates the catalytic zinc-domain to preserve the latency of the pro-
MMP (258). Additionally, MMPs contain domains such as a hemopexin region or a 
fibronectin region that are essential for substrate recognition (258). A subset of MMPs are the 
membrane-type MMPs (MT-MMPs). which are not secreted but remain attached to the cell 
surface via a transmembrane domain (258). 
MMP activity is controlled at multiple levels. MMP expression is regulated by a wide 
variety of cytokines and growth factors. such as TNF-o;, IL-L IL-6. TGF-P and PDGF (259). 
MMP expression may also be mediated by components of the ECM (260-262). MMP pro-
teins are secreted or membrane-bound as latent enzymes that require proteolytic processing 
to release the catalytically active enzyme (258). This processing can be achieved by other 
MMPs (e.g .. MMP-3 can activate proMMP-1, -2, and -9) or by proteases like plasmin (263-
267). MTl-MMP has been demonstrated to be an activator of proMMP-2 and proMMP-13. 
Neutrophil proteinases may participate in this process (266, 268, 269). 
The major endogenous regulators of M:rviP activity are the tissue inhibitors of metal-
loproteinases (TIMPs). At present four different TIMPs have been described (TIMP-L 2. 3, 
and 4) (270). TIMPs inhibit MMP activity via non-covalent binding of the active MMP forms 
at a molecular equivalence (270). TIMP-l and -2 can also bind proMMP-9 and proMMP-2, 
respectively (270). In addition to inhibition by TIMPs. MMP activity may also be inhibited 
by o;Tmacroglobulin (257). 
Besides inhibition of MMP activity. TIMPs may also exert a number of other effects. 
For example. TIMP-2 may be involved in the activation of MMP-2 by MTl-MMP (271). 
TIMPs may also modulate cell proliferation. influence cell morphology. inhibit angiogenesis 
and promote apoptosis (270. 272). 
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Table 2. Matrix metalloproteinases according to substrate specificity 
Family 
Collagenases 
Gclatinases 
Stromclysins 
Membrane type-MJ.\1P 
MT!-MMP 
MT2-MMP 
MT3-MMP 
MT4-MMP 
MT5-MMP 
MT6-MMP 
Unclassified 
Substrates 
fibrillar collagens. type-I. II. 
ill 
non-fibrillar colLagens, type-
VIT. X. gelatins, 
protcoglycan core protein 
fibrillar collagen type-V 
non-fibrillar collagens. typc-
IV. VIT. X. XII. gelatin. 
fibroncctin. elastin. 
protcoglycan core protein 
non-fibrillar collagen type-
IV. laminin. gelatin. elastin. 
proteoglycans. fibronectin. 
cntactinlnidogcn, protcoglycan 
core protein 
elastin, non-fibrillar 
collagen (IV. VI. vn. vm. 
IX. X. XII. XIV) 
pro-MMP-9, undefined 
undefined 
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MMP-1 
MMP-8 
MMP-13 
MMP-18 
:MMP-2 
MMP-9 
MMP-3 
MMP-10 
MMP-7 
MMP-14 
MMP-15 
MMP-16 
MMP-17 
MMP-24 
MMP-25 
MMP-19 
MMP-20 
MMP-21 
MMP-22 
MMP-23 
Descriptive Namc(s) 
interstitial collagenase 
collagenase-! 
neutrophil collagenase. col-
lagenase-2 
collagenasc-3 
Xenopus collagenase, col-
lagenasc-4 
gelatinase-A. 
72kDa gclatinase. 
72kDa type-IV 
collagenase 
gelatinase-B, 
92kDa gclatinase. 
92kDa type-IV collagenase 
stromclysin-1. tr:.msin, 
proteoglycano.se. 
procollagenase activator 
stromelysin-2. transin-2 
matrilysin, matrin, PUMP-
I, uterine-metallopro-
teinasc 
stromclysin-3 
metalloelastase. 
macrophage elastase 
enamelysin 
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MMPs in pulmonary fibrosis 
A role for MMPs in the pathogenesis of acute lung injury and pulmonary fibrosis has 
become clear from animal studies. Increased gelatinolytic activity has been described in lung 
tissue from rabbits after intratracheal instillation of bleomycin (273). In the early stages after 
bleomycin. gelatinolytic activity due to MMP-9 increased, while in the later stages of disease 
MMP-2 was the predontinant form (273). MMP-2 and 9 were found to be expressed by infil-
trating macrophages. bronchial and bronchiolar epithelial cells. and intra-alveolar fibroblasts 
(273). Denholm et al. demonstrated that alveolar macrophages indeed secreted increased 
amounts of MMP-9 after bleomycin stimulation (274). After bleomycin. MMP-2 was found 
to be expressed by regenerating type-IT pneumocytes and MMP-9 by infiltrating neutrophils 
(273). Therefore. MMP-9 was suggested to contribute to the injury of the alveolar basement 
membrane in the early stages of bleomycin-induced pulmonary fibrosis, while a role for 
MMP-2 was suggested in the reepithelialization of the alveoli in the later stages of disease 
(273). Increased immunolocalization of MMP-1 has been described in bronchial and bron-
chiolar epithelial cells. type-IT pneumocytes and alveolar macrophages. Increased TIMP-2 
expression was found to colocalize with MMP-1. TIMP-2 was also expressed by fibroblasts 
in fibrotic lesions. suggesting that the TWP-2 counteractivity to MMP-1 in fibroblasts may 
promote excessive collagen deposition in pulmonary fibrosis (273). 
In BAL fluid, increased collagenase activity against type-I and -IV collagen and col-
lagen degradation products occurred as early as 3 days post-bleomycin in rats. Peak levels of 
MMP-2 and -9 were demonstrated in BAL fluid in the first week post-bleomycin after which 
MMP-9 almost completely disappeared while MMP-2 gradually declined (275). Maximum 
basement membrane degradative activity coincided with the onset of alveolar epithelial cell 
proliferation one week after bleomycin. Therefore. it was suggested that basement mem-
brane-bound growth factors may be released by MMPs and then stimulate epithelial cell 
regeneration (275). Other studies have confirmed that both MMP-2 and MMP-9 may play an 
important role in the reepithelialization of the injured alveoli after bleomycin (276. 277). 
Different MMPs may regulate the epithelial repair at different levels of the airways (276). 
Several in vitro studies support a role for different MMPs in the reepithelialization 
process after injury. In vitro wound repair has been shown to require MMP-9 to facilitate 
bronchial epithelial cell ntigration (278. 279). In addition to MMP-2 and MMP-9. MMP-7 
has also been implicated in the repair of airway epithelium after injury. It was demonstrated 
that human tracheal epithelium required MMP activity. likely due to MMP-7. to ntigrate and 
reepithelialize wounds in tracheal explants. Furthermore. wounds in tracheas from MMP-7 
knock-out mice showed no evidence of epithelial migration. and wound opening did not 
change during the study period (280). MMP-1 is known to be required for keratinocyte 
migration during epidermal repair and has also been shown to facilitate in vitro alveolar 
epithelial repair by facilitating cell ntigration on type-! collagen (281, 282). 
In ntice it has been demonstrated that intraperitoneal injection of bleomycin induced 
MMP-2 and metalloelastase (MMP-12) gene expression and that this remained elevated for 
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a long period (283). In this study. no effect of bleomycin was found on MMP-13. MMP-3 and 
MMP-9 gene expression. However. others did find increased MMP-9 gene expression after 
bleomycin (276. 283). Bleomycin had the strongest effect on MMP-12 gene expression. 
which was paralleled by a marked elevation of mRNA encoding type-! procollagen and 
TIMP-1 (283). Increased TIMP-1 mRNA expression in lung tissue after bleomycin has been 
confirmed by others and was demonstrated to be restricted to areas of lung injury (276. 284). 
Additionally. lung extracts of bleomycin-treated mice contained increased metalloproteinase 
inhibitory activity and BAL fluid of bleomycin treated mice showed increased TIMP-1 and -
2 protein levels (284 ). 
Recently. it was demonstrated that administration of the synthetic MMP inhibitor bati-
mastat reduced bleomycin-induced puhuonary fibrosis in mice and limited the increase in 
MMP-2 and MMP-9 activity as well as TIMP-1 in BAL fluid (285). Batimastat did not 
reduce the bleomycin-induced increase in TGF-~ but did inhibit the influx of inflarmuatory 
cells (285). These data indicate that MMPs are involved in the modulation of tissue inflam-
mation and remodeling. However. in MMP-9 knockout mice. the bleomycin-induced pul-
monary fibrosis and inflarmuatory cell influx were not inhibited. Thus MMP-9 does not seem 
to play an essential role in the initiation or evolution of the inflarmuation and fibrotic changes 
after bleomycin (276). In a model of immune complex-mediated acute alveoli tis in wild-type 
and MMP-2 and MMP-3 knock-out mice it was demonstrated that both MMP-2 and MMP-3 
were involved in the pathogenesis of the acute lung injury. Only MMP-3 appeared to be 
involved in the recruitment of neutrophils into the lung (286). 
Other animal models of acute lung injury and fibrosis. such as hyperoxia-induced lung 
injury and experimental silicosis have also been shown to be associated with an upregulation 
ofMMP-2. MMP-9. MMP-13 and TIMPs. It was suggested that an imbalance in the expres-
sion of MMPs and TIMPs contributed to the lung injury and fibrosis (287. 288). Indeed. 
decreased collagenolytic activity in lung tissue has been found to be associated with the phase 
of active fibrogenesis (i.e .. collagen accumulation) in animal models of lung fibrosis (289). 
In adult patients with fibrosing lung disease increased collagenase activity has been 
detected in BAL fluid. and was associated with the alveolitis (290. 291). Studies by Sehuan 
et al. confirm that increased BAL collagenase or collagenolytic activity indeed might reflect 
the presence of activated inflammatory cells in the lavage fluid or the inflammatory stage of 
the disease. Increased BAL collagenase or collagenolytic activity not necessarily reflects the 
collagen turnover that occurs in the parenchymal ECM during active fibrogenesis. In contrast 
to BAL fluid. collagenolytic activity in lung tissue from patients was decreased when there 
was a predominance of fibrosis over inflarmuation when compared to control lung (289). 
Furthermore. it was demonstrated that the collagenolytic activity decreased in patients with 
hypersensitivity pneumonitis who deteriorated (with risk of pulmonary fibrosis). compared to 
patients with hypersensitivity pneumonitis who improved or healed (289). Although the iden-
tity of the MMPs contributing to the determined activity remained unclear in these studies. 
the higher rates of MMP activity in control tissue suggest that stromal cells rather than the 
inflarmuatory cells are the source of the MMP activity. These findings support the hypothe-
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sis that decreased local collagenolysis may be a crucial event in the development of pul-
monary fibrosis. Fibrotic lung tissue has been demonstrated to contain increased collagenase 
inbibitory activity and fibroblasts isolated from fibrotic lungs have a diminished capacity to 
synthesize MMP-1 resulting in an increased TIM.P/MMP-1 ratio with decreased col-
lagenolytic activity as a consequence (289. 292). 
Fukuda et al. demonstrated immunolocalization of MMP-1 in interstitial cells present 
in fibrotic foci. They also demonstrated that interstitial cells (predominantly myofibroblasts) 
stained intensely for TIM.P-2 in irreversible lung fibrosis (idiopathic pulmonary fibrosis). 
while interstitial cells of reversible lung fibrosis (bronchiolitis obliterans organizing pneu-
monia) stained predominantly for MMP-1 (62). These data have been commned by others 
and suggest that decreased collagenolytic activity, due to increased TIMP expression, con-
tributes to ECM deposition in progressive pulmonary fibrosis (62. 63. 293). Furthermore. 
increased expression of MMP-1. MMP-2. MMP-8. MMP-9. MTI-MMP. TIMP-1. TIM.P-2. 
TIM.P-3 and TIM.P-4 has been demonstrated in regenerating alveolar epithelial cells. myofi-
broblasts. alveolar macrophages. inflammatory cells. interstitial cells. endothelial cells. and 
smooth muscle cells. MMPs and TIM.Ps have also been detected in association with the ECM 
(61-63). 
BAL fluid from patients with fibrosing lung disease has been demonstrated to contain 
increased levels ofMMP-2 and MMP-9 (63. 252.253.293. 294). These MMP-2 and MMP-
9 levels correlated with the presence of basement membrane degradation products. 
Furthermore. MMP-2 levels correlated with the number of lymphocytes and MMP-9 levels 
with the number of neutrophils in BAL fluid (252. 253. 293). 
In vitro studies have suggested a role for MMPs in the migration ofT lymphocytes 
across the basement membrane (295). Another in vitro study demonstrated that activated neu-
trophils secrete MMP-9 and elastase. and use these enzymes to migrate across the basement 
membrane (296). This suggests that neutrophils can be considered as an important source of 
MMP-9 in fibrosing lung disease. Alveolar macrophages may also be an important source of 
MMP-9 as these cells were found to secrete increased amounts of MMP-9 in pulmonary 
fibrosis (294 ). In addition to MMPs. increased levels of TIMP-1 have been detected in BAL 
fluid from patients at risk of developing pulmonary fibrosis (252. 253. 294). 
Altogether these data suggest an important role for MMPs in basement membrane 
degradation. inflammatory cell infiltration. epithelial repair processes and disordered ECM 
remodeling in pulmonary fibrosis. 
2.2. Pulmonary fibrosis in bronchopulmonary dysplasia 
Besides a large number of studies that have demonstrated histological evidence of col-
lagen deposition in the lungs of infants who died because ofBPD (discussed in chapter 1.3.) 
several studies have examined the collagen content of the lungs from these infants. These 
studies will be discussed hereafter. In addition. the little information available on fibrogenic 
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mediators in the pathogenesis of BPD will be discussed. 
2.2.1. Collagen in the lungs of infants with BPD 
Increased hydroxyproline levels. implicating increased collagen levels. have been 
reported in the lungs from infants with RDS and BPD compared to age-matched controls 
(297. 298). Cherukupalli et al. found a decrease in type-Vtype-III collagen ratios in the lungs 
from infants with BPD (298). This decrease implies a relatively increased synthesis of type 
III collagen. which is in concordance with biochemical and immunohistochemical studies of 
early fibrosis in the adult human lung (8. 41. 42). In addition to this. theN-terminal propep-
tide of type-III collagen has been detected in tracheal aspirates and serum from infants at risk 
for the development of BPD. Tracheal aspirate levels of theN-terminal propeptide of type-
III collagen did not correlate with BPD development. while increased serum N-terminal 
propeptide of type-Ill collagen levels were detected when infants developed BPD (299). 
Shoemaker et al.. however. described elevated type-Vtype-III collagen ratios in the lungs 
from infants ventilated because of respiratory insufficiency due to various causes (300). The 
discrepancy between the studies by Shoemaker et al. and Cherukupalli et al. may be due to 
differences in the control and experimental groups. Increased urinary excretion of 
hydroxyproline has been observed in infants with BPD and may also indicate increased pul-
monary collagen synthesis (301). Altogether. these data implicate that there is an altered col-
lagen metabolism in infants with BPD with a resultant increase in total lung collagen. 
2.2.2. Fibrogenic meduaors in the pathogenesis of BPD 
Only few and largely descriptive data are available on fibrogenic mediators in BPD. 
Nothing is known yet about the contribution of fibrogenic mediators to the fibroproliferation 
and fibrogenesis in the pathogenesis of BPD. 
Fibronectin (Fn) is known to stimulate fibroblast proliferation and chemotaxis and 
excessive amounts of Fn have been associated with pulmonary fibrosis (see table 1). 
Decreased levels of Fn in plasma have been shown to be associated with early RDS (302). It 
was demonstrated that Fn was higher in tracheal aspirates at weeks 3 and 4 oflife in infants 
with BPD compared to infants with RDS at I week of life (302). It was suggested that low 
plasma Fn concentrations in early RDS contributed to the pulmonary capillary leak. and that 
high tracheal lavage Fn contributed to the development of pulmonary fibrosis in BPD (302). 
Watts et al. distinguished between plasma Fn (pFn; which is synthesized by the 
liver) and cellular Fn (cFn; which. in the lung. is synthesized by alveolar macrophages. 
epithelial cells. fibroblasts. smooth muscle cells and endothelial cells) in tracheal aspirates 
(303. 304). Despite the structural differences between these two forms ofFn. their biological 
and immunological functions are remarkably similar (304). Watts et al. described increased 
levels of pFn in tracheal aspirates during the first two weeks of life from infants who devel-
oped BPD compared to those who recovered from RDS. suggesting a greater pulmonary 
capillary permeability in infants developing BPD (303). cFn levels in aspirates from infants 
with BPD were also higher in the first rwo weeks of life in comparison with infants who 
recovered from RDS. This suggested that increased synthesis of cFn occurs in the lungs dur-
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ing BPD development and that this excessive Fn could contribute to the development of the 
pulmonary fibrosis in BPD (303). 
Immunohistochemical findings are also suggestive for a role of cFn in the 
development of pulmonary fibrosis in BPD, as it has been demonstrated that the highest cFn 
expression in the BPD lung coexisted with excessive fibroblast proliferation (305). 
TGF-f3. Kotecha et al. found increased levels of both active and total (active+ latent) 
TGF-~1 in BAL fluid in the first week of life in infants who developed BPD compared to 
infants who recovered from the initial RDS and infants who required ventilation for non-pul-
monary reasons (306). Findings for TGF-~1 sintilar to those described by Kotecha et al. have 
been observed in tracheal aspirate fluids (307). Additionally, it has been demonstrated that 
tracheal aspirates from infants who were oxygen dependent at the time of discharge from the 
hospital contained higher levels of active TGF-~ within the first 24 h of life than infants who 
were discharged without oxygen supplementation (308). 
Immunocytochentical analysis of BAL cells with a pan-TGF-~ antibody revealed 
alveolar macrophages and to a lesser extent neutrophils and epithelial cells as potential 
sources for TGF-~ in the pathogenesis of BPD (306). Intense immunoreactivity for TGF-~ 
has been found in alveolar macrophages and myofibroblasts in lung tissue from infants who 
died because of BPD. and myofibroblasts were found to infiltrate alveoli at sites rich in TGF-
~ (309). In addition to TGF-~. increased expression of TGF-a and its receptor (epidermal 
growth factor receptor) has been demonstrated in alveolar epithelium. vascular smooth 
muscle cells and alveolar macrophages in lung tissue from late stage BPD (310). 
En.dothelin-1 is a mediator with both chemoattractant and ntitogenic properties as well 
as a stimulant of fibroblast collagen synthesis and has been associated with pulmonary fibro-
sis (125-128). A role for endothelin-1 has been implicated in BPD development, as increased 
levels were present in tracheal aspirates during the first week of life from infants who subse-
quently developed BPD (311). 
Inflammatory cytokines such as IL-l and TNF-a have clearly been shown to be asso-
ciated with pulmonary fibrosis and have been found to be increased in lung effluent fluids 
from infants who develop BPD compared to resolving RDS. Data on IL-l and TNF-a in BPD 
and their contribution to acute lung injury and fibrosis have been discussed in the section 
"Inflammation in the pathogenesis of BPD" (chapter 1.4.4.) of this thesis. 
So far only limited data is available on the presence of "classical" fibrogenic media-
tors in the pathogenesis of BPD. Furthermore, no data is available on the mechanisms via 
which fibrogenic mediators could be involved in the pathogenesis of BPD. 
2.2.3. Coagulation cascade in the pathogenesis of BPD 
Intravascular and intra-alveolar deposition of fibrin has been described in preterm 
infants with RDS (312, 313). These fibrin deposits are the result of activation of the coagu-
lation system. In concordance with tltis, it has been demonstrated that levels ofTATIII (a sen-
sitive and specific marker of thrombin generation) were increased in the plasma from infants 
with severe RDS compared to infants with ntild to moderate RDS (314-316). Viscardi et al. 
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demonstrated that procoagulant activity. mainly related to tissue factor associated with factor 
VII. was detectable in BAL fluid from infants with both RDS and BPD and did not differ 
from control infants (317). Furthermore. it has been demonstrated in a premature baboon 
model for BPD development that procoagulant activity. mainly due to tissue factor 
associated with factor VII. increased in BAL fluid after 6 and 21 days of hyperoxia compared 
to the first 24 hours of RDS (318). Although there is indirect evidence of thrombin activation 
in the alveolar compartruent during the development of BPD. to date no reports have been 
published on thrombin activity or TATIII in the alveolar compartruent of these infants. 
2.2.4. Matrix metalloproteinases in the pathogenesis of BPD 
Increased levels of the collagenase MMP-8 in tracheal aspirate and BAL fluid within 
the first week of life have been found to be associated with BPD development from RDS 
(319. 320). As opposed to MMP-8. the collagenase MMP-1 was undetectable in BAL fluid. 
obtained during the first 6 postnatal days. from infants with resolving RDS and infants who 
developed BPD (319). Recently. it was demonstrated that oxidative stress increased the 
expression of the gelatinase MMP-9 and the inhibitor TIMP-1 in BAL fluid obtained within 
the first 6 postnatal days of ventilated premature infants. The ratio of MMP-9 to TIMP-1 
levels. however. did not alter with increasing oxygen toxicity. But the methods used in this 
study did not enable the detennination of changes in net enzyme activity (321). It has been 
described that tracheal aspirate levels of both MMP-2 and MMP-9 within the first 5 postna-
tal days were not associated with BPD development from RDS. while low levels of TIMP-2 
were found to be associated with an unfavorable respiratory outcome in ventilated premature 
infants with RDS (320). 
This data suggests the possible involvement of different MMPs and TIMPs in the 
pathogenesis of BPD. Data on MMP expression in BAL fluid during RDS and BPD 
development is still scarce. Also. nothing is known yet about the long-term expression and 
cellular source of different MMPs and TIMPs in the pathogenesis of BPD. 
2.3. Effect of corticosteroid treatment on collagen and fibrogenic medi· 
ators in pulmonary fibrosis and BPD 
Corticosteroids have the capability to directly regulate collagen synthesis by 
fibroblasts via different mechanisms. It has been demonstrated that dexamethasone (Dex) 
reduced collagen synthesis by fibroblasts in vitro and in vivo (322. 323). Such an effect of 
Dex on collagen synthesis by fibroblasts might be species or organ specific. as recent evi-
dence indicated that Dex increased collagen production by human fetal lung fibroblasts (324). 
Furthermore. Dex may decrease the collagenase expression by fibroblasts or influence 
fibroblast proliferation (324-326). 
Several studies have demonstrated that steroids such as methylprednisolone and Dex 
inhibit lung inflammation and pulmonary fibrosis in different animal models (327-330). 
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Corticosteroid treatment is the mainstay of therapy in pulmonary fibrosis. however. the 
response of such patients to corticosteroids is minimal (331 ). Although alveolar macrophages 
from patients with pulmonary f1brosis have been shown to contain glucocorticoid receptors. 
corticosteroid treatment did not alter the secretion of fibroblast mitogens by these cells (332). 
Therefore. it has been suggested that the inability of steroids to suppress the release of 
fibroblast mitogens by alveolar macrophages may account in part for the limited effect of 
steroids in pulmonary fibrosis (332). In patients who did respond to corticosteroid treatment 
a decrease in serum procollagen type-III peptide has been observed (333). This implicates 
that a good response to treatment does interfere with collagen synthesis. 
It has been suggested that corticosteroids may only be effective when there is a major 
inflammatory component associated with the disease state (334). Acute respiratory distress 
syndrome (ARDS) is a rapid fibrosing lung disease characterized by an early inflammatory 
and fibroproliferative phase. The inflammatory phase is increased and persists in non-sur-
vivors with ARDS (335). It has been reported that unresolving ARDS patients with histolog-
ical evidence of dense acellular fibrosis at open lung biopsy do not improve with methyl-
prednisolone treatment. Such treatment was found to be more effective when given early in 
the fibroproliferative phase. before the occurrence of dense acellular fibrosis. In this early 
phase the treatment led to a decrease in plasma and BAL fluid levels of the N-terminal 
propeptides of type-! and -III collagen (336. 337). This antifibrotic action of methylpred-
nisolone was associated with improvement of pulmonary function (337). From this it 
becomes clear that the initiation time of corticosteroid treatment may be crucial for its effect 
on the development of pulmonary fibrosis. 
Dex treatment has been clearly shown to result in a clinical improvement and a 
reduced inflammatory response in the lungs of infants with or at risk of BPD. as has been dis-
cussed in chapter 1.5. of this thesis. However. little is known about the effect of Dex treat-
ment on fibrogenic mediators and fibrosis in the lungs from infants with or at risk of BPD. 
Gerdes et al. demonstrated that Dex treatment did not influence Fn concentrations in BAL 
fluid from infants who had developed or were developing BPD (338). From this study it was 
concluded that Dex treatment may not inhibit the development of pulmonary fibrosis in 
infants with BPD. 
Watts et al. demonstrated that Dex did decrease total Fn, cFn and pFn in tracheal aspi-
rates from infants with BPD who clinically improved and survived (339). Additionally. in 
infants without clinical improvement who died after Dex. Fn levels were three to four times 
greater at start of the Dxm therapy than in the surviving infants. Although the levels of Fn 
decreased in this group after Dex. they remained increased compared to levels in surviving 
infants throughout therapy. A third group of infants initially showed clinical improvement. 
but died. This group had significantly lower levels of Fn at the start of the therapy than the 
survivors had. however. their levels remained unchanged after Dex (339). From this study it 
was suggested that Dex has the potential to decrease the lung production of Fn and thereby 
may limit the ongoing fibrosis in BPD. 
Treatment with Dex or hydrocortisone has been shown to have no effect on the levels 
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of total TGF-~ 1 and biologically active TGF-~ in lung fluids from infants with or at risk of 
BPD (307. 308). This is in concordance with a study by Khalil et al. demonstrating that Dex 
did not alter the increased TGF-~ secretion by alveolar macrophages that were activated in 
vivo by bleomycin-induced injury (180). 
Co et al. demonstrated that Dex treatment of infants with BPD resulted in decreased 
urinary hydroxyproline excretion. indicating decreased collagen synthesis (301). Although 
the assay used in the study by Co et al. was not specific for lung collagen. the authors spec-
ulated that Dex therapy resulted in an overall suppression of collagen synthesis including a 
reduction in pulmonary fibrosis (301). No data are available yet on the effect of Dex treat-
ment on fibroblast activit~ and on the collagen synthesis and accumulation in the lungs from 
infants with or at risk of BPD. Therefore. the effect of Dex treatment on pulmonary fibrosis 
in BPD remains unclear. 
2.4. Concluding remarks 
Pulmonary fibrosis develops after a pulmonary insult followed by tissue injury. sub-
sequent inflammation and a repair attempt. In this process the control of fibroblast function 
is lost. presumably due to an overproduction and sustained presence of fibrogenic mediators 
that may be derived from inflammatory cells. resident lung cells or the blood. Eventually this 
results in excessive fibroblast proliferation and collagen deposition which may lead to BPD. 
So far only limited data is available on the production of fibrogenic mediators and their con-
tribution to fibroblast activation in BPD.In addition. little insight is available on the effect of 
the commonly used Dex treatment on the pulmonary expression levels of fibrogenic 
mediators and progression of fibrosis in BPD. 
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Aims of the studies 
The overall aim of the studies was to increase the insight into the process of fibropro-
liferation and fibrogenesis during the development ofBPD. The studies described in this the-
sis are based on the analysis of BAL fluid from RDS infants with and without subsequent 
BPD development and on immunohistochemical analysis of lung tissue from infants who 
died at different phases of BPD development. In addition. studies were performed in which 
pulmonary fibrosis was induced in rats via intratracheal instillation of the antitumor agent 
bleomycin. 
Fibroblast proliferation is a central process in the development of pulmonary fibrosis. 
In adult patients with fibrosing lung disease it has been demonstrated that BAL fluid con-
tained increased mitogenic activity for fibroblasts as well as increased concentrations of 
fibrogenic mediators. 
Increased numbers of fibroblasts and excessive collagen deposition are hallmarks in 
lung tissue from infants that died with BPD. Increased serum levels of theN-terminal propep-
tide of type-III collagen have been observed in the serum of infants who develop BPD. In 
addition to this. fibrogenic mediators such as fibronectin and TGF-~ have been found 
increased already within the first week of life in the lungs of infants with subsequent BPD. 
These data suggest that increased fibroproliferation and fibrogenesis may already occur with-
in the first week of life in infants who develop BPD. 
In chapter 4 the mitogenic potential of BAL fluid for human fetal lung fibroblasts is 
described. The analyzed BAL fluids were obtained at different postuatal ages from premature 
ventilated infants with resolving RDS and from infants that acquired BPD. Thrombin. which 
exerts a central role in blood coagulation, is a fibroblast mitogen that is present in increased 
levels in the lungs of adult patients with pulmonary fibrosis and in animal models of pul-
monary fibrosis. The presence of fibrin-rich hyaline membranes in the lungs during BPD 
development suggests that extravascular coagulation occurs in the lungs when BPD develops. 
Indeed. procoagulant activity has been demonstrated in BAL fluid from infants with RDS and 
subsequent BPD. However. thrombin activity has never been described in the lungs from pre-
mature infants with RDS and subsequent BPD. Therefore. the presence of active thrombin in 
BAL fluid and its contribution to BAL fluid-induced fibroblast proliferation was determined. 
In addition to thrombin activity in BAL fluid. the thrombin-antithrombin III complex 
(TATIII) was determined as a marker of thrombin generation. 
Dexamethasone (Dex) treatment is commonly used in infants with or at risk of BPD. 
Dex clearly improves pulmonary function in such infants and the effect is probably partly 
established via downregulation of pulmonary inflammation. The effect of Dex treatment on 
fibroblast activity and fibrogenic mediators in the lungs of infants at risk of BPD is unclear 
yet. In chapter 5 the effect of Dex treatment on the BAL fluid mitogenic potential and the 
fibrogenic mediator PDGF-BB are described. As a marker of fibrogenesis in the lungs, the 
N-terminal propeptide of type-III collagen was determined in BAL fluid. To address the 
anti-inflammatory effect of Dex. the cytokine IL-l~ and the inflammatory cell population 
were examined in BAL fluid. 
MMP-1 (interstitial collagenase) is an enzyme capable of degrading the fibrillar col-
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lagens (type-! and -III) that are deposited in the lungs in the case of fibrosis. Studies have 
implicated that dysregulation ofMMP-l activity by its inhibitors TIMP-l and TIMP-2 is like-
ly to contribute to excessive collagen accumulation in the lungs. Furthermore, MMP-1 has 
been implicated in reepithelialization after injury. As the pathology of BPD is characterized 
by excessive pulmonary injury followed by reepithelialization of the injured areas and the 
development of fibrosis. MMP-l may play an important role in BPD development. In chap-
ter 6 the immunolocalization and staining intensity of MMP-l. TIMP-l and TIMP-2 are 
described in lung tissue in different phases of BPD development. 
MMP-2 (gelatinase A) and MMP-9 (gelatinase B) have been described to participate 
in pulmonary fibrotic disorders in both adult patients and animal models. Gelatinases are sug-
gested to play a role in the acute injury phase of lung disease as well as in the regeneration 
of the epithelium after lung injury. It has been described that oxidative stress in newborn 
babies increases both MMP-9 and its inhibitor TIMP-l. The presence and kinetics of expres-
sion of gelatinases in BAL fluid and lung tissue from infants with RDS and subsequent BPD 
are unclear yet. In chapter 7 these aspects were investigated during the first l 0 days of life 
in BAL fluid from infants who did and did not develop BPD. Additionally. the 
immunolocalization of MMP-9 is described in lung tissue from infants who died at different 
phases of BPD development. 
Bleomycin-induced pulmonary injury with subsequent pulmonary fibrosis is a well-
characterized animal model to study the pathogenesis of the fibrotic response in the lungs. 
This model is characterized by recruitment and activation of inflammatory cells and 
increased proliferation and collagen synthesis by fibroblasts. A variety of cytokines and 
growth factors such as IL-l. PDGF. TGF-~1 and thrombin are implicated in the modulation 
of the inflammatory response and in regulating the pathogenesis of the developing pulmonary 
fibrosis. Corticosteroids are the mainstay of treatment in patients with pulmonary fibrosis and 
have been shown to reduce pulmonary fibrosis in the bleomycin model. Short-course Dex 
treatment has been demonstrated to increase survival without BPD in prematurely born 
infants. So far the effect of a short-course Dex treatment on the fibrotic reponse in the lungs 
is unclear. Therefore. we studied whether a three-day course of Dex. initiated three days after 
the induction of lung injury by bleomycin. was able to reduce the developing pulmonary 
fibrosis. In addition. we studied whether the effect of short-course Dex treatment could be 
related to cell proliferation and to the levels of the fibrogenic mediators TGF-~1 • PDGF-AB 
and thrombin in BAL fluid. The results of this study are described in chapter 8. 
In chapter 9. the findings presented in chapters 4 through 8 are discussed in the con-
text of current literature data. In this chapter also suggestions are done for further studies in 
this field. 
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BAL fluid mitogenicity in preterm infants 
Abstract 
Aims: To determine whether bronchoalveolar lavage (BAL) fluid from preterm 
infants with resolving respiratory distress syndrome (RDS) and those developing bron-
chopulmonary dysplasia (BPD) differ in their mitogenic activity for fibroblasts. and if throm-
bin contributes to the mitogenic activity and is detectable in BAL fluid. Methods: Sequential 
BAL (postnatal days 2-14) was obtained from 37 ventilated infants with RDS. Twenty six 
infants developed BPD whereas eleven resolved. BAL fluid mitogenic activity was deter-
mined in a proliferation assay using human fetal lung fibroblasts. The contribution of throm-
bin to the mitogenic activity was determined using the thrombin inhibitor PPACK. 
Furthermore. thrombin levels in BAL fluids were measured using a specific substrate to 
detect thrombin activity and by measuring thrombin-antithrombin III complex (TATIII). 
Results: BAL fluid mitogenic activity was comparable between BPD and RDS (BPD: 33% 
proliferation on d2 to 41% on dl4: RDS: 21% on d2 to 54% on d7). Thrombin inactivation 
by PPACK completely inhibited mitogenic activity in BAL samples obtained from d2 and d4 
(BPD: p < 0.001 on d2 and d4; RDS: p < 0.05 on d4). From d7 onwards. inhibition of throm-
bin only partly reduced (p < 0.05) BPD BAL fluid mitogenic activity. indicating that other 
mitogenic factors contribute as well. Surprisingly. thrombin activity and TATIII were 
decreased in BAL fluid from BPD compared with RDS patients at d2 and d4. Conclusions: 
Our study shows that BAL fluid from infants with and without BPD development is equally 
mitogenic for lung fibroblants and that thrombin is a major mitogen in these samples. This 
study suggests that fibroproliferation occurs early in the lungs of pretenn infants with both 
BPD and RDS and that thrombin may play an important role in these disorders. 
Introduction 
Neonatal respiratory distress syndrome (RDS) is mainly caused by lung immaturity 
with concomitant surfactant deficiency. RDS may resolve (uncomplicated RDS). or progress 
towards bronchopulmonary dysplasia (BPD) also named chronic lung disease of prematurity 
(!). 
Histologically. RDS is characterized by the presence of alveolar and bronchiolar 
fibrin-rich hyaline membranes (2). During the progression towards BPD. excessive fibroblast 
proliferation occurs and hyaline membranes are replaced by fibrous tissue (3). In infants who 
developed BPD. increased levels of fibrogenic growth factors such as transforming growth 
factor-~ 1 (TGF-~ 1 ) and fibronectin have been described in BAL fluid during the first week 
of life ( 4. 5). Furthermore. N-terminal propeptide of collagen type-III. an indicator of colla-
gen type-ill synthesis. is present in lung effluent fluids and increased in serum from infants 
at risk for BPD (6). These data suggest that increased fibroproliferation and flbrogenesis may 
already occur during the first week of life. and play a role in the pathogenesis of BPD. 
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However, still little is known about the nature of mediators involved in these processes. 
The serine protease thrombin plays a central role in the coagulation cascade by con-
verting fibrinogen to insoluble fibrin (7). In addition to its role in haemostasis. thrombin may 
also act as a profibrotic mediator as it has been shown to stimulate fibroblast chemotaxis. pro-
liferation and synthesis of extracellular matrix components as well as the production of fibro-
genic mediators such as platelet-derived growth factor (PDGF) and TGF-~ 1 (8-11). Tbrombin 
activity has shown to be present in BAL fluid from experimental animals and adult patients 
with fibrosing lung disease and to contribute to BAL fluid-induced fibroblast proliferation 
(12. 13). 
It has been demonstrated that vascular blood clotting is activated in infants with RDS 
and that the degree of activation correlated with disease severity (14). In addition. the appear-
ance of intra-alveolar fibrin-rich hyaline membranes during the pathogenesis of RDS/BPD 
implies that extravascular coagulation occurs in the injured lung. Procoagulant activity has 
been shown to be present in BAL fluid when BPD develops (15). However. the presence of 
thrombin activity in BAL fluid during BPD development has never been shown. 
Given the increased presence of markers for fibroproliferation and fibrogenesis in the 
first week of life when BPD develops. we hypothesized that BAL fluid from infants who 
develop BPD contains increased mitogenic activity for lung fibroblasts compared to BAL 
fluid from infants with an uncomplicated course of RDS. In addition. we expected thrombin 
levels to be increased and to contribute to BAL fluid mitogenicity when BPD develops. 
Therefore. in this study we included patients who did and did not develop BPD from RDS. 
BAL fluid. obtained during the first 14 days of life. was examined for mitogenic activity for 
human fetal lung fibroblasts. We determined the presence of thrombin activity in BAL fluid 
and assessed whether thrombin contributed to this mitogenic activity. In addition. as a mark-
er for thrombin generation. we determined the thrombin-antithrombin III complex (TATIII) 
in BAL flnid. 
Materials and methods 
Patients 
Thirty seven prematurely born infants. admitted to the neonatal intensive care unit. 
were included in this study. Inclusion criteria were: (I) gestational age :> 30 weeks and (2) 
requirement for mechanical ventilation on the first day of life because ofRDS. Informed con-
sent was obtained and the study was approved by the local medical ethics committees. Serial 
BAL was performed in a standardized way on postnatal days 2. 4. 7. I 0. and 14. as long as 
the infant remained intubated. BPD was defined as having an abnormal chest radiograph and 
requirement for supplemental oxygen at 28 days oflife (16). 
Bronchoalveolar lavage 
BAL was performed as follows. the infant was placed in supine position with its head 
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turned left. A 5" French straight suction catheter was inserted via the sideway of a 3-way 
endotracheal tube connector. The catheter was placed into wedge position and two aliquots 
of lmllkg of saline were instilled. BAL samples were aspirated into a suction trap using 60 
em H20 negative pressure. The total lavage time was less than 1 min. Samples were put on 
ice immediately and processed within one hour. Samples were centrifuged (1 0 min. 1500 
rpm. 4°C). Thereafter. the fluid fraction was centrifuged for 10 min at 10000 rpm at 4 oc to 
remove debris and stored in aliquots at -80°C. Cell numbers were determined using a haemo-
cytometer. May Griinwald Giemsa staining was performed and cell differentials were deter-
mined by counting 300 cells per cytospin. 
Fibroblast culture and proliferation assay 
The human fetal lung fibroblast cell line HFL-1 (American Type Culture Collection. 
Maryland. U.S.A) was cultured in Dulbecco·s modified Eagle"s medium (DMEM; Bio 
Whittaker Europe, Verviers, Belgium) supplemented with 10% fetal calf serum (FCS; Bio 
Whittaker Europe). 4 mM ultraglutamine-1. antibiotics (penicillin. 100 U/ml and strepto-
mycin. 100 J.Lg/ml), and 15 mM Hepes buffer (Bio Whittaker Europe). Cells were grown in a 
humidified atmosphere of 5% C02 in air at 37°C. Proliferation was assessed by seeding 
fibroblasts (6 x 103 cells per well in 50 J.Ll DMEM containing 0.4% FCS) into 96-well 
microtitre plates and allowing them to adhere for 24 h. BAL fluid was diluted 8 times in 
DMEM containing 0.4% FCS and in DMEM/0.4% FCS containing 2.3 x l0-6 M of the 
thrombin inhibitor PPACK (D-Phenylalanine-Proline-Arginine-Chloromethyl Ketone. 
Dihydrochloride; Calbiochem. Darmstadt. Germany). 50 J.Ll of the 1/8 dilutions ofBAL fluid 
was added in triplicate to the fibroblasts (yielding a final 1/16 dilution of BAL fluid as pre-
liminary experiments showed this to be optimal). As control. fibroblasts were stimulated with 
thrombin (1 U/ml DMEM/0.4% FCS; ICN Biomedicals Inc. Oh) and thrombin plus PPACK. 
After 72 h, the proliferative response was determined using a colorimetric assay based on the 
uptake and subsequent release of methylene blue dye (17). Briefly. medium was aspirated and 
cells were washed with phosphate buffered saline. Cells were fixed with 10% formal saline 
for 112 hand then stained with 1% methylene blue in 0.01 M borate buffer. pH 8.5. Excess 
dye was removed from the plate and bound dye was eluted from the cell layer by the addi-
tion of 100 J.Ll of acidified alcohol (0.01 M HCl-ethanol absolute. 1;1). Absorbance was mea-
sured at a wavelength of 650 nm on a microplate spectrophotometer. Fibroblast proliferation 
was expressed as a percentage change in mean absorbance above that of cells exposed to 
medium containing 0.4% FCS alone. DMEM supplemented with 5% FCS was used as a 
positive control for fibroblast proliferation. Fibroblast proliferation assessed by this assay 
was validated against proliferation assessed by direct cell counting and tritium thymidine 
incorporation and revealed comparable results. 
Analyses of BAL fluid 
Thrombin activity was detemtined using the thrombin specific chromogenic substrate 
Tos-Gly-Pro-Arg-pNA (Sigma. StLouis, MO) (18). Briefly, 25 J.Ll of BAL fluid was diluted 
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in 25 fll Tris-buffered saline (TBS; pH 8.3) and 25 fll BAL fluid was diluted in TBS con-
taining 4 x I Q-6 M of the thrombin inhibitor PPACK. These mixtures were added to a 96 well 
microtitre plate and incubated for 20 min at 37 oc to allow thrombin-PPACK complexes to 
form. Thereafter, 50 fll of lmM Tos-Gly-Pro-Arg-pNA (in 1.5 mM HCL) was added to the 
BAL fluid dilutions and incubated at 37 °C. The optical density (OD) was measured at 405 
ruu for a period of 48 h. During this time period a linear increase in optical density of the BAL 
samples was found (data not shown). Thrombin activity in every BAL sample is expressed as 
an OD value at 405 ruu. which was determined as the difference in OD, measured at 48 h, 
between the BAL sample without and with PPACK. As a control for the assay I x I Q-6 M of 
thrombin (Sigma. St Louis, MO) was also added to the substrate. This resulted in an optical 
density which was never reached by one of the BAL fluid samples. Preincubation of 
thrombin with PPACK resulted in complete inhibition of thrombin activity. 
TATIII levels were determined using a commercially available enzyme immunosor-
bent assay (Kordia Laboratory Supplies. Leiden, The Netherlands). Results were expressed 
as picomolar (pM) TATIII in BAL fluid. 
Active TGF-/31 levels were determined using a commercially available enzyme-linked 
immunosorbent assay (Promega Corp .. Madison, Wis.). Results were expressed as pg/ml 
BAL fluid. 
Statistical Analysis 
Results for BAL fluid-induced fibroblast proliferation within the patient groups are 
presented as median values. Because BAL was performed in a standardized way, we did not 
use a marker of dilution, but expressed measurements per volume unit of BAL fluid as 
recommended by the ERS task force on BALin children (19). Data for measurements in BAL 
fluid are presented as mean values(± SEM) (4). The Mann-Whitney U test was used to com-
pare between groups. The effect of thrombin inhibition by PPACK on BAL fluid-induced 
fibroblast proliferation was analyzed using the paired students !-test. Pearson's correlation 
was used to compare the relationship between different parameters determined in BAL fluid 
and parameters in BAL fluid with patient characteristics. A p value < 0.05 was considered 
significant. 
Results 
Patient characteristics 
Seventy BAL procedures were performed in 37 preterm infants. Twenty six infants 
subsequently developed BPD and II recovered from the initial RDS. Infants who developed 
BPD were more immature and had a lower birthweight than those that recovered from RDS 
(table 1). 
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Table 1. Patient characteristics 
Number 
Gestation* 
(weeks) 
Birth weight* 
(grams) 
SurfactantS 
Antenatal steroidsS 
* median value (range) 
BPD 
26 
27.4 
(25.6-29.4) 
930 
(760-1525) 
24 
(92.3%) 
22 
(84.6%) 
$number of patients treated (percentage treated) 
§ p < 0.05 vs BPD 
Bronchoalveolar lavage 
BALfluid mitogenicity in prererm infants 
RDS 
11 
28.3* 
(26.7-30) 
1125* 
(780-1650) 
9 
(81.8%) 
8 
(72.7%) 
For all performed BAL procedures the recovery was 50± 2% (mean± SEM) from the 
initial lavage volume used. No difference in recovery was observed between the different 
groups at the different postnatal ages or within a patient group during the study period. Due 
to extubation. BAL samples from RDS patients were only obtained until day 7. The BAL cell 
population consisted mainly of neutrophils and macrophages of which neutrophils were pre-
dominant (Fig. 1). No significant difference in the number of neutrophils and macrophages 
per m1 BAL fluid was observed between RDS and BPD. and the number of neutrophils 
remained relatively constant during the study period (Fig. lA). In contrast an increase in the 
number of macrophages per ml BAL fluid was observed in the BPD group. but not in the 
RDS group during the study period (Fig. !B). 
BAL fluid-induced fibroblast proliferation 
All BAL fluids. apart from one (BPD day 2). stimulated fibroblast proliferation above 
media control levels. In the BPD group the median BAL fluid-induced fibroblast prolifera-
tion ranged from 33% on day 2 to 41 % on day 14. In the RDS group median BAL fluid-
induced fibroblast proliferation ranged from 21% on day 2 to 54 % on day 7 (Fig. 2). 
Although the mitogenic activity of BAL fluid from the BPD group tended to be greater than 
that of the RDS group at postnatal day 2. no statistical significant difference was observed at 
any time-point between the BPD and RDS group. 
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45 A 
0 RDS II BPD 
4 7 
postnatal age (days) postnatal age (days) 
Figure 1 
The number (mean± SEM) of neutrophils (A) and m:1crophages (B) per ml BAL fluid at different postnat:ll ages in 
RDS and BPD group. ** p < 0.05 compared to postnat:ll day 2. n represents the number of patients in each group at 
the different postnatal ages. Due to unavailability of cell differentials from some samples. no value for BPD at a post~ 
natal age of 14 days is shown. 
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The effect of a 1/16 dilution of BAL fluid on fibroblast proliferation per individual at postnatal ages of 2, 4. 7. 10 
and 14 days. Bars represent median values within each group (o = RDS. • = BPD). 
Inhibition ofBALf/.uid-inducedfibroblast proliferation by PPACK. Thrombin (I U/ml) 
induced fibroblast proliferation was completely blocked by PPACK (data not shown). 
PPACK inhibited the fibroblast mitogenic activity of BAL fluid in 16 of the 17 BPD samples 
on day 2. This resulted in significant inhibition (p < 0.00 I) of fibroblast proliferation to media 
control levels. PPACK inhibited day 4 BAL fluid-induced fibroblast proliferation in all 14 
BPD samples. For the whole group this resulted in significant inhibition (p < 0.001) down to 
control levels. Comparable to day 2 some BAL fluid samples retained mitogenic activity after 
addition of PPACK. PPACK inhibited day 7 BAL fluid-induced fibroblast proliferation in 8 
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out of 12 BPD samples. resulting in a significant inhibition (from 40% to 23 %proliferation: 
p < 0.05) for the whole group (Fig. 3). PPACK inhibited day I 0 BPD BAL fluid-induced pro-
liferation in 2 out of 4 samples without reaching statistical significance for the whole group 
(from 40% proliferation without PPACK to 30% with PPACK). In contrast, PPACK 
inhibited proliferation from all 5 day 14 BPD samples. resulting in a reduction of prolifera-
tion from 41% to 31% (p < 0.05) for the whole group. 
In the RDS group, PPACK inhibited day 2 BAL fluid-induced fibroblast proliferation 
in 5 out of 9 samples. resulting in a reduction of proliferation from 21% to 17% for the whole 
group (not significant). PPACK blocked BAL fluid-induced fibroblast proliferation in all day 
4 RDS samples. resulting in inhibition of proliferation (p < 0.05) down to media control 
levels for this group. Inhibition of BAL fluid-induced fibroblast proliferation with PPACK 
was not attempted for the day 7 RDS samples because there were only 2 samples available. 
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Figure3 
The effect of the thrombin inhibitor PPACK on BAL fluid-induced fibroblast proliferation from BPD patients with 
a postnatal age of 7 days. Lines represent individual BAL fluid samples with and without PPACK. Bars represent 
median values. 
Analyses of BAL fluid 
Thrombin activity. Day 2 RDS samples contained increased thrombin activity com-
pared to BPD (p = 0.06). Thrombin activity in day 4 samples from infants with resolving RDS 
was significantly (p < 0.05) increased compared to the BPD group (Fig. 4). Thrombin activ-
ity in BAL fluid significantly increased (p < 0.05) in the BPD group with increasing age. to 
a level comparable with the RDS group at all examined time-points (Fig. 4 ). 
To determine whether the lower thrombin activity in the BPD group was related to rel-
ative immaturity of these infants compared to infants with resolving RDS. we determined the 
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correlation between thrombin actlV!ty in day 2 BAL samples witb tbe gestational age. 
Thrombin activity in day 2 samples showed a significant positive correlation with 
gestational age (r = 0.463; p < 0.05). 
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Figure 4 
Thrombin activity (mean value± SEM) in BAL fluid at different postnatal ages in RDS and BPD group. * p < 0.05 
compared to BPD; ** p < 0.05 compared to postnatal day 2. n represents the number of patients in each group at the 
different postnatal ages. 
TATIII. Antithrombin 1TI (ATITI) is a naturally occurring inhibitor of thrombin which 
inactivates thrombin by forming a thrombin-antithrombin 1TI complex (TATITI). TATITI has 
been used as a biochemical marker of thrombin generation (20). BAL fluid from infants witb 
resolving RDS at postnatal days 2 and 4 revealed increased levels of TATITI compared to tbe 
BPD group at tbese ages. However, tbe difference in TATITI was not statistically significant 
(day 2: p = 0.16 and day 4: p = 0.06: Fig. 5.). As for thrombin activity, TATITI in BAL fluid 
increased significantly during BPD development reaching a maximum at day 10 (Fig. 5.) No 
correlation was found between TATITI levels in day 2 BAL fluid and gestational age. TATITI 
was determined in a total of 64 BAL samples. In these samples TATITI levels correlated 
positively witb thrombin activity (r = 0.616: p < 0.001: Fig. 6). 
Active TGF-/31. Active TGF-~1 has been described to be increased in BPD BAL fluid 
obtained during tbe first week of life compared to RDS BAL fluid, and to gradually decline 
with increasing age (4). To compare the samples in our patient groups with this previous 
study we determined active TGF-~1 in a total of 54 BAL fluid samples. Active TGF-~ 1 was 
elevated in BPD BAL fluid at postnatal day 4 compared to tbe RDS group at this age but 
declined thereafter (Fig. 7). No correlation was observed between active TGF-~1 levels and 
thrombin activity or TATITI levels. Furthermore, no correlation was observed between tbe 
concentration of active TGF-~ 1 in BAL fluid from postnatal day 2 witb gestational age. 
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Figure 5 
TATIIT level (mean value± SEM) in BAL fluid at different postnatal ages in the RDS and BPD group. ** p < 0.05 
compared to postnat:l.l day 2. n represents the number of patients in each group at the different postnat:l.l ages. Due 
to shortage of BAL fluid TATIII was not determined in day 7 RDS samples. 
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Figure 6 
Correlation between BAL fluid TATIII levels and thrombin activity in 64 BAL fluid samples. 
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Figure 7 
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Active TGF~~ 1 levels (mean value± SEM) in BAL fluid at different postnatal ages in RDS and BPD group. n 
represents the number of patients in each group at the different postnatal ages. Due to shortage of BAL fluid TATI~ 
II was not determined in day 7 RDS samples. 
Discussion 
In our study we found no difference in mitogenic activity of BAL fluid between the 
BPD and RDS groups in the first week of life. Acute lung injury begins with an inflanunato-
ry phase that is followed by a repair phase. It is generally accepted that orderly repair involves 
the migration and proliferation of endothelial cells. epithelial cells and fibroblasts (21. 22). 
Therefore. it is likely that the mitogenic activity in BAL fluid from infants with resolving 
RDS is a normal physiological response to the initial lung injury and presumably contributes 
to repair. We were not able to obtain samples from resolving RDS after 7 days of age for 
ethical reasons. Therefore. it is not possible to draw definite conclusions regarding the like-
lihood that prolonged mitogenic activity in the lungs from patients with BPD plays an impor-
tant role in driving the fibrotic response in these patients. Nevertheless. the observation that 
BAL fluid from patients with BPD contained significant mitogenic activity to a postnatal age 
of 14 days makes it tempting to speculate that prolonged mitogenic activity in the lungs may 
result in chronic fibroblast activation leading to excess fibroblast proliferation. thereby con-
tributing to the development of fibrosis in BPD. 
PPACK inhibited BAL fluid-induced fibroblast proliferation in only 5 out of 9 day 2 
RDS samples. indicating that factors other than thrombin are present and contribute to pro-
liferation. PPACK inhibited BAL fluid-induced fibroblast proliferation in all (except one) 
BAL samples from the BPD group at postnatal ages of 2 and 4 days and the RDS group at 
day 4. In the majority of the samples PPACK completely inhibited mitogenic activity. indi-
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eating that thrombin is a major fibroblast mitogen present in these samples. Although PPACK 
attenuated BAL fluid-induced fibroblast proliferation in BPD patients from l week of age. 
remarkable fibroblast mitogenicity remained present in these samples. This indicates that 
mitogenic factors other than thrombin become important from l week of age when BPD 
develops. Alveolar macrophages play an important role in pulmonary fibrosis as producers of 
fibroblast mitogens such as PDGF. insulin like growth factor (!OF) and tumor necrosis fac-
tor (TNF)-a (21). We observed an increase in alveolar macrophages in BAL samples from l 
week of age in the BPD group. Therefore. it is likely that these alveolar macrophages pro-
duce and secrete fibroblast mitogens which contribute to BAL fluid-induced fibroblast pro-
liferation from postnatal day 7 onwards. 
Although thrombin clearly contributed to BAL fluid mitogenicity at postnatal ages of 
2 and 4 days in the BPD group. we surprisingly found that these samples contained .lower 
thrombin activity than the RDS samples. There are four possible explanations for these find-
ings. First. BAL fluid at postnatal days 2 and 4 from BPD patients may contain increased 
amounts of factors that synergistically increase the proliferative effect of thrombin present in 
BAL fluid compared to the RDS group. Indeed it has been demonstrated that the presence of 
basic fibroblast growth factor (bFGF) is essential for thrombin to exert its full mitogenic 
effect (23). It is therefore possible that factors like bFGF are present in the BPD samples to 
enhance the proliferative effects of the relative low thrombin levels. Second. thrombin pres-
ent in BAL fluid. may upregulate the autocrine production of factors by fibroblasts that syn-
ergistically increase fibroblast proliferation induced by a factor present in BPD BAL fluid 
only. Third. BAL fluid from BPD patients may and from RDS patients may not upregulate 
the number of thrombin receptors on fibroblasts and in such a way increase the mitogenic 
effect of thrombin. TGF-~ 1 • TNF-a and interleukin-1~. which are present in elevated levels 
in BAL fluid when BPD develops. have been shown to upregulate thrombin receptor expres-
sion (24). Fourth. it has been described that thrombin is able to release growth factors from 
the peri-cellular matrix (25). Therefore. thrombin may release factors from the peri-cellular 
matrix of the fibroblasts that influence the proliferative activity of these cells. 
TATIII levels in BAL fluid during BPD development revealed comparable kinetics as 
thrombin activity in BAL fluid. and a positive correlation between TATIII and thrombin 
activity was observed. TGF-~1 levels in BAL fluid revealed the opposite of thrombin activi-
ty and TATIII as it tended to be increased in the BPD group at day 4 and decreased thereafter 
towards postnatal day 14. Our results for TGF-~ 1 are comparable to those described by 
Kotecha et al. (4) although they failed to reach statistical significance at day 4 between BPD 
and RDS patients. possibly due to the small patient number in our study. Importantly. no cor-
relation was observed between TGF-~1 with either thrombin activity or TATIII levels. 
Therefore. it is unlikely that the differences in thrombin activity and TATIII between BPD 
and RDS are due to dilutional differences of the BAL samples. 
We found a positive correlation between BAL fluid thrombin activity and gestational 
age. This is consistent with the notion that the most premature infants maybe less effective in 
generating thrombin in the bronchoalveolar compartment than older patients. It is known that 
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term neonates have a mild coagulation deficiency at birth and that premature neonates have 
a more definite deficiency which becomes more severe with increasing prematurity (26). The 
generation of active thrombin requires the conversion of the zymogen prothrombin into 
active thrombin via the activation of the coagulation cascade. It has been described that pro-
thrombin mRNA in the liver and prothrombin plasma levels rise with increasing gestation 
(27-29). Conversion of prothrombin to thrombin in the lung is primarily generated via the 
extrinsic pathway of coagulation (30). Parameters of the extrinsic pathway of coagulation. 
such as factor VII and X increase in plasma with increasing gestational age (31-33). In the 
extrinsic pathway a complex of tissue factor-factor VII activates factor X. Activated factor X 
is involved in the conversion of prothrombin to active thrombin. Viscardi et al. described the 
presence of procoagulant activity due to activation of factor X by tissue factor-factorVII in 
BAL fluid from both RDS and BPD patients. But they did not find a difference in BAL fluid 
factor X activating activity between RDS and BPD (15). However. the patients used were less 
premature (gestational age$ 34 weeks) than the patients used in our study (gestational age,; 
30 weeks) and there was no difference in gestational age between RDS and BPD groups. In 
our BPD group the gestational age was significantly lower compared to the RDS group. 
Therefore. we speculate that the lower thrombin activity in the BPD group compared to the 
RDS group at the postnatal ages of 2 and 4 days may be explained by a more immature 
coagulation system in the BPD group. The increase in thrombin activity during BPD 
development may then be explained by disease associated persistent pulmonary vascular leak 
and gradual development of the coagulation system as the infants become older. 
Alternatively, Brus et al. demonstrated activation of the coagulation system in plasma ofRDS 
patients and additionally demonstrated that the degree of activation correlated with RDS 
severity (14). Therefore. it is likely that prothrombin consumption is increased in the vascu-
lar system from infants with subsequent BPD compared to self-resolving RDS. Such 
increased prothrombin consumption in the vasculature would leave smaller amounts of pro-
thrombin available to be converted to thrombin in the alveolar compartment from infants with 
subsequent BPD. 
Increased thrombin activity in BAL fluid from the resolving RDS group compared to 
the BPD group in our study may indicate a role for thrombin in normal repair after acute lung 
injury. Interestingly, Schmidt et al. have shown that treatment with antithrombin in preterm 
infants who suffer from RDS significantly prolonged the duration of mechanical ventilation 
and supplemental oxygen (34). This indirectly also suggests a role for thrombin in the restora-
tion of normal lung function in premature infants after acute lung injury. 
In conclusion. our study shows that BAL fluid from infants with developing BPD and 
uncomplicated RDS contains mitogenic activity for human fetal lung fibroblasts, and that 
thrombin is a major mitogen present in these samples. This suggests that fibroproliferation 
occurs early in the lungs of preterm infants with both BPD and RDS and furthermore that 
thrombin may play an important role in these disorders. 
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Dex treatment increases BALjluid mitogenicity 
Abstract 
Pulmonary fibrosis results from excessive fibroblast proliferation and increased colla-
gen deposition and occurs in bronchopulmonary dysplasia (BPD). Platelet-derived growth 
factor (PDGF)-BB is mitogenic for fibroblasts and is increased in fibrotic lung disorders. 
Systemic dexamethasone (Dex) treatment improves pulmonary function and reduces inflam-
mation in infants with or at risk of BPD. However. the effect of Dex treatment on fibroblast 
activity. PDGF-BB and collagen synthesis in lungs from BPD patients is uncertain. We ana-
lyzed BAL fluids obtained before and after Dex treatment from 15 infants at risk of BPD. for 
fibroblast mitogenicity. PDGF-BB. N-terminal-propeptide of collagen type-III (P!IINP). 
IL-l~ and inflammatory cells. BAL fluid-induced fibroblast proliferation significantly 
increased after Dex treatment. The change in mitogenicity correlated with a change in BAL 
fluid PDGF-BB levels. Furthermore. BAL fluid-induced fibroblast proliferation was blocked 
using a specific inhibitor of the PDGF-receptor. Dex treatment did not influence the levels of 
PIIINP. but did reduce IL-l~ levels and inflammatory cell numbers in BAL fluid. This study 
implies that Dex treatment might promote fibroproliferation despite an apparent downregu-
lation of inflammation. Therefore. Dex treatment may not inhibit the development of 
pulmonary fibrosis and contribute to persistent BPD. 
Introduction 
Neonatal respiratory distress syndrome (RDS) is characterized by pulmonary inflam-
mation with neutrophils and macrophages as the main cell types (1. 2). RDS can progress 
towards bronchopulmonary dysplasia (BPD). also known as chronic lung disease of prema-
turity. Risk factors for the development of BPD include premature birth with concomitant 
lung immaturity. mechanical ventilator-induced lung injury. oxygen toxicity. and pulmonary 
inflammation (3). 
Pulmonary fibrosis is characterized by excessive fibroblast proliferation and increased 
collagen deposition (4) and is a common feature in infants dying because of BPD (5). 
Increased pulmonary levels of fibrogenic mediators such as fibronectin and transforming 
growth factor-~ 1 • which increase proliferation and collagen synthesis by fibroblasts have 
been associated with BPD development (6. 7). 
Treatment with systemic dexamethasone (Dex) is commonly used in infants with or at 
risk of BPD and improves pulmonary function. facilitates weaning from the ventilator. and 
reduces pulmonary inflammation (8). However. it has been suggested that Dex treatment may 
not inhibit the development of pulmonary fibrosis in BPD. as it did not decrease fibronectin 
concentrations in bronchoalveolar lavage (BAL) fluid (6). On the other hand. Dex treatment 
of BPD infants resulted in decreased urinary excretion of hydroxyproline. indicating sup-
pressed collagen synthesis in these infants (9). However. the specific effect of Dex treatment 
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on lung collagen synthesis during BPD development remains unclear, as urinary excretion of 
hydroxyproline reflects total body collagen synthesis. 
BAL fluid from adults with acute respiratory distress syndrome. who are at risk of pul-
monary fibrosis, is mitogenic for lung fibroblasts in vitro, indicating the presence of soluble 
mitogens (10). Platelet-derived growth factor (PDGF)-BB is a potent mitogen for fibroblasts. 
and increased pulmonary levels are associated with pulmonary fibrosis (4). Additionally. 
PDGF-BB has been shown to contribute to BAL fluid-induced fibroblast proliferation in an 
animal model of bleomycin-induced acute lung injury (II). It has been reported that expres-
sion of PDGF-B mRNA by alveolar macrophages. which are considered as an important 
source of PDGF in the development of pulmonary fibrosis. is upregulated by Dex (12). 
Because excessive fibroblast proliferation is a central event in the pathogenesis of 
pulmonary fibrosis and may be driven by PDGF. we studied if Dex treatment influenced the 
fibroblast mitogenic activity of BAL fluid from infants at risk of BPD. Additionally. the 
effect of Dex treatment on PDGF-BB levels in BAL fluid was exaruined. To analyze the 
effect of Dex treatment on pulmonary collagen synthesis we determined the N-terminal-
propeptide of type-III collagen (PIIINP) as a marker for collagen type-Ill synthesis and pul-
monary fibrosis (13). To determine the anti-inflammatory effect of Dex. interleukin (IL)-1~ 
and BAL cells were exaruined. 
Methods 
Patients and Dex regimen 
Included were fifteen ventilated preterm infants with a gestational age < 30 weeks. 
Criteria for inclusion were: I) ventilator dependency because of RDS. and 2) treatment with 
Dex because of risk of BPD development. Informed consent from the parents and approval 
by the local medical ethics committees were obtained. All infants received 0.5 mg!kg per day 
of Dex sodium-phosphate. administered intravenously in two doses for three days. This was 
followed by 0.3 mg!kg per day in two divided doses for an additional three days. after which 
the Dex dose was weaned over the next 2 to 4 weeks. BPD was defined as having an 
abnormal chest radiograph and oxygen dependency at 28 days of age (14). 
Bronchoalveolar lavage 
BAL was performed as described by Grigg. using two aliquots of I mi saline per kg 
bodyweight (15) within 24 hours prior to initiating Dex treatment and between 24-72 hours 
after initiation of treatment. or just before weaning from the ventilator whichever occurred 
first. The recovered volume was determined and BAL fluid was stored at -80°C until analy-
sis. Cell numbers were determined using a haemocytometer. May Griinwald Giemsa staining 
was performed on cytospin preparations and cell differentials were determined by counting 
300 cells per cytospin. 
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Fibroblast proliferation assay 
The human fetal lung fibroblast cell line HFL-1 was cultured in Dulbecco's modified 
Eagle's medium (DMEM) supplemented with I 0% fetal calf serum (FCS), 4 mM ultragluta-
mine-L antibiotics (penicillin, I 00 U/ml and streptomycin, I 00 !-lg/ml), and 15 mM Hepes 
buffer. BAL fluid-induced fibroblast proliferation was determined using a colorimetric assay 
based on the uptake and subsequent release of methylene blue dye (16). Briefly, fibroblasts 
were seeded (6 x J03 cells per well) into 96-well microtitre plates in DMEM/0.4% FCS and 
allowed to adhere for 24 h. A 1116 dilution of BAL fluid in DMEM/0.4% FCS was used to 
determine the effect on fibroblast proliferation. as dilution experiments revealed this to be the 
optimal dilution to stimulate proliferation. Proliferation was determined after 72 h and 
expressed as percentage change in mean absorbance above that of cells exposed to 
DMEM/0.4% FCS only. DMEM/5% FCS was used as a positive control. The assay was 
validated by direct cell counting and tritium thymidine incorporation. 
Analyses of BAL fluid 
PDGF-BB was determined with an enzyme-linked immunosorbent assay (ELISA) 
(R&D Systems, Abingdon, UK). PIIINP was determined using a radioimmunoassay (Orion 
diagnostica, Espoo, Finland). IL-l~ was determined by ELISA (Human Il-l~ cytosettm, 
Biosource International. Camarillo. CA). Assays were performed according to the 
methodology of the manufactors. The detection limits were 4.6 pg/ml, 0.2 /.lg/L and 1.6 
pg/ml for PDGF-BB, PIIINP and IL-l~, respectively. Concentrations below the detection 
limit were interpreted as< detection limit. No marker for dilution was used, and PDGF-BB, 
PIIINP and IL-l~ levels in BAL fluid are presented as volume concentration, according to 
the most recent ERS task force gnidelines on BALin children (17). 
Inhibition of BAL fluid-induced fibroblast proliferation 
Tyrphostin AG 1296 is a compound that specifically inhibits the platelet-derived 
growth factor receptor tyrosine kinase, thereby inhibiting PDGF induced proliferation (18). 
After adherence of the cells for 24 h, the medium was changed to DMEM/0% FCS for 6 h. 
Thereafter, fresh DMEM/0% FCS containing 30/.lM of the tyrphostin AG1296 (Calbiochem, 
Darmstadt, Germany) in vehicle (dimethylsulfoxide (DMSO)) or vehicle alone was added for 
another 18 h. Medium was replaced by BAL fluid (known to contain PDGF-BB) in 
DMEM/0.4% FCS for 48 h (three replicates per BAL fluid sample for AG1296 and vehicle 
alone). As control. HFL-1 pre-incubated with AG1296 or vehicle were stimulated with 50 
ng/ml PDGF-BB (R&D Systems, UK). 
Statistical analysis 
Patient characteristics and BAL cell-values are presented as mean values ± standard error of 
the mean (SEM). Results for fibroblast proliferation, PDGF-BB, PIIINP and ILl~ are pre-
sented as median values and range. The paired students t-test was used for comparison 
between values obtained before and after initiation of Dex treatment. Pearson's correlation 
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was used to compare the relationship between BAL fluid ntitogenic activity and PDGF-BB 
concentrations. A p value < 0.05 was considered to indicate statistical significance. 
Results 
Patients and Dex regimen 
The patients (n=l5) had a gestational age of 27.2 ± 0.3 weeks (ranging from 26-30 
weeks) and a birthweight of972.6 ± 66.2 gram (ranging from 650-1529 gram). Dex treatment 
was initiated at an age of 18.3 ± 2 days after birth (ranging from 7-33 days). All patients 
responded to the Dex therapy as they were extubated within days after initiation of treatment. 
However. despite treatment. all patients developed BPD. 
Bronchoalveolar lavage 
BAL was performed at 2.3 ± 0.2 days after initiation of Dex treatment (ranging from 
1-3 days). BAL-recovery was deterntined before and after initiation of treatment. No differ-
ence was observed in BAL-recovery before and after initiation of Dex ( 40.1 ± 5.2 and 33.9 
±4.2% of the initial lavage volume used. respectively). Table I shows the results of cell num-
bers and composition of the cell population obtained by BAL. The total number of cells as 
well as the number of cells per ml BAL fluid was significantly decreased after Dex treatment. 
Percentages of neutrophils and macrophages in the cell population were not influenced by 
Dex treatment. However. absolute numbers of macrophages per ml BAL fluid decreased 
significantly after Dex. The number of neutrophils per ml BAL fluid also declined after Dex. 
however. without reaching significance. 
Table 1. Effect of Dex treatment on cell population in neonatal lung lavage 
patients (n=l5) 
total# cells obtained by BAL (x106) 
total# cells/ml BAL fluid (x106) 
% macrophagcs in BAL fluid 
% neutrophils in BAL fluid 
total# macrophageslml BAL fluid (xJ06) 
total# ncutrophils/ml BAL fluid (x106) 
* = mean ± standard error of the mean 
$=p<0.05 
before .initiation of Dex* 
1.39 ± 0.31 
1.74 ± 0.39 
43.7 ± 5.8 
48.6 ± 6.0 
0.7 ± 0.16 
0.93 ± 0.27 
106 
after initiation of Dex* 
0.51 ± 0.07S 
0.9 ± 0.26S 
39.8 ± 6.4 
47.3 ± 7.0 
0.28 ± 0.06S 
0.54 ± 0.23 
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BAL fluid-induced fibroblast proliferation 
For the whole group of patients. BAL fluid-induced fibroblast proliferation increased 
from 34.7% (7.7-75.3% proliferation above medium control) before Dex to 51.2% (17.8-
115.1 %) after initiation ofDex treatment (p < 0.05). From the fifteen patients. twelve showed 
an increase and three a decrease in BAL fluid-induced fibroblast proliferation after the initi-
ation of Dex treatment (Fig. lA). Interestingly. the three patients with decreasing BAL fluid 
mitogenicity contained the highest mitogenic activity before initiation of Dex. When 
fibroblast proliferation was expressed relative to the 5% FCS similar results were obtained 
(data not shown). 
Analyses of BAL fluid 
A summary of the analyses per individual BAL sample is presented in table 2. Dex 
treatment did not influence the PDGF-BB concentration in BAL fluid from the fifteen 
patients before and after Dex (11.8 ( < 4.6-92.9 pg/ml BAL fluid) compared to 27 ( < 4.6-80.4 
pg/ml BAL fluid. respectively). However. when the mitogenic activity of BAL fluid from 
patients (n=3) decreased after Dex. it was accompanied by a decrease in PDGF-BB levels. 
From the twelve patients with increased mitogenic activity after Dex. ten showed an increase 
in PDGF-BB levels after Dex. one patient showed a minimal decrease and one had unde-
tectable PDGF-BB levels before and after Dex (Fig. !B). A statistically significant positive 
correlation was observed between the change in PDGF-BB levels in BAL fluid and the change 
in BAL fluid-induced fibroblast proliferation after initiation ofDex treatment ( r = 0.7; p < 0.01). 
A 1)<0.05 B 
120 100 
• • 
:::::- 100 
'0 80 
c e ., 
g§ = 
80 -" ~0 <( 
.l'>E 
"' 
60 c; .::! ~ """ 60 o.m ;;E s 
!!!~ 
"' 
40 
-"o 40 "' e.o u.
-"• 
"' = t 0 20 a. 20 
• 
before Dex afterDex 
0 
before Dex 
Figure 1 
The effect ofBAL fluid (1116 diluted) on fibrobl:lSt proliferation for each individual (lA), twelve patients show an 
increase in BAL fluid mitogenic activity after Dex. and three patients a decrease. Horizontal bars represent median 
values. lB depicts PDGF-BB concentrations in BAL fluid before and after Dex treatment. Horizontal bars represent 
median values. The three patients with a decrease in BAL fluid mitogenic activity after Dex (lA) also show a 
decrease in PDGF-BB levels mter Dex (lB). From the twelve patients with increasing mitogenic activity (lA) ten 
have increased PDGF-BB levels after Dex, one has a minimal decline in PDGF-BB after Dex. and in one patient 
PDGF-BB was undetectable before and after Dex treatment (lB). When PDGF-BB was undetectable in a BAL 
sample it is depicted as 4.6 pg/ml BAL fluid. which is the detection limit of the used assay. 
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Table 2. Analyses of BAL fluid per individual patient 
Fibroblast 
proliferation 
(% above ctrl) 
patient before aftec 
Dex Dex 
I 38.9 50.0 
2 23.3 38.3 
3 42.6 58.1 
4 45.9 II5.! 
5 7.7 40.3 
6 19.5 60.8 
7 20.5 30.2 
8 34.7 94.4 
9 46.0 79.2 
10 28.3 80.8 
II 8.3 17.8 
12 12.1 44.2 
13 66.2 51.2 
14 75.3 57.6 
15 62.2 31.3 
median 34.7 51.2$ 
range 7.7- 17.8-
75.3 115.1 
-$ p < 0.05 compared to before Dex 
n.d. = not determined 
PDGF-BB 
(pg/ml BAL fluid) 
before after 
Dex Dex 
15.2 46.1 
15.1 12.3 
II.8 42.1 
<4.6 29.7 
< 4.6 80.4 
<4.6 20.9 
37.1 39.1 
II 30.4 
12.6 22.8 
9.3 27.0 
<4.6 <4.6 
10.5 57.5 
74.0 19.7 
13.6 <4.6 
92.8 <4.6 
II.8 27 
<4.6~ < 4.6~ 
92.8 80.4 
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PIIINP IL-l~ 
(Mg/L BAL fluid) (pg/ml BAL flu;d) 
before aftec before aftec 
Dex Dex Dex Dex 
n.d. n.d. 52.3 26.1 
n.d. n.d. n.d. n.d. 
7.7 16.2 n.d. n.d. 
n.d. n.d. n.d. n.d. 
7.6 215 78.8 68.2 
51.2 18.2 < 1.6 < 1.6 
43.1 25.9 23.2 5.3 
12.3 23.2 n.d. n.d. 
9.5 6.6 30.7 < 1.6 
n.d. n.d. 48.9 < 1.6 
9.5 6.6 n.d. n.d. 
n.d. n.d. n.d. n.d. 
9.5 6.8 31.8 < 1.6 
24.5 6.0 30.7 < 1.6 
11.4 6.3 n.d. n.d. 
10.5 II.S 31.3 < 1.6$ 
7.6- 6.0- < 1.6- < 1.6-
51.2 215 78.8 68.2 
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PIIINP levels were detennined in BAL fluid from ten patients (based on sample avail-
ability). Dex treatment did not significantly change the levels of PIIINP in these ten patients 
(10.5 (7.6-51.2 ~giL BAL fluid) before Dex compared to ll.5 (6-215 ~giL BAL flnid) after 
Dex). 
Due to limited amounts of BAL flnid. IL-l~ levels were investigated for eight 
patients. A significant decrease ofiL-1~ levels in BAL fluid was observed after Dex treat-
ment (31.3 ( < 1.6-78.8 pg/ml BAL fluid) before Dex compared to ( < 1.6 ( < 1.6-68.2 pg/ml 
BAL fluid) after Dex: p < 0.05). Seven patients showed decreased IL-l~ levels after com-
pared to before Dex treatment. in one patient IL-l~ was undetectable before and after Dex 
treatment. 
Inhibition of BAL flnid-induced fibroblast proliferation 
To determine whether PDGF-BB contributed to BAL fluid-mitogenicity. the PDGF 
receptor system in fibroblasts was blocked by using the specific inhibitor AG1296. AG1296 
was able to inhibit BAL fluid-induced fibroblast proliferation and to block PDGF-BB 
induced proliferation (Fig. 2). AG 1296 had no effect on HFL-1 proliferation after 48 h in 
DMEM containing 0.4% FCS compared to pre-incubation with vehicle alone. 
Figure 2 
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Tyrphostin AG1296 blocks PDGF-BB (50 ng/ml) and BAL fluid-induced fibroblast proliferation as indicated by a 
reduction in optical density after methylene blue elution. Results for three BAL samples from three individual 
patients (denoted 1-3) are depicted in this graph.*= p < 0.05 
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Discussion 
Pulmonary fibrosis is a feature of BPD (5), and is a consequence of excessive 
fibroblast proliferation and increased collagen synthesis (4). PDGE is a potent proliferative 
stimulus for mesenchymal cells such as fibroblasts and known to be involved in pulmonary 
fibrosis (4). PDGF is composed of two polypeptide chains, termed A and B, and may exist 
as either one of the homodimers or as a heterodimer ( 4 ). Although it is known that Dex treat-
ment of infants with or at risk of BPD improves pulmonary function, and decreases pul-
monary inflammation (8) and total body collagen synthesis (9, 19). the effect on lung 
fibroblast proliferation, pulmonary collagen synthesis and PDGF levels in infants at risk of 
BPD is uncertain. 
As reported previously (8. 20), our study demonstrates an anti-inflammatory effect of 
Dex, reflected by a reduction in IL-l~ levels and inflammatory cells in BAL fluid. A novel 
fmding, however, is that the mitogenic activity of BAL fluid from premature infants at risk 
for pulmonary fibrosis, increases after treatment with systemic Dex and that this increase is 
associated with an increase of PDGF-BB levels in these patients. In our study three patients, 
with a relatively higb BAL fluid mitogenicity before initiation of Dex treatment, showed a 
decrease in BAL fluid mitogenicity after Dex. In contrast, twelve with a relatively low BAL 
fluid mitogenicity before Dex showed an increase after Dex. The observed change in BAL 
fluid mitogenicity and PDGF-BB levels after Dex treatment did not correlate with surfactant 
treatment. antenatal steroids. type of ventilation. birth weight or gestational age (data not 
shown). 
In animal models of acute lung injury and pulmonary fibrosis increased expression of 
PDGF-B mRNA and PDGF-BB protein preceded DNA synthesis and tissue repair (lL 2L 
22). Additionally, PDGF-BB has been shown to contribute to fibroblast mitogenic activity of 
BAL fluid. and inhibition of PDGF-BB reduces pulmonary fibrosis in experimental models 
(I L 23). In line with this is the correlation we found in our study between the change in BAL 
fluid-induced fibroblast proliferation and the concomitant change in PDGF-BB levels before 
and after Dex treatment. This suggests that the increase in PDGF-BB is, at least partly, 
responsible for the observed increase in BAL fluid-induced fibroblast proliferation after Dex 
treatment. Furthermore, we demonstrated that PDGF indeed contributed to BAL fluid-
induced fibroblast proliferation as blocking the PDGF-receptor system in fibroblasts reduced 
BAL fluid-induced proliferation. Therefore, PDGF may be an important fibroblast mitogen 
in the pathophysiology of BPD. However, other mitogens are likely to contribute as well 
since blocking the PDGF receptor system did not completely inhibit the BAL fluid mitogenic 
activity. 
Alveolar macrophages are considered as a main source of PDGF in pulmonary fibro-
sis and increased numbers are present in the pathogenesis of BPD (2, 4). In our study, the 
BAL cell population obtained from infants prior to Dex treatment contained considerable 
numbers of alveolar macrophages that can be considered as a potential source of the 
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detected PDGF-BB. It has been demonstrated that macrophages stimulated with Dex express 
increased amounts of PDGF-B mRNA. secrete increased amounts of PDGF protein. and 
stimulate fibroblast proliferation and collagen synthesis (12. 24). Although we found that the 
number of alveolar macrophages decreased after Dex treatment. it may well be that this treat-
ment increases the net production of PDGF-BB per cell. This could result in increased total 
PDGF-BB levels in the bronchoalveolar compartment. resulting in increased fibroblast pro-
liferation. Activation of such a pathway may result in a profibrotic environment in the lungs 
from infants with or at risk ofBPD and therefore Dex may not inhibit the development of pul-
monary fibrosis in these infants. However. Dex itself may also influence fibroblast activation. 
as it has been reported that Dex stimulates the proliferation of rat lung fibroblasts in vitro. 
presumably by increasing the expression of the PDGF-a receptor (25). In vitro studies with 
Dex in primary human fetal lung fibroblasts. however. revealed reduced proliferation and 
increased collagen synthesis (26). Increased pulmonary vascular leak is a pathogenetic hall-
mark of BPD development (3). It is therefore possible that. in our study. leakage of Dex from 
the vascular compartment into the alveolar space has occurred. As a consequence of such 
leakage. Dex may have been present in the BAL samples obtained after Dex treatment and 
may have influenced BAL fluid-induced fibroblast proliferation. However. we found that 
Dex itself was unable to stimulate fibroblast proliferation in our culture system. Furthermore. 
the addition of the glucocorticoid antagouist RU 38486 to BAL fluid obtained after Dex treat-
ment did not influence BAL fluid-induced fibroblast proliferation and neither did the addi-
tion of Dex to BAL samples obtained before Dex treatment (data not shown). Therefore. it is 
unlikely that if Dex was present in BAL fluid that it influenced the observed BAL fluid-
induced fibroproliferation. 
In vitro experiments have shown that Dex reduces collagen synthesis by fibroblasts 
(27. 28). However. recent evidence indicates that Dex increases collagen synthesis by human 
fetal lung fibroblasts (26). Interestingly. Chen et al. demonstrated that prenatal Dex 
administration with prolonged exposure of preterm rats to hyperoxia resulted in a pulmonary 
pathologic picture similar to BPD. and with even greater severity of septal fibrosis compared 
to hyperoxia exposed control rats (29). As it is likely that postnatal Dex administration may 
exert comparable effects these data make the possible effect of Dex on pulmonary collagen 
synthesis in BPD uncertain. We observed no difference in PIIINP levels before and after Dex 
treatment, indicating that Dex treatment does not influence collagen synthesis in the lungs 
from infants at risk of BPD. However. the fact that no difference was observed may be due 
to the limited number of patients and great variability in PIUNP levels. which has also been 
shown to exist for PIIINP levels in BAL fluid from adult patients with acute respiratory 
distress syndrome (10). Alternatively. an effect ofDex on PIIINP levels may be obscured due 
to drainage of PIIINP from the lung by lymph vessels (30). 
We suggest that Dex treatment of infants at risk of BPD does not decrease the 
development of pulmonary fibrosis. presumably due to increased PDGF-BB driven pul-
monary fibroblast proliferation with increased collagen synthesis as a consequence. We can 
not exclude that the observed differences of the determined parameters in BAL fluid before 
Ill 
Chapter 5 
and after Dex treatment are just the natural course of the disease. as no control patients were 
included in this study. Because of the variation in initiation of Dex treatment in our patient 
population (7-33 days after birth) and the fact that both centers find it unethical to withdraw 
patients who are at risk of BPD from Dex treatment we did not include a placebo control 
group. However, regarding the expected and observed anti-inflammatory effects ofDex treat-
ment and the heterogeneity of initiation of Dex treatment, the effects on BAL fluid mito-
genicity and PDGF-BB levels are likely to be due to Dex treatment and not to reflect the 
natural disease course. 
In conclusion. our study implies that Dex treatment ntight promote fibroproliferation 
despite an apparent downregulation of inflammation. and therefore may not inhibit the 
development of pulmonary fibrosis and contribute to persistent BPD. 
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MMP-1. T1MP-1 and T1MP-2 localization in BPD 
Abstract 
Bronchopulmonary dysplasia (BPD) can evolve in prematurely born infants who 
require mechanical ventilation because of hyaline membrane disease (HMD). The 
development of BPD can be divided in an acute. a regenerative. a transitional. and a chronic 
phase. During these different phases, extensive remodelling of the lung parenchyma. with 
reepithelialization of the alveoli and formation of fibrosis occurs. Matrix metalloproteinase-1 
(MMP-1) is an enzyme that is involved in reepithelialization processes, and dysregulation of 
MMP-1 activity contributes to fibrosis. Localization of MMP-1 and its inhibitors, tissue 
inhibitor of metalloproteinase (TIMP)-l and TIMP-2. were investigated in lung tissue 
obtained from infants who died during different phases of BPD development. In all studied 
cases (n=50) type-IT pneumocytes were found to be immunoreactive for MMP-L TIMP-L 
and TIMP-2. During the acute and regenerative phase of BPD, type-II pneumocytes 
reepithelialize the injured alveoli. This may suggest that MMP-1 and its inhibitors, expressed 
by type-II pneumocytes. play a role in the reepithelialization process after acute lung injury. 
Although MMP-1 staining intensity remained constant in type-II pneumocytes during BPD 
development. TIMP-1 increased during the chronic fibrotic phase. This relative elevation of 
TIMP-1 compared with MMP-1 is indicative for reduced collagenolytic activity by type-II 
pneumocytes in chronic BPD and may contribute to fibrosis. Fibrotic foci in chronic BPD 
contained fibroblasts immunoreactive for MMP-1 and TIMP-l and -2. This may indicate that 
decreased collagen turnover by fibroblasts contributes to fibrosis in BPD development. 
Introduction 
Respiratory distress syndrome develops within minutes after birth in premature infants 
and is associated with surfactant deficiency of the immature lung (I, 2). Pathologically. it is 
called hyaline membrane disease (HMD). with the formation of hyaline membranes in the 
terminal airways being one of the most striking pathologic features (3). 
Hyaline membrane formation is caused by necrosis and desquamation of epithelial 
cells lining the alveolar basement membrane and the occurrence of pulmonary edema (3-5). 
To sustain life. infants are treated with mechanical ventilation and supplemental oxygen, 
which are both risk factors for the progression of HMD toward bronchopulmonary dysplasia 
(BPD) (6). 
BPD, also called chronic lung disease of prematurity, can be regarded as the end stage 
of HMD treatment and is associated with mortality and long term pulmonary morbidity (6. 
7). The development from HMD to BPD is characterized by extensive tissue remodelling and 
can be divided into four phases based on days after birth: acute (2-4 days). regenerative (4-8 
days). transitional (8-16 days), and chronic(> 16 days) (8). A main feature of the acute and 
regenerative phase is reepithelialization of the denuded alveoli. The transitional and chronic 
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phases are characterized by alveoli primarily lined with type-11 pneumocytes and the 
occurrence of fibrotic areas and increased numbers of fibroblasts (3. 9. 10). 
During the reepithelialization process. hyaline membranes form a matrix on which 
type-II pneumocytes adhere and regenerate. This process incorporates hyaline membranes 
into the alveolar septal waiL Incorporated hyaline membranes. which contain fibronectin, are 
associated with areas of fibrosis during BPD development (9. I I. 12). 
Matrix metalloproteinases (MMPs) are a group of enzymes capable of degrading 
extracellular matrix proteins. MMPs play a critical role in normal physiological processes 
like development. tissue remodelling. inflammation, angiogenesis. wound healing. and cell 
migration (13). The expression of MMPs is regulated at the transcriptional level by cytokines. 
growth factors. and extracellular matrix components (14. 15. 16). MMPs are secreted as latent 
pro-enzymes and require proteolytic cleavage for activation. MMP-1 is capable of degrading 
the fibrillar collagens- type-I. -II. and -ill. collagen type-X. gelatin and proteoglycans (17). 
In vitro studies have shown that type-II pneumocytes. the cells that initiate alveolar 
reepithelialization. are able to produce MMP-1 and thereby promote their own migration (18. 
19). Therefore. MMP-1 may play a role in the reepithelialization process of the alveoli 
during the acute and regenerative phase of BPD development. comparable with the role for 
MMP-1 in reepithelialization of the skin after injury (20. 21). Tissue inhibitors of matrix met-
alloproteinase (TIMP)-1 and TIMP-2 inhibit active MMP-1 (22). It was shown that disturbed 
MMP-1. TIMP-1. and TIMP-2 regulation plays an important role in pathologic processes like 
fibrotic liver disease and pulmonary fibrosis (23-26. 27). 
Therefore. we expect MMP-1. TIMP-1. and TIMP-2 to contribute to the remodelling 
process of lung tissue when HMD progresses toward BPD. This urged us to study the 
immunohistochemical localization of MMP- I. TIMP- I. and TIMP-2 in lung tissue obtained 
from infants who died during different phases of BPD development. 
Materials and methods 
Patients 
Autopsy lung specimens were selected in the files of the department of Pathology 
from the years 1988-1998. based on premature infants who were histologically and clinical-
ly diaguosed as HMD/BPD. HMD was clinically defined as respiratory distress for which 
ventilation was necessary and a pulmonary x-ray pattern compatible with HMD (28). All 
patients were still on oxygen when they clied. Therefore. per definition all patients that died 
after 28 days fulfilled the clinical BPD definition accorcling to Bancalari (29). Staging of the 
histologic samples was performed according to Rosan (8). In total. 50 prematurely born 
infants with pathologic findings of BPD or HMD. who died of respiratory insufficiency were 
selected (all patients before 1990 (n=l2) died because of respiratory insufficiency alone: after 
1990. 26 infants died because of respiratory insufficiency alone: in the other 12 patients 
respiratory insufficiency coexisted with heart failure or intraventricular hemorrhage). 
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As controls. specimens were taken from three term infants who died of nonpulmonary caus-
es and lived for 9. 14. and 30 d. respectively. 
Immunohistochemistry 
Paraffin embedded lung tissue was cut into 4 J..lill sections. incubated overnight at 
37°C. deparaffinized. and rehydrated. Afterward, the slides were washed in phosphate-
buffered saline (PBS. pH 7 .8) for 5 min and incubated with 0.1% pepsin A (Sigma Chemical 
Company. StLouis. MO. U.S.A.) in O.OlM HCl for 30 min at 37°C for antigen retrieval. The 
slides were subsequently rinsed in PBS of 4 oc for 5 min, followed by blocking of endoge-
nous biotin activity with an avidin/biotin blocking kit (Vector Laboratories. Burlingame. CA. 
U.S.A.). Afterward. the slides were rinsed for 15 min in PBS followed by 10 min in PBS con-
taining 0.2% Tween 20. The slides were then incubated for 5 min with PBS containing 1% 
bovine serum albumin (BSA) followed by a 1 h incubation with PBS containing 1% BSA and 
10% normal human serum (NHS). This was followed by rinsing the slides for two times 5 
min in washbuffer (PBS containing 0.1 %BSA and 0.2% Tween 20). Subsequently. the slides 
were incubated for I h with 10% normal goat serum diluted in PBS containing I% BSA for 
MMP-1 and TIMP-2 staining or 10% normal rabbit serum diluted in PBS containing l% BSA 
for TIMP-1 staining. Then the slides were incubated with the primary antibodies diluted in 
PBS containing l% BSA and 10% normal goat or rabbit serum (mouse anti-human MMP-1; 
1:200 dilution. mouse anti-human TIMP-2: 1:20 dilution. ICN Biomedicals. Aurora. Ohio. 
and goat anti-human TIMP-1; 1:40 dilution. Santa Cruz Biotechnology. Santa Cruz, CA. 
U.S.A.) overnight at 4°C. Afterward. the slides were rinsed for 5 min in washbuffer. which 
was followed by two wash steps of 15 min. Subsequently. the slides were incubated for 30 
min with biotin-labeled goat-anti-mouse (Biogenex. San Ramon. CA. U.S.A.) or rabbit-anti-
goat (DAKO, Glostrup. Denmark) at a l :50 and l :20 dilution in PBS containing l% BSA and 
10% NHS. respectively. Then the slides were rinsed for 5 min followed by two times 15 min 
in washbuffer. This was followed by incubating the slides for 30 min with a I :50 dilution of 
Streptavidin-alkaline-phosphatase (Biogenex) in PBS containing l% BSA. Afterward, the 
slides were rinsed once 5 and once 15 min with washbuffer and rinsed for 5 min in 0.2M Tris-
HCl (pH 8.0). Subsequently. the slides were incubated for 30 min with New Fuchsin substrate 
(Chroma, Stuttgart, Germany). Finally the slides were rinsed with PBS. counterstained with 
Mayers hematoxylin (Merck. Darmstadt, Germany) and mounted in Kaiser's glycerol 
(Merck). Control staining was performed by substitution of the primary antibody with PBS. 
R.R.d.K. and L.B. performed the evaluation of the stained sections in a blinded fashion. The 
cells and structures examined in this study were the alveolar macrophage, the alveolar type-
[[ pneumocyte. the alveolar basement membrane. and fibroblasts in fibrotic foci. The stain-
ing intensity of the sections was scored in a semiquantitave manner according to the follow-
ing method: no staining = 0. diffuse very faint staining = 1, diffuse faint staining = 2. diffuse 
moderate staining = 3. and diffuse strong staining = 4. 
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Statistical analysis 
Data on staining intensity are presented as median and percentiles (10 to 90%) for the 
different phases of BPD development. For evaluation of differences in staining intensity 
between different phases of BPD development the Mann-Whitney U test was used. A p value 
less than 0.05 was considered significant. 
Results 
Patients 
BPD is considered as a gradually developing sequel of the original diagnosed HMD 
(acute phase of BPD development) and its treatment (8). Therefore, we applied the time 
phases for BPD development, according to Rosan, to the patient group (8). Twenty seven 
patients were included in the acute phase (0-4 d), seven in the regenerative phase (5-8 d), nine 
in the transitional phase (9-16 d), and seven in the chronic phase (>16 d). The control patients 
were regarded as one group, independent of their age at death. Clinical data of the different 
phases of BPD development and of control patients are shown in table 1. 
Table 1. Clinical data of BPD and control patients 
BPD stage gestational age at death weight at death male : female number of patients 
age (weeks)* (days)* (kilograms)* 
Acute phase 28.9 (24.9-36) 2 (0.08-4) 1.1 (0.58-3.0) 2:1 27 
Regenerative phase 25.6 (25-30) 6 (5-8) 1.1 (0.56-1.4) 4:3 7 
Transitional phase 27.9 (26.3-30) 13 (9-16) 1.1 (0.77-1.7) 7:2 9 
Chronic phase 28 (25-31.7) 35 (21-304) 1.1 (0.85-5.0) 6:1 7 
Controls term 14 (9-30) 2.9 (2.9-3.7) 1:2 3 
* Median value (range) 
MMP-1, TIMP-1 and TIMP-2 expression. 
An overview of the immunohistochemical detection for MMP-1. TlMP-1. and 
TIMP-2. presented as positive or negative immunoreactivity. is shown in table 2. 
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Acute phase Regenerative phase Tmnsitional phase Chronic phase Control tissue 
~H\'lP-1 TiiviP-1 Tli\W-2 i'vfl\·W-1 TIMP-1 TIMP-2 MMP-1 TIMP-1 TIMP-2 MMP-1 1ThW-l Tfl\IP-2 i\1:MP-l TI1-IP-l TllviP-2 
'I)vc-II pneumocytes + + + + + + + + + + + + + + + 
Alyeolar basement + + + + + 
membrane 
~ 
'" Alveolar· macrophages + + + + + + + + + + + + + + + ~
Fibroblasts in fibrotic + + + 
area 
+::: immunoreactivity 
~=no immunoreactivity 
~ 
" 
,... 
:::j 
~ 
'" ~ 
:::j 
~ 
'" 
f ,. 
~ 
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Control lung tissue 
Control lung tissue revealed scattered MMP-1. TIMP-1 and -2 positive type-II pneu-
mocytes and alveolar macrophages. TIMP-1 reactivity was also detected in the alveolar base-
ment membrane (Fig. 1). 
Figure 1 
Immunohistochemical staining of control lung tissue. MMP~l (A). TWP-1 (B). and TIMP~2 (C) immunoreactivity 
is detected in type~ II pneumocytcs (arrow) and alveolar macrophages. TIMP-1 (B) immunoreactivity is detected in 
the alveolar basement membrane (arrowhead). 
Acute phase (0-4 d) 
Lung tissue of the patients who died early in the acute phase ( < I d) was characterized 
by extensive loss of alveolar epithelial cells and the formation of hyaline membranes. 
Because of extensive loss of alveolar epithelial cells. virtually no reactivity with MMP-1. 
TIMP-1. and TIMP-2 was observed in the alveolar epithelium. However, if cuboidal type-II-
like pneumocytes were present. they stained positive for MMP-1. TIMP-1. and TIMP-2. 
During progression toward day 4 in the acute phase. the lung tissue showed hyaline mem-
branes covering cells positive for MMP-1. TTh1P-1. and TTh1P-2. Furthermore. regenerating 
epithelial cells positive for MMP-1. TIMP-1. and TIMP-2 epithelialized the hyaline mem-
branes. incorporating them into the alveolar septum. In most cases a clear positive staining 
for TIMP-1 was localized to the alveolar basement membrane, which was observed under-
neath epithelial cells as well as underneath hyaline membranes. Alveolar macrophages 
showed no difference in imrnunostaining for MMP-1. TIMP-1. and TIMP-2 compared with 
control lung tissue. 
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Regenerative phase (5-8 d) 
During the regenerative phase hyaline membranes were still present in the tissue and 
clearly became incorporated into the alveolar wall. The incorporated membranes were 
covered by cuboidal type-Il-like pneumocytes that stained positive for MMP-L TIMP-1, and 
TIMP-2 (Fig. 2). In most cases TIMP-1 positivity was also observed in parts of the alveolar 
basement membrane. similar to the situation in the acute phase. Alveolar macrophages pres-
ent in this phase showed a similar positivity for MMP-L TIMP-1, and TIMP-2 as detected in 
the control lung tissue. 
Figure 2 
Immunohistochemical smining of lung tissue in the regenerative phase of BPD development. MMP-1 (A). TlL\1P-1 
(B). :md TIMP-2 (C) immunoreactivity is detected in type-II pneumocytes reepithelializing the alveoli and incorpo-
rating hyaline membranes (arrow). 
Transitional phase (9-16 d) 
During the transitional phase less hyaline membranes were present. If present, they 
were covered with cuboidal type-Il-like pneumocytes. which stained positive for MMP-L 
TIMP-L and TIMP-2. Furthermore. the alveolar surface appeared to be covered exclusively 
with type-Il-like pneumocytes. which were MMP-L TIMP-L and TIMP-2 positive. Alveolar 
macrophages. which were more frequently present than in the previous stages. also stained 
positive for MMP-L TIMP-L and TIMP-2 (Fig. 3). TIMP-1 immunoreactivity in the 
alveolar basement membrane differed from barely detectable in some patients to prominent 
in others. 
Chronic phase (> 16 d) 
During the chronic phase hyaline membranes were virtually absent. The alveoli 
appeared to be covered exclusively with type-Il-like pneumocytes immunoreactive for 
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Figure3 
Immunohistochemical staining of lung tissue in the transitional phase of BPD development. MMP~l (A), TIMP~l 
(B). and TIMP-2 (C) immunoreactivity is detected in type~II pneumocytes covering the entire alveolar surface 
(arrow) and in alveolar macrophagcs. 
MMP-1. TIMP-1. and TIMP-2. In some cases the alveoli appeared emphysematous. Alveolar 
macrophages also revealed positive staining for MMP-1. TIMP-1. and TIMP-2. During this 
chronic phase. interstitial fibrosis was a prominent feature. Fibrotic areas contained fibroblasts 
positive for MMP-1. TIMP-1. and TIMP-2 (Fig. 4). Immunostaining for TIMP-l in the alve-
olar basement membrane varied from barely detectable in some patients to prominent in oth-
ers. If the primary antibody was omitted no immunoreactivity was detected (Fig. 4D). 
Figure 4 
Immunohistochemical staining of lung tissue in the chronic phase of BPD development. MMP~l (A). TIMP~l (B). 
and TIMP~2 (C) immunoreactivity is detected in fibroblast.<; present in fibrotic foci (arrow) and in type~ II pneumo~ 
cytes covering the entire alveolar surface. 4D is negative controL 
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Semiquantitative analysis of immunoreactivity during BPD development 
Semi-quantitative analysis of immunoreactivity revealed no difference in MMP-1 and 
TIMP-2 staining intensity between the four phases of BPD development. However, TIMP-1 
showed a marked increase in staining intensity in the type-II pneumocytes that formed the 
alveolar lining in the chronic phase of BPD compared with the earlier phases (Fig. 5) . 
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4 
tt 
* 
3 T tt tt ·~ c + 2 ·" 2 ~ c . ., .• 
.. 
0 
acute regenerat1ve tranStt1onal chron1c 
Figure 5 
Semiquantitative an:llysis of MMP-1 and TIMP-1 in type-II pneumocytes during different developmental phases of 
BPD. Results for staining intensity are expressed as median and percentiles (10 to 90%) per group of patients in the 
four different phases of BPD development. Semiquantitative scoring was assessed as follows: no staining = 0. 
diffuse very faint staining= 1. diffuse faint staining= 2, diffuse moderate staining= 3. and diffuse strong staining= 
4. * p < 0.05 compared to acute phase. 
Discussion 
In the present study we investigated the expression pattern of MMP-1 and its 
inhibitors, TIMP-1 and TIMP-2, in the lung during the development of BPD. MMP-1 colo-
calized with TIMP-1 and TIMP-2 in type-IT pneumocytes and alveolar macrophages. TIMP-
1 also localized to the alveolar basement membrane. 
The expression of MMP-L TIMP-L and TIMP-2 by type-11 pneumocytes and 
alveolar macrophages in the healthy lung may play a role in the extracellular matrix turnover. 
which is a constant feature in lung tissue (30, 31). The presence of TIMP-1 in the basement 
membrane may prevent this structure from degradation by MMPs or may provide a barrier 
function for active MMPs to reach the lung interstitium to control extracellular matrix 
turnover. 
After lung injury and during lung development. the type-II pneumocyte is the progen-
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itor cell for the formation of a functional alveolar epithelium (32. 33). Migration of type-II 
pneumocytes over hyaline membrane-like matrices has been suggested to play an important 
role during reepithelialization after acute injury. The o:2~ 1 -integrin on type-II pneumocytes 
mediates the migration on collagen type-!. a substrate for and inducer of MMP-1 production 
(17. 34. 35). Recently. an in vitro srudy described that MMP-1 decreased the type-II pneu-
mocyte cytoskeleton stiffness. the adbesion to collagen type-!. and increased cell migration 
across collagen type-! (19). Regarding these observations and the expression of MMP-1. 
TIMP-1. and TIMP-2 by type-II pneumocytes on hyaline membranes in the acute and 
regenerative phases of BPD development. we speculate that MMP-1 is involved in reepithe-
lialization of the alveolar surface during the acute and regenerative phase of BPD 
development. The colocalization of TIMP-1 and TIMP-2 with MMP-1 indicates that these 
inhibitors regulate the activity of NlJ\IlP-1 during this process. Analysis of lung homogenates 
could reveal information about in vivo MMP-1 activity and the ratio of MMP-lffiMPs. 
Furthermore. the relative amounts of active and latent MMP-1 could be determined. because 
both forms are recognized with the antibody used in this study. 
The saccular stage of fetal lung development is characterized by alveoli mainly lined 
by type-II pneumocytes. During this stage, thinning of the interstitial matrix between alveoli 
occurs. It has been suggested that epithelial cells over-expressing MMP-1 relative to 
TIMP-1 contribute to the net degradation of interstitial collagens during this process (36-39). 
During the transitional and chronic phase of BPD we observed virtually no hyaline mem-
branes and the alveoli were almost exclusively lined by hyperplastic MMP-1. TIMP-1, and 
-2 positive type-II pneumocytes. Furthermore. fibrotic areas in the alveolar septa were clear-
ly present in chronic BPD. Fibrotic areas are characterized by increased numbers of 
fibroblasts and accumulation of fibrillar collagens. mainly collagens type-! and type-III (3, 
40-43). MMP-1 exerts collagenolytic activity against fibrillar collagen. We observed 
increased staining intensity for TIMP-1 in type-II pneumocytes in the chronic phase of BPD 
compared with the earlier phases. whereas no difference in MMP-1 staining intensity in type-
IT pneumocytes was observed. This might result in an increased TIMP-1/MMP-1 ratio lead-
ing to decreased collagenolytic activity by type-II pneumocytes. thereby favoring interstitial 
collagen accumulation (fibrosis) as is observed in chronic BPD and is opposed to normal lung 
development. 
Fibroblasts are the key cells in a fibrotic response. contributing to collagen deposition 
via increased proliferation. increased collagen synthesis, or decreased collagen breakdown 
(44). Lung tissue from patients with idiopathic pulmonary fibrosis has been shown to contain 
decreased collagenolytic activity and lung fibroblasts from these patients show an increased 
ratio of TIMP/MMP-1 compared with normal lung fibroblasts (25, 45). It has been suggest-
ed that co-expression of MMP-1 and TIMP-2 in fibroblasts in fibrotic foci from patients with 
idiopathic pulmonary fibrosis contributes to progressive collagen deposition caused by 
decreased collagenolytic activity. On the other hand, a predominance of MMP-1 in 
fibroblasts in fibrotic foci in bronchiolitis obliterans organizing pneumonia could explain the 
reversibility of fibrotic changes in that disease (27). Our study revealed that during the chron-
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ic phase of BPD. fibroblasts in fibrotic areas were associated with the expression of MMP-1. 
TIMP-l. and TIMP-2. Inhibition of collagen degradation by decreasing the production of 
MMP-1 and increasing the production of TIMPs by fibroblasts has been reported for trans-
fornting growth factor-~ (TGF-~ 1 ) (46). Interestingly, intense immunoreactivity for TGF-~1 
has been shown in alveolar macrophages and fibroblasts in lung tissue during the regenera-
tive and transitional stages of BPD (37). Therefore. during BPD development TGF-~1 
could increase the TIMP/MMP-1 ratio in fibroblasts. This would lead to a decreased 
collagenolytic activity and favors net deposition of collagen by fibroblasts. thereby con-
tributing to fibrosis of the lung tissue. 
In the present study we observed MMP-1 expression in type-II epithelial cells 
reepithelializing the injured alveoli. From the literature there is abundant evidence that 
M?v1P-1 is involved in reepithelialization after injury. Therefore. this may suggest a role for 
MMP-1 expressed by type-II pneumocytes in the reepithelialization process after acute injury 
during the acute and regenerative phase of BPD development. The increase in intensity of 
TIMP-1 relative to MMP-1 in type-II pneumocytes during the chronic phase of BPD ntight 
result in decreased interstitial collagen breakdown. thereby contributing to fibrosis as 
observed in chronic BPD. Furthermore. fibroblasts co-expressing MMP-1 and TIMPs in 
fibrotic areas may contribute to fibrosis in chronic BPD via a decreased collagenolytic activ-
ity. due to an increased TIMP/MMP-1 ratio. 
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Abstract 
Neonatal respiratory distress syndrome (RDS) in ventilated preterm neonates can 
either resolve or develop into bronchopulmonary dysplasia (BPD). Pulmonary inflammation. 
injury. diminished alveolization and fibrosis characterize the disturbed lung development in 
BPD. We analyzed sequential bronchoalveolar lavage (BAL) fluids from infants with 
resolving disease and from those developing BPD for matrix metalloproteinase-2 (MMP-2) 
and MMP-9. These MMPs degrade native type-IV collagen. fibronectin and elastin. and thus 
are likely to play a prominent role in the disturbed lung development in BPD. Unexpectedly. 
MMP-9 levels were increased at postnatal day 2 in BAL fluid from patients with resolving 
RDS compared to patients developing BPD (p < 0.05). After day 4. however, MMP-9 levels 
increased in BAL fluid from BPD patients and exceeded levels as observed in RDS at day 2. 
MMP-2 levels were equal in RDS and BPD and remained constant or showed a small 
increase after day 4 for BPD patients. Immunostaining revealed that the increased levels of 
MMP-9 in RDS and BPD appear to originate from neutrophils and macrophages. and for 
BPD also alveolar type-II epithelial cells. These findings indicate that the difference between 
resolving RDS or developing BPD may be related to the ability to raise an early adequate 
response to the initial injury. 
Introduction 
To save life, preterm infants with neonatal respiratory distress syndrome (RDS) are 
artificially ventilated. RDS can resolve within days after birth (uncomplicated RDS) or 
progress towards bronchopulmonary dysplasia (BPD) (1). BPD is characterized by intersti-
tial fibroplasia. fibrosis and diminished alveolization. The exact mechanism of progression 
from RDS towards BPD is unknown. but involves artificial ventilation. oxygen toxicity and 
inflammation (1-3). 
It has been proposed that proteases degrading components of the extracellular matrix 
(ECM). such as matrix metalloproteinases (MMPs) and neutrophil elastase. may lead to the 
impaired alveolar septation and fibrosis in BPD (2). In line with this proposal. neutrophil 
elastase and matrix metalloproteinase (MMP)-8 (neutrophil collagenase) have both been 
found to be increased in lungs from infants who develop BPD (2, 4 ). Furthermore, we demon-
strated that an imbalance between MMP-1 and tissue inhibitors of metalloproteinases 
(TTh1Ps) correlated with excessive collagen accumulation in the lungs from premature infants 
who died of BPD (5). 
MMP-2 (Gelatinase A) and MMP-9 (Gelatinase B) degrade native type-IV collagen, 
fibronectin, elastin and denatured collagens (gelatin) (6-9). Both MMPs are secreted as latent 
proteases that require proteolytic processing to yield active enzyme (10). Analyses of bron-
choalveolar lavage (BAL) fluid from patients with acute respiratory distress syndrome 
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(ARDS). which has a pathophysiology comparable to RDS. revealed increased levels of 
MMP-2 and MMP-9 ( 11. 12). Oxygen toxicity. one of the risk factors for the development of 
BPD. resulted in increased MMP-2 and MMP-9 levels in an animal model of hyperoxia (9). 
Also. oxidative stress in lungs from newborns was associated with increased MMP-9 levels 
(13). Finally. increased levels ofMMP-2 and MMP-9 were detected in the lungs from patients 
with idiopathic pulmonary fibrosis (14). A causal relationship between fibrosis and MMP-2 
and MMP-9 is suggested from studies in which mice received an intranasal injection of 
bleomycin together with the MMP inhibitor batimastat. This led to inhibition of MMP-2 and 
MMP-9 activity in BAL fluid and prevented the bleomycin induced pulmonary fibrosis (15). 
Therefore. both MMP-2 and MMP-9 are likely to play a role in the pathophysiology of BPD, 
although opposing findings have been reported (16. 17). 
To determine whether MMP-2 and MMP-9 may play a role in the development of 
BPD we examined whether sequential BAL fluids from infants with uncomplicated RDS and 
from infants with developing BPD differed in the expression of MMP-2 and MMP-9. We 
found marked differences for MMP-9 but not for MMP-2. To reveal the possible sources of 
MMP-9 in BAL fluid. BAL cells from uncomplicated RDS and BPD patients and lung tissue 
from BPD patients were analyzed for antigenic MMP-9. 
Materials and methods 
Patients 
Thirty two prematurely born infants, athnitted to the neonatal intensive care unit. were 
included in this study. Inclusion criteria were: (l) gestational age:;; 30 weeks and (2) require-
ment for mechanical ventilation on the first day of life because of RDS. BAL was performed 
on postnatal days 2. 4. 7 and 10. as long as the infant remained intubated. BPD was defined 
as having an abnormal chest radiograph and requirement for supplemental oxygen at a post-
natal age of 28 days (18). Informed consent from parents was obtained. The study was 
approved by the local medical ethics committees. 
Bronchoalveolar lavage 
BAL was performed in a standardized way using 2 times 1 ml saline per kg body 
weight as described before (19). No marker for dilution was used, in accordance with the 
most recent guidelines from the ERS task force on BAL in children (20). The fluid fraction 
was separated from the cellular fraction by centrifugation and stored in aliquots at -80° C until 
analysis. Cell numbers were determined using a haemocytometer. May Grunwald Giemsa 
staining was performed and cell differentials were determined on 300 cells per patient per 
time-point. 
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Zymography 
SDS-polyacrylamide (10%; w/v) gels containing 0.2% (w/v) gelatin (Sigma. StLouis. 
MO) were used to identify proteins with gelatinase activity in BAL fluid. With this method 
even latent MMP-9 and -2 bands show gelatinase activity. After electrophoresis. the gels were 
washed extensively in a solution of 2.5% (v/v) Triton X-100 to remove SDS. and incubated 
overnight at 37°C in Tris-HCl pH 7.5 containing 0.5M CaC\2• 0.02% (w/v) NaN3 and I% 
(v/v) Triton X-100. The gels were stained with PhastGel™ BlueR (Amersham Pharmacia 
Biotech AB; Upsala. Sweden) and destained in a solution of 7% (v/v) acetic-acid and 20% 
(v/v) methanol. Gelatinase activity appeared as a clear band against a blue background. 
Purified MMP-2 and MMP-9 (Roche; Mannheim. Germany) and prestained molecular 
weight marker (Bio-Rad, Richmond. CA) were used to identify the different gelatinase bands. 
The gelatinase activities were quantified using densitometry. Values (arbitrary units (A.U.)) 
were related to a control collagenase (Clostridium histolyticum type lA; Sigma) which was 
run in parallel on every zymogram. Representative zymograms are shown. 
Immunocytochemistry 
Cytospins were fixed with 4% (w/v) paraformaldehyde in PBS. Endogenous peroxi-
dase was blocked by 3% (v/v) hydrogen peroxide in PBS/0.1% (w/v) saponin. Thereafter 
cytospins were blocked with 10% (v/v) normal rabbit serum in PBS/0.1% saponin. followed 
by I h incubation at 37 oc with 1.5 !lg/ml (in PBS/0.1% saponin) goat polyclonal anti-human 
MMP-9 antibody (Santa Cruz Biotechnology. Santa Cruz, Ca), or goat lgG (Zymed, San 
Francisco, Ca) as negative control. Then cytospins were incubated for 30 min at room tem-
perature with a biotin-labeled rabbit-anti-goat antibody (1.6 !lg/ml in PBS/0.1% saponin; 
Dako. Glostrup. Denmark). followed by incubation (30 min at room temperature) with a 
horse-radish peroxidase-labeled streptavidin (Dako; 1/50 dilution in PBS/0.1% saponin). 
Hereafter. an amplification step was performed using the TSA ™ Biotin System (NEN™ 
Life Science Products, Inc .. Boston. MA). Subsequently, cytospins were incubated for 3 min 
with diaminobenzidine (Sigma Fast™ DAB. Sigma). counterstained with hematoxylin 
(Merck Diagnostica, Darmstadt. Germany) and embedded in Kaiser's gelatin glycerine 
(Merck Diagnostica). 
Immunohistochemistry 
Immunohistochemical staining for MMP-9 was performed on 4 !LID lung tissue sec-
tions from infants who died during different phases of BPD development. The same antibody 
and concentration as mentioned in the section immunocytochemistry was used. The method 
used and clinical data from these infants were described before (5). Twenty five infants died 
in the acute phase (0-4 days after birth). seven in the regenerative phase (5-8 d), nine in the 
transitional phase (9-16 d) and seven in the chronic phase (> 16 d). 
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Statistical analyses 
Results are presented as mean ± standard error of the mean (SEM) and were analyzed 
using the Mann Whitney U test. Pearsons correlation was used to examine relations between 
gelatinase bands with BAL cells. gestational age. birth weight and BAL fluid recovery. A 
p value < 0.05 was considered to indicate statistical significance. 
Results 
Patients 
Sixty eight lavage procedures were performed in 32 preterm infants who were initial-
ly ventilated because of RDS. All patients were included before postnatal day 7. Twenty two 
infants subsequently developed BPD and 10 recovered from the initial RDS. Infants who 
developed BPD had a shorter period of gestation and tended to have lower birth weight than 
infants who recovered from RDS (table 1). 
Table 1. Patient characteristics 
BPD (n=22) RDS (n-10) p valueS 
Gestational age* (weeks) 27.1 (25.7-29.4) 28.3 (26.7-30) 0.02 
Birth weight* (g) 958 (720-1525) 1110 (780-1650) 0.1 
* median (range) 
$ Mann \Vhitney U test 
Bronchoalveolar lavage 
Recovery of lavage fluid was 49 ± 2% (mean ± SEM) of the used lavage volume. 
Recoveries did not significantly differ between patient groups and between postnatal ages. 
Due to extubation. BAL samples from RDS patients were obtained only until day 4. The 
number of BAL samples obtained during the different postnatal ages were: day 2: RDS = 9. 
BPD = 13: day 4: RDS = 4, BPD = 18: day 7: BPD = 15: day 10: BPD = 9. The BAL cell 
population consisted mainly of neutrophils and macrophages. of which neutrophils were 
more numerous (Fig. 1). No significant differences in total leukocytes. neutrophil and 
macrophage cell numbers per rnl of BAL fluid were observed between RDS and BPD for 
days 2 and 4. Witltin the BPD group, there was a significant increase in the number of 
macrophages per rnl BAL fluid on postnatal days 4. 7. and 10 as compared to postnatal day 
2. Neutrophils were significantly increased only on postnatal day 10. compared to postnatal 
day 2 (Fig. 1). 
136 
30 A 
2 4 7 10 
postnatal age (days) 
Figure 1 
Number of neutrophils (A) and macrophages (B) per ml BAL fluid from RDS and BPD patients during the study 
period. * p < 0.05 (Mann Whitney U test) compared with day 2. 
Zymography 
Analyses of BAL fluid from RDS and BPD patients revealed several bands with 
gelatin zymography. Most markedly. a 92 and a 135 kDa band were found. representing latent 
MMP-9 and presumably neutrophil-gelatinase B-associated lipocalin (NGAL) associated 
with MMP-9 (NGAL associated with MMP-9. will from here be further indicated as NGAL). 
respectively. Occasionally a 86 kDa and a high molecular weight (-200 kDa) band were 
observed, likely to represent activated MMP-9 and a homodimer of MMP-9. which is resist-
ant to dissociation by SDS. The identity of the MMP-9 bands was confirmed by immuno-
precipitation. using protein A-Sepharose beads. removing MMP-9-anti-MMP-9 complexes 
from the BAL fluid and by Western blotting (data not shown). Finally. a 72 kDa and some-
times a weak 68 kDa band were found. typical of latent MMP-2 and activated MMP-2. 
respectively. 
Comparison of gelatinases in RDS and BPD BAL fluids revealed marked differences 
at postnatal day 2 (Fig. 2) and. to a lesser extent. at day 4 (data not shown). By densitomet-
ric analyses, latent MMP-9 and NGAL were shown to be significantly increased at postnatal 
day 2 in BAL fluid from patients who recovered from RDS (Fig. 3). In contrast. latent 
MMP-2 was detected equally in BAL fluid from both RDS and BPD patients at postnatal 
days 2 and 4. The amount of NGAL showed a weak but significant correlation with the num-
ber of neutrophils per ml BAL fluid (r = 0.448; p = 0.04). but did not correlate with 
macrophage or total white blood cell numbers per ml BAL fluid. The amount of latent 
MMP-9 showed no significant correlation with the total number of white blood cells or the 
number of neutrophils and macrophages per ml BAL fluid. There was a significant correla-
tion between the amount of NGAL and latent MMP-9 (r = 0.931; p < 0.001). No statistical-
ly significant correlation was observed between latent MMP-9 and NGAL with gestational 
age. birth weight or BAL recovery. After day 4, particularly amounts of latent MMP-9 and 
NGAL increased substantially in BAL fluid from BPD patients to levels higher than seen for 
MMP-9 and NGAL in RDS patients at day 2 (compare Figure 4A with Figure 2A). while 
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Figure 2 
Zymograms ofRDS and BPD BAL fluid samples from postnatal day 2. Lane I is collagenase control. Lanes 2~5 are 
BAL samples from individual patients. I MMP-2 is latent MMP~2. 
1 MMP~9 is latent MMP-9, NGAL is neutrophil gclatinase B-associated lipocalin associated with MMP-9. 
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Figure 3 
Densitometric analyses of latent MMP-9 (A) and NGAL (B) in postnatal day 2 BAL fluid samples from RDS (n = 
9) and BPD (n = 13) patients. Densitometric value is expressed relative to a control collagenase (A.U.) that was run 
parallel with the samples on every zymogram. * p < 0.05 (Mann Whitney U test) compared with BPD. 
latent MMP-2 remained relatively constant or. at most. showed a slight increase over the 
study period (Fig. 4). 
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Figure 4 
(A). Zymogram ofBAL fluid samples obtained at postnatal day 10 from BPD patients. Lanes 1~3 and lane 5 arc BAL 
samples from individual patients. lane 4 is a collagenase control. (B). Sequential BAL samples obtained at postna-
tal days 2. 4. 7 and 10 from an infant developing BPD. MMP-2 is active MMP~2.1 MMP-2 is latent MMP-2.1 MMP-
9 is latent MMP-9. NGAL is neutrophil gelatinase B-associated lipocalin associated with MMP-9. 
Immunocytochemistry 
Immunocytochemical analyses ofBAL cells revealed immunoreactivity for MMP-9 in 
neutrophils and macrophages from both RDS and BPD patients. However. also numerous 
MMP-9 negative neutrophils and macrophages were observed (Fig. 5). 
Immunohistochemistry 
Lung tissue from infants who died in the acute phase (0-4 days) was characterized by 
absence or sparse scattered immunostaining for MMP-9 (Fig. 6A). In the regenerative phase 
of the disease (5-8 days). clusters of MMP-9 immunoreactive cells (comprising inflammato-
ry cells such as monocytes/macrophages and neutrophils) became evident (Fig. 6B). In the 
transitional phase (9-16 days). numerous clusters of immunoreactive cells were present and 
stained more intensely compared to the previous phase (Fig 6C). In the chronic phase (>16 
days). MMP-9 expressing inflammatory cells were still present (data not shown). 
Additionally. from the regenerative phase to the chronic phase onwards. weak MMP-9 
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FigureS 
Immunocytochemical staining with anti-MMP-9 antibody (A) and control IgG (B) on BAL cells from an RDS patient 
at postnatal day 2. NIMP-9 immunoreactivity was. observed in ncutrophils (arrow) and macrophagcs (arrowhead). 
immunoreactivity was observed in regenerating alveolar type-II epithelial cells and persisted 
into the chronic phase (Fig 6C). In the chronic phase. fibroblasts in fibrotic foci were 
immunoreactive for MMP-9 (data not shown). 
Discussion 
Here we show that MMP-9 levels in BAL fluid from premature infants (gestational 
age $ 30 weeks) who develop BPD as compared to infants with resolving RDS are signifi-
cantly reduced at postnatal day 2. After postnatal day 4. however. MMP-9levels in BAL fluid 
from BPD patients increased markedly and remained high during the study period. Levels of 
MMP-2 were comparable between RDS and BPD at day 2 and remained constant or showed 
a small increase after day 4 for BPD patients. 
The higher MMP-9 levels in BAL fluid at day 2 from patients who recover from RDS 
is a novel finding. The neutrophil is considered an important source of MMP-9 and is known 
to secrete different molecular weight forms of MMP-9 (21). In the zymograrns of BAL fluid 
collected at postnatal day 2 we observed MMP-9 bands which. based on molecular weight 
represent NGAL. latent MMP-9 and the homodimer of latent MMP-9. The presence of 
NGAL indicates that neutrophils contributed to the MMP-9 detected in BAL fluid. which is 
supported further by the significant correlation between absolute numbers of neutrophils per 
ntl of BAL fluid and the levels of NGAL. Furthermore. MMP-9 immunoreactive neutrophils 
were present in the BAL fluid from RDS and BPD patients at postnatal day 2. No such cor-
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Figure 6 
Immunohistochemical stlining for MMP-9 on lung tissue from patients at different phases of BPD development. 
Sparse MMP-9 immunoreactivity was observed during the acute phase (0-4 dafter birth) of BPD (A). In the regen-
erative phase (5-8 d) clusters of MMP-9 immunoreactive inflammatory cells became evident (B). In the transition-
al phase (9-16 d) of BPD (C) strong MMP-9 immunoreactivity was still observed in inflammatory cells and weak 
MMP-9 immunoreactivity was present in regenerating type-IT epithelial cells (arrow). 
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relation existed for latent MMP-9, indicating that other cellular sources such as monocytes, 
macrophages and alveolar type-II epithelial cells may also contribute to the increased levels 
of MMP-9 in RDS during the initial stage of the disease, Indeed, MMP-9 immunoreactivity 
was observed in macrophages, monocytes and alveolar type-II epithelial cells, in line with 
previous studies (22-25), 
In the present study we determined MMP-9 levels which do not necessarily reflect 
MMP-9 activity in BAL fluid, particularly as proteolytic activation and natural inhibitors 
(TIMPs) modulate MMP-9 activity (24), Nevertheless, the presence of MMP-9 on day 2 in 
BAL fluid from patients with resolving RDS and its relative absence in patients with 
developing BPD suggests that early activation and/or recruitment of cells. among which 
neutrophils. is an important mechanism leading to the clearance of RDS. Given that activa-
tion and recruitment of cells require initial triggers it is likely that these initial responses 
are adequate in patients with resolving RDS and inadequate (too low and/or too slow) in 
patients who develop BPD, Such an inadequate response in BPD patients may result in 
delayed reepithelialization of the injured alveoli, a process in which MMP-9 is implicated 
(26), 
After day 4, MMP-9 levels increase in BAL fluid from BPD patients and actually 
increase to much higher levels than seen for MMP-9 in RDS patients on day 2, Here too, neu-
trophils appear an important source of MMP-9, but the involvement of alveolar type-II 
epithelial cells and fibroblasts is likely too, This prolonged and extensive increase of 
MMP-9 ntight be implicated in lung damage in BPD, as it has been demonstrated that 
increased MMP-9 levels in BAL fluid from ARDS patients coexisted with the 7S portion of 
type-IV collagen, which is considered as a marker of basement membrane disruption (12), 
The latter data on MMP-9 are in line with those reported in a prelintinary report by 
Sweet and co-workers (16), but are conflicting with those from Cederqvist et al (17) who 
reported no difference in the levels of MMP-9 between RDS and BPD, In their srudy, how-
ever, tracheal aspirates were analyzed instead of BAL fluid, thus sampling another compart-
ment of the airways, Furthermore, the data for the initial five postnatal days were pooled and 
presented as one value, thereby possibly overlooking the temporal differences in MMP-9 
levels as described here, Taken together it is likely that these methodological differences may 
account for the observed discrepancy, 
In conclusion. our study provides evidence that the difference in resolving RDS or 
developing BPD may be related to the ability to raise an early response to the initial changes 
in the lung, The low MMP-9 levels, particularly those of NGAL at postnatal day 2, may help 
to identify RDS patients who are at risk of developing BPD, 
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Post~injury short~course Dex inhibits fibrosis 
Abstract 
Bronchopulmonary dysplasia (BPD) is a neonatal chronic lung disease with varying 
degrees of fibrosis that can develop over days to weeks following mechanical ventilation for 
neonatal respiratory distress syndrome. Recently. it was demonstrated that a short-course of 
dexamethasone (Dex). initiated 12-48 hours postnatally. increased survival without develop-
ing chronic lung disease in these infants. However. whether or not this treatment regimen 
inhibits fibrosis. is not known. In this study. we examined the effect of treating rat lungs 
exposed to bleomycin. with a 3-day course of Dex (0.5 mglkg/body weight. comparable to 
the dose in infants at risk of BPD). initiated three days after injury. on cell proliferation and 
collagen production. We clearly demonstrated that treating the animals with Dex for three 
days. inhibited collagen accumulation in their lungs compared with bleomycin exposed 
untreated animals despite initiating treatment three days after initiation of lung injury. Dex 
treatment reduced the number of proliferating cells in the lung parenchyma of bleomycin 
exposed rats but did not influence BAL fluid mitogenic activity for lung fibroblasts or alter 
the BAL fluid levels of the fibrogenic mediators TGF-~ 1 • PDGF-AB. or thrombin. We con-
clude that a 3-day course of Dex treatment initiated after induction of fibrosis by bleomycin. 
reduces lung collagen accumulation but this occurs by mechanisms other than through reduc-
tion of TGF-~ 1 • PDGF-AB or thrombin levels in BAL fluid. We propose that the beneficial 
effects of short-course Dex treatment of infants likely to develop BPD. may be. at least 
partly. due to antifibrotic effects. 
Introduction 
Pulmonary fibrosis is the end stage of a heterogeneous group of disorders of known 
and unknown etiology. Despite the wide variety of insults associated with this condition. such 
as bacterial infection, inhalation of organic and inorganic dusts. radiation. drugs. and trauma 
the mechanisms involved appear largely the same (1). It is assumed that in response to injury. 
inflammatory cells enter the lung and. together with resident lung cells. release mediators that 
stimulate fibroblast proliferation and collagen deposition within the lung interstitium (1). A 
host of mediators have been implicated in the pathogenesis of pulmonary fibrosis because 
they fit three basic criteria: l) As mentioned. they stimulate fibroblast replication or procol-
lagen synthesis. 2) The gene expression and protein production of the mediator is increased 
in the lungs of patients with pulmonary fibrosis and 3) Inhibitors of its function attenuates 
fibrosis in animal models of the disease (2). Mediators which fit these criteria include: 
platelet-derived growth factor (PDGF). transforming growth factor-~ 1 (TGF-~ 1 ). insulin-like 
growth factor-!. endothelin-1. fibronectin and thrombin (1. 3-9). 
Bronchopulmonary dysplasia (BPD: also named chronic lung disease of prematurity) 
is a neonatal chronic lung disease associated with varying degrees of fibrosis. that develops 
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within days to weeks after mechanical ventilation treatment for neonatal respiratory distress 
syndrome (RDS) (10. 11). Early and prolonged pulmonary inflammation is thought to play a 
critical role in tissue injury. tissue remodelling and fibrosis in the pathogenesis ofBPD (12). 
Infants with. or at risk of developing BPD. are routinely treated with a systemic course of the 
corticosteroid dexamethasone (Dex) for a prolonged period of time. The Dex regimen used 
in our neonatal intensive care unit at Erasmus MC, University Medical Center Rotterdam. is 
generally initiated after the first week of life. It comprises 0.5 mg/kg per day of Dex sodium-
phosphate for three days. followed by 0.3 mglkg per day for an additional three days. after 
which the Dex dose is weaned over the next 2 to 4 weeks. This treatment has proven to be 
beneficial as it facilitates weaning from the mechanical ventilator and reduces pulmonary 
inflammation (13). However. the effect of this treatment on lung fibrosis is uncertain as it 
does not downregulate the pulmonary expression levels of fibrogenic mediators such as 
fibronectin and TGF-~ 1 in these infants (14. 15). Recently. it was found that a short-course 
of Dex (using a dose comparable to what we use to initiate treatment in our hospital) starting 
at 12-48 hours postnatally. increased survival without BPD and reduced the requirement for 
subsequent late Dex therapy (16. 17). It was stated that the pulmonary benefits of early 
short-course Dex in these infants should be weighed against the side-effects such as 
gastrointestinal perforation. However. it is not known if a short-course of corticosteroid 
treatment initiated early after injury is able to prevent lung fibrosis. 
Intratracheal instillation of the antitumor agent bleomycin is the most commonly used 
animal model for pulmonary fibrosis. This model is characterized by an early. predominant-
ly neutrophilic inflammatory response. increased fibroblast proliferation and enhanced colla-
gen deposition due to increased collagen synthesis and decreased collagen degradation (18. 
19). Prolonged administration of corticosteroids such as methylprednisolone or Dex. initiat-
ed prior to. or simultaneously with bleomycin. reduces pulmonary inflammation. lung injury 
and collagen deposition in this model (20-22). However. as treatment for BPD commences 
after lung injury in infants. the clinical relevance of experimentally treating animals with anti-
inflammatory therapy prior to or at the time of injury is questionable. 
The current study was undertaken to determine if a 3-day course of Dex treatment (0.5 
mglkg body weight which is comparable with the initial three-day dose of the Dex regimen 
used in our neonatal intensive care unit). initiated after the induction of lung injury with 
bleomycin. affected collagen deposition and cell proliferation and modulated the expression 
profile of the profibrotic mediators TGF-~ 1 • PDGF-AB. and thrombin in BAL fluid. 
Methods 
Male Lewis rats weighing 140-210 g were anesthetized by intramuscular injection of 
0.75-l.O mllkg body weight Hypnorm (fentanyl citrate 0.315 mglml and fluanisone 10 
mglml: Janssen Pharmaceutical. High Wycombe. UK). Bleomycin disulphate (Kyowa 
Hakko. Slough. UK) was administered by a single intratracheal injection ( 1.5 mg/kg body 
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weight in 0.3 ml of sterile saline) as described previously (6). Control animals received 0.3 
ml of saline alone. 
Corticosteroid treatment 
Three days after administering bleomycin. animals receiving corticosteroid treatment 
were given a daily intraperitoneal (i.p.) injection of Dex sodium-phosphate (0.5 mg/kg body 
weight in 0.5 ml of sterile saline: Sigma. StLouis. MO) from days three to five. Control ani-
mals received an i.p. injection of sterile saline. Four different experimental treatment groups 
were included in this study: 1) bleomycin receiving saline i.p. (BLM): 2) bleomycin 
receiving Dex i.p. (BLMdex): 3) control receiving saline i.p. (CTRL). and 4) control 
receiving Dex i.p. (CTRLdex). Groups of 6 rats were killed 3. 7 and 14 days after bleomycin 
or saline instillation by an overdose of pentobarbitone. Lungs were lavaged 3 times with 4 ml 
of sterile saline and total and differential cell counts were performed. BAL fluid was aliquot-
ed and stored at -sooc for further analyses. The lungs were removed. blotted dry and imme-
diately snap-frozen in liquid N2 after removing the trachea and major airways. Lung collagen 
content and BAL fluid mitogenic activity and growth factor levels were measured in 6 ani-
mals for all groups except CTRL on day 7 (n = 3). and CTRLdex at day 7 (n = 5) 
Groups of 3 animals were also killed 3 and 5 days after bleomycin or saline injection 
with and without Dex treatment and proliferating cells were identified by bromodeoxyuridine 
(BrdU) immunoreactivity. Briefly. animals were injected i.p. with BrdU (15 J.Lgl g body 
weight in 0.3 ml sterile saline: Sigma) 1 h prior to killing and the lungs fixed by intratracheal 
instillation of freshly prepared 4% paraformaldehyde in phosphate-buffered saline (PBS) at a 
pressure of 25 em H20. The trachea was ligated and the thoracic contents removed en bloc. 
Mter overnight immersion in fixative (4 °C), tissues were transferred to 15% sucrose in PBS 
(overnight. 4 °C). dehydrated and embedded in paraffin wax. 
Collagen measurement 
Lung collagen was assessed by measuring hydroxyproline levels in proteins by high-
pressure liquid chromatography (HPLC) as previously described (6). Briefly. approximately 
100 mg of powdered lung tissue (obtained by crushing tissue while frozen at -196 oq was 
weighed and hydrolyzed in 2 ml of 6 M HCl at II 0°C for 16 h. Hydrolysates were mixed with 
activated charcoal and filtered (Milipore. type DA. pore size 0.65 J.Lm). A 200 J.Ll aliquot of a 
1-in-10 dilution of filtered hydrolysate was dried using a centrifugal vacuum concentrator. 
Hydroxyproline was isolated and measured by reverse-phase-HPLC after derivatization with 
7-chloro-4-nitrobenz-2-oxa-1.2.-diazole (NBD: Sigma) (6). The hydroxyproline content in 
each sample was determined by comparing peak areas of samples from the chromatogram 
with those generated from standard solutions. The amount of collagen in total lung tissue was 
calculated assuming that lung collagen contains 12.2% w/w hydroxyproline (23). and 
expressed as mg collagen/lung. 
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Fibroblast proliferation assay 
Fibroblast proliferation was assessed using a colorimetric assay based on the uptake 
and subsequent elution of the dye methylene blue as previously described (24). Briefly. cells 
(human fetal lung fibroblasts; HFL-1) were seeded at 6 x 103 cells/well into 96-well plates in 
50 J.ll Dulbecco 's modified Eagle's medium (DMEM: Gibco. Renfrewshire. UK) supplemen-
ted with 0.4% normal calf serum (NCS). L-glutamine and antibiotics and allowed to adhere 
for 24 h. Thereafter. 50 J.ll of a 1/4 dilution of BAL fluid in DMEM/0.4% NCS was added to 
the fibroblasts cultures (six replicates per BAL fluid sample; yielding a 1/8 dilution of BAL 
fluid) and proliferation assessed after 48 h. The medium was removed and the plates 
immersed in PBS and blotted on absorbent paper. Cells were fixed in I 0% formol saline and 
then stained for 30 ntin with I% methylene blue (Sigma) in 0.01 M borate buffer, pH 8.5. 
Excess dye was removed with 0.01 M borate buffer using an automatic plate washer. Excess 
moisture was removed from the plate by blotting on absorbent paper and the dye eluted from 
the cells by the addition of 100 J.1] of acidified alcohol (0.01 M HCL-ethanol. 1:1). 
Absorbance was measured at a wavelength of 650 nm on a nticroplate spectrophotometer. 
Fibroblast proliferation was expressed as a percentage change in mean absorbance above that 
for cells exposed to DMEM/0.4% NCS alone. 
Measurement of growth factors in BAL fluid 
Levels of total protein in BAL fluid were measured using a Bradford-based reagent 
(Bio-Rad; Miinchen, Germany). Briefly. the Bradford-based reagent was diluted 5 times with 
ntilli Q H20. Thereafter. 5 J.ll of BAL sample was added to I 00 J.l] of reagent. Bovine serum 
albuntin (BSA) was used to generate a standard curve. Absorbance was measured at a wave-
length of 620 nm and protein contents of the BAL samples were calculated from the standard 
curve. 
TGF-/31 was measured by enzyme-linked immunosorbent assay (ELISA; Promega; 
Madison WI) after acid activation of the BAL fluid samples to deterntine total TGF-~ 1 (both 
latent and active TGF-~ 1 ). 
PDGF-AB levels were deterntined using a human PDGF-AB ELISA (R&D systems; 
Abingdon. UK) which bas previously been shown to be cross-reactive with rat (25). 
The ELISA assays were performed according to the methods outlined by the manu-
facturer. All BAL fluid samples were analyzed undiluted in duplicate. Results were expressed 
as pg/ml BAL fluid. The sensitivity of the assays was 25 pg/ml and 8.4 pg/ml for TGF-~ 1 and 
PDGF-AB. respectively. 
Thrombin activity was determined using the thrombin specific chromogenic substrate 
Tos-Gly-Pro-Arg-pNA (Sigma) as described previously (26). Briefly. 25 J.ll of BAL fluid was 
diluted in 25 J.ll Tris-buffered saline (TBS; pH 8.3) and 25 J.ll BAL fluid was diluted in TBS 
containing 4 x IQ-6 M of the thrombin inhibitor PPACK (Bachem; Bubendorf. Switzerland). 
These solutions were added to a 96 well nticrotitre plate and incubated for 20 ntin at 37 oc 
to allow thrombin-PPACK complexes to form. Thereafter. 50 J.ll of ImM Tos-Gly-Pro-Arg-
pNA (in 1.5 mM HCL) was added to the diluted BAL fluid and incubated at 37 °C. The opti-
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cal density (OD) was measured at 405 nm for 24 h. During this time, a linear increase in opti-
cal density of the BAL samples was found (data not shown). Thrombin activity in each BAL 
sample is expressed as an OD value at 405 nm, which was determined as the difference in 
OD. measured at 24 h. between the BAL sample with and without PPACK. As a positive con-
trol. I x J0-6 M thrombin (Sigma) was added to the substrate. Preincubation of thrombin with 
PPACK resulted in complete inhibition of thrombin activity (data not shown). 
Cell proliferation by BrdU incorporation 
Paraffin sections (5 IJ.m) were dewaxed. rehydrated and boiled for 15 min in citric acid 
(pH 6.0). BrdU staining was performed using a BrdU Staining Kit (ZYMED Laboratories 
INC.; South San Francisco. CA) according to the manufacturer's instructions. Slides were 
examined by light microscopy (Zeiss; Axiolab) and the number of BrdU positive cells deter-
mined in 10 high power fields ( 400x magnification) per section of lung tissue in groups of 3 
bleomycin exposed and unexposed animals. Data are presented as the mean number of 
positive cells per high power field. 
Statistical analyses 
Results are presented as mean ± standard error of the mean (SEM). Data between 
groups were compared using the unpaired Students t-test. A p value< 0.05 was considered to 
be statistically significant. 
Results 
Animal Weights 
Rats injected with bleomycin lost weight during the first 3 days after treatment but 
gained weight thereafter. Rats treated with bleomycin and receiving Dex continued to lose 
weight during the three days of Dex administration and started to gain weight again when 
Dex administration was stopped. Control animals receiving Dex also lost weight during the 
Dex treatment and started to gain weight again when Dex administration was stopped. 
BAL fluid cell connt and differential 
Table I shows the total leukocyte counts and composition of the cell population in 
BAL fluid from the different groups at the different time-points examined. Three days after 
bleomycin the total number of cells in BAL fluid was significantly increased compared with 
control. Furthermore. the percentage of neutrophils was significantly increased and the 
percentage of macrophages significantly decreased compared with control. 
!51 
day 3 day 7 
CTRL BLM CTRL CTRLdex BUvl BLMdex 
# cells/ml BAL fluid 5.2±1.0 26.8±5.7* 10.0±3.0 5.5±1.3 10.0±3.8 7.3±2.8 
(x J04) 
% neutrophils 4.1±2.9 47.0±5.2* l.6±o.7 l.O±o.4 24.4±8.6 15.7±7.4 
~ 
v. % macrophages 95.1±2.9 46.9±6.8* 98.3±o.6 98.3±0.5 73.2±9.3 81.1±8.3* 
'" 
% lymphocytes 0.9±0.3 6.1±1.9 O.l±o.l 0.7±o.2 2.4±o.9 3.1±1.1 
* p < 0.05 (Mann Whitney U test) compared to appropriate control group 
day 14 
CTRL CTRLdex BLM 
5.8±1.3 4.8±o.6 10.4±2.0* 
0.7±o.3 1.0±0.2 2.0±1.0 
99.0±0.4 98.9±o.3 97.1±1.1 
0.3±o.1 0.1±o.1 1.0±0.5 
BLMdex 
7.2±1.4 
5.6±2.1 
93.6±2.1* 
0.9±o.3* 
9 {J 
~ 
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At day 14, the total number of cells was still elevated in bleomycin treated animals, 
however, the proportions of cell types comprising the BAL cell population was comparable 
with controls. There was a trend towards decreased lavage cell numbers in Dex treated 
animals compared with their respective controls at days 7 and 14 but these changes were 
not statistically significant. However. there was a significantly decreased percentage of 
macrophages at day 7 and day 14 compared with control animals, while the percentage of 
lymphocytes was increased at day 14 compared with control. 
Collagen measurement 
Figure 1 shows the changes in total lung collagen 3, 7 and 14 days after instillation of 
bleomycin with and without Dex treatment. Bleomycin did not change lung collagen content 
at day 3. At day 7, the collagen content was significantly increased in BLM compared with 
BLMdex (14.2 ± 1.6 mg collagenJ!ung compared with 9.7 ± 0.7 mg collagenJ!ung: p < 0.05). 
The collagen content continued to increase in the BLM group, and by dayl4 was double that 
of controls (22.5 ± 2.1 mg compared with 11.2 ± 1.1 mg for controls: p < 0.05). Lung colla-
gen content in bleomycin exposed Dex treated animals did not increase compared with Dex 
treated or untreated controls at either 7 or 14 days. Bleomycin exposed animals treated with 
Dex had significantly reduced lung collagen at day 14 compared with bleomycin alone (22.5 
± 2.1 mg for BLM compared with 15.2 ± 2.2 for BLMdex; p < 0.05). There was no signifi-
cant change in total lung collagen for controls at any of the times examined. Dex treatment 
of control animals did not influence total lung collagen content at any of the times examined. 
0 CTAL 0 CTALdex 1:1 BLM Ill BLMdex 
day3 day7 day 14 
Figure 1 
Change in lung collagen content at various times following bleomycin instillation. Collagen content was measured 
3-14 days after intratrache::tl instillation of bleomycin or saline with and without a three-day course of Dex treat-
ment. Each value represents the mean ± SEM. 
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BAL fluid-induced fibroblast proliferation 
Figure 2 shows the mitogenic effect of the BAL fluid from animals in each group on 
fibroblast proliferation over 48 h. There was a significant increase in BAL fluid-induced 
fibroblast proliferation at day 3 in bleomycin compared with saline treated animals ( 28.4 ± 
1.8% proliferation above medium control compared with 5.7 ± 1.4% for control; p < 0.05). 
No differences were observed between bleomycin treated and control animals at days 7 and 
14. Dex treatment did not significantly influence the mitogenic activity of BAL fluid from 
bleomycin treated animals at days 7 and 14. At day 7. BAL fluid from control animals 
exposed to Dex revealed significantly decreased mitogenic activity compared with bleomycin 
exposed animals treated with Dex (20.2 ± 4.9% proliferation for BLMdex compared with 0.3 
± 4.6% for CTRLdex; p < 0.05). No significant change in BAL fluid mitogenic activity was 
observed for Dex treated and untreated controls at any of the times examined. 
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Figure 2 
The effect of :1 1/8 dilution of BAL fluid on fibrobl:lst prolifemtion 3-14 days after intratracheal instillation of 
bleomycin or saline with and without a three-day course of Dex treatment. Each value represents the mean± SEM. 
Measurement of growth factors in BAL fluid 
Total protein levels were significantly increased 3 days after bleomycin treatment 
(631.1 ± 56.4 j.tg/ml BAL fluid compared with 118.8 ± 47.6 j.tg/ml for controls; p < 0.05). 
Thereafter. total protein levels declined in bleomycin treated animals but were still signifi-
cantly increased compared with control at day 14 (158.5 ± 26.7 j.tg/ml BAL fluid compared 
with 78.1 ± 12.3 for controls; p < 0.05). Treatment with Dex did not influence BAL fluid total 
protein levels in bleomycin treated or control animals. There was no significant change in 
BAL fluid total protein levels for controls at any of the times examined (Fig. 3A). 
TGF-{31 levels in BAL fluid were significantly increased at day 3 after bleomycin 
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treatment (616.4 ± 165.9 pg/ml BAL fluid compared with 98.9 ± 27.9 pg/ml BAL fluid for 
controls: p < 0.05). TGF-~ 1 levels declined at 7 days after bleomycin, but were still signifi-
cantly increased compared to control (194.6 ± 48.0 pg/ml BAL fluid compared with 46.1 ± 
12 pg/ml BAL fluid for controls: p < 0.05). At day 14 after bleomycin. TGF-~1 in BAL fluid 
was still significantly increased (230.6 ± 177.7 pg/ml BAL fluid compared with 24.9 ± 7.6 
pg/ml BAL fluid for controls: p < 0.05). Dex treatment of bleomycin exposed and control ani-
mals did not influence TGF-~ 1 in BAL fluid at any of the times examined. There was no 
significant change in BAL fluid TGF-~ 1 levels for controls at any of the times examined 
(Fig. 3B). 
PDGF-AB levels in BAL fluid were significantly increased at day 3 after bleomycin 
(209.9 ± 25.8 pg/ml BAL fluid compared with 90 ± 6.2 pg/ml BAL fluid for controls: 
p < 0.05) and remained elevated at relative constant levels during the study period. Dex treat-
ment of bleomycin exposed and control animals did not influence PDGF-AB in BAL fluid at 
any of the times examined. There was no significant change in BAL fluid PDGF-AB levels 
for controls at any of the times examined (Fig. 3C). 
Thrombin activity in BAL fluid was significantly increased at day 3 after bleomycin 
exposure (0.6 ± 0.07 OD units at 405nm compared with 0.1 ± 0.03 OD units at 405nm for 
800 
'0 
'5 700 '0 
= '5 
-' 600 = eli -' 
"' i 500 "' ~ 
0 .e, 
~ ;;;, 
~ u. 
:;; "' .... 
.9 
'0 'E 
'5 c 
= 
~ 
-' 
0 
"' 
~ 
"' " ~ 2. 
.e, f 
"' 1 • c 
"' 
:0 
" 
E 
"-
e 
o5 
Figure 3 
1 
0.8 
0.7 
0.6 
0.5 
0.4 
0.3 
0.2 
0.1 
0 
p<O.OS 
~
day3 
p<O.OS 
~
P<O.OS 
~
day 7 day 14 
Changes in BAL fluid total protein (A). total TGF-~ 1 (B). PDGF-AB (C). and thrombin activity (D) 3-14 days after 
bleomycin or saline instillation with and without a three-day course of Dex treatment. Each value represents the mean 
±SEM. 
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controls: p < 0.05). 
Thereafter thrombin activity gradually declined in BAL fluid of bleomycin treated ani-
mals but remained significantly elevated at all times examined compared with controls 
(Fig. 3D). Dex treatment of bleomycin exposed and control animals did not influence 
thrombin activity in BAL fluid at any of the times examined. In control animals. BAL fluid 
thrombin activity was elevated at day 3 compared to controls at day 7 and 14 (Fig. 3D). 
Cell proliferation by BrdU incorporation 
Very few cells were proliferating in control lung tissue as assessed by BrdU 
immunoreactivity with staining limited to a few alveolar type-II epithelial cells (Fig. 4A). In 
animals exposed to bleomycin. increased numbers of BrdU positive alveolar type-II epithe-
lial cells and interstitial cells were clearly evident both in fibrotic (Fig 4B-D) and normal 
areas of lung parenchyma at all times examined. Treatment of bleomycin exposed animals 
with Dex significantly reduced the number of BrdU positive cells both in areas of fibrosis and 
normal lung parenchyma (Fig. 5). 
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Figure 4 
BrdU immunoreactive cells (arrow) in control lung tissue 3 days after saline instillation (A). 3 days after bleomycin 
instillation (B), 5 days after bleomycin instillation without Dex treatment (C) and 5 days after bleomycin instillation 
with Dex treatment (D). Magnification is 400x. 
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Figure 5 
The number of BrdU immunoreactive cells per high power field at 400 times magnification. (A) shows the number 
of BrdU positive cells in areas of normal appe:ning lung tissue at 3 and 5 days after bleomycin or saline instillation 
with and without Dex treatment. (B) shows the number of BrdU positive cells in fibrotic lung tissue 3 days after 
bleomycin instillation and 5 days after bleomycin instillation with and without Dex treatment. 
Discussion 
Previous studies have shown that prolonged administration of corticosteroids. 
initiated prior to or together with bleomycin-administration inhibited the development of 
lung fibrosis in rats (20-22). Although an important finding. its relevance clinically is ques-
tionable as anti-inflammatory therapy is always given after lung damage has occurred. In this 
study we clearly show that a 3-day course of Dex treannent. initiated three days after 
bleomycin-induced lung injury. inhibits excessive collagen deposition in the lungs of rats, 
suggesting that this treannent regimen. comparable to the Dex dose initially used for three 
days in our neonatal intensive care unit to treat infants at risk for BPD. may be useful in 
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reducing fibrosis in these infants. 
The current theory on the pathogenesis of pulmonary fibrosis is based on the 
hypothesis that mediators released by inflammatory cells and resident lung cells as well as 
blood born mediators induce fibroblasts to proliferate and/or to produce excess collagen (1). 
We observed no significant difference in the inflammatory cell population between Dex treat-
ed and untreated bleomycin exposed animals. This may have accounted for the fact that no 
differences were observed in BAL fluid levels of TGF-~ 1 and PDGF-AB between these 
groups of animals. TGF-~1 is a potent stimulator of collagen synthesis by fibroblasts (27) 
and TGF-~ 1 mRNA expression is elevated prior to increases in type-I and type-III procolla-
gen mRNAs in bleomycin-induced lung fibrosis (28). Different approaches to inhibit TGF-~ 
have been successfully used to prevent bleomycin-induced pulmonary fibrosis. Neutralizing 
TGF-~ antibodies. soluble TGF-~ type II receptors, and decorin are all able to inhibit 
TGF-~ 1-activity and reduce collagen accumulation after bleomycin treatment (29-31). In our 
study we detected increased levels ofTGF-~ 1 in BAL fluid after bleomycin. comparable with 
levels reported previously (31. 32). We found that Dex did not downregulate TGF-~ 1 levels 
in BAL fluid at any of the times examined after bleomycin treatment. Although we did not 
examine protein expression by BAL cells, it is likely that alveolar macrophages substantial-
ly contributed to the TGF-~ 1 levels in BAL fluid as these cells have been demonstrated to 
express and secrete TGF-~ after bleomycin exposure (33. 34 ). Additionally. it has been 
described that Dex application to alveolar macrophages previously activated in vivo by 
bleomycin did not reduce TGF-~ secretion by these cells (34). Our observation that Dex treat-
ment did not influence BAL fluid TGF-~1 levels after bleomycin exposure may therefore be 
a reflection of the inability of Dex to downregulate TGF-~ secretion by activated alveolar 
macrophages. 
BAL fluid from bleomycin treated animals has previously been demonstrated to con-
tain mitogenic activity for lung fibroblasts, to which both PDGF and thrombin contributed 
(35. 36). Additionally. in vivo inhibition of thrombin and PDGF activity has been shown to 
reduce bleomycin-induced pulmonary fibrosis in rats (3, 9). We found the mitogenic activity 
of BAL fluid to be significantly increased three days after bleomycin and comparable with 
control animals at day 7 and 14. which supports previously reported findings (35). Dex treat-
ment had no effect on the BAL fluid mitogenic activity in bleomycin exposed animals. Both 
PDGF-AB levels and thrombin activity were significantly increased at day 3 after bleomycin. 
and presumably contribute to BAL fluid mitogenicity at that time-point. Thrombin activity 
decreased gradually thereafter but remained significantly increased compared with controls. 
The PDGF-AB levels remained increased at a relative constant level during the whole study 
period. Thrombin activity and PDGF-AB levels in BAL fluid were not modulated by Dex 
treatment of bleomycin exposed animals. These data suggest that although a 3-day course of 
Dex is able to inhibit bleomycin induced pulmonary fibrosis in rats, its actions are not 
through reducing levels of the fibrogenic mediators TGF-~ 1 • PDGF-AB or thrombin in BAL 
fluid. 
However. we can not rule out the possibility that Dex treatment affects parenchymal 
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levels or activity of these growth factors. For instance fibroblasts have also been identified as 
a source of TGF-~ 1 in pulmonary fibrosis (37). and it has been demonstrated that Dex reduces 
TGF-~1 mRNA and TGF-~ secretion by lung fibroblasts (38). In addition. Dex is known to 
reduce collagen synthesis and steady state levels of procollagen mRNA by lung fibroblasts 
(39). Therefore. the Dex regimen used in our study may have reduced parenchymal TGF-~ 1 
expression by fibroblasts with subsequent decreased autocrine stimulation of collagen syn-
thesis. Alternatively. stimulation of fibroblasts with Dex stimulates the production of the pro-
teo glycan decorin that binds and inactivates TGF-~ ( 40). Transient expression of decorin in 
the lungs from bleomycin treated animals has been demonstrated to reduce pulmonary fibro-
sis without reducing total TGF-~1 levels in BAL fluid (31). Therefore. it is possible that the 
Dex treatment in our study reduced parenchymal TGF-~1 activity by increasing the decorin 
levels in the lung with a resultant decrease of collagen deposition_ 
We found that intratracheal instillation of bleomycin resulted in BrdU incorporation 
into alveolar type-II epithelial cells in areas of normal lung architecture and fibrotic foci indi-
cating an increase in the number of proliferating cells. This finding supports previous studies 
and reflects active repair of the injured epithelial surface (41). Dex treatment reduced the 
number of BrdU stained cells in both fibrotic and normal areas of the lung parenchyma in 
bleomycin treated animals. This suggests that Dex either prevents cell proliferation or 
reduces the amount of epithelial damage and apoptosis. Excessive apoptosis of bronchiolar 
and alveolar epithelial cells has shown to be associated with bleomycin-induced lung fibro-
sis as well as with the development of BPD ( 42. 43). Dex has indeed been demonstrated to 
inhibit Pas-induced apoptosis of alveolar epithelial cells in vitro (44). Furthermore, a 
previous study demonstrated that prolonged administration of methylprednisolone sup-
pressed the expression of Fas and Fas ligand mRNA. bronchial and alveolar epithelial apop-
tosis. as well as evidence of histological fibrosis induced by bleomycin (45). Therefore. the 
Dex regimen used in our study may have reduced epithelial cell apoptosis and limited fibro-
genesis_ 
In conclusion, this study demonstrates that a 3-day course of Dex treatment. started 
after initiation of bleomycin-induced fibrosis. is able to reduce excessive pulmonary collagen 
accumulation in rats. The observed effect of Dex is established without a reduction of the 
fibrogenic mediators TGF-~1 • PDGF-AB, or thrombin in the alveolar space. We speculate 
that the anti-fibrotic effect of Dex is mediated via other pathways. which may include a 
reduction in cell proliferation, decreased epithelial apoptosis or inhibition of tissue 
profibrotic mediator activity. Our findings are of clinical relevance as we show that a 3-day 
course of Dex, in a comparable dose with that used to treat premature infants who are at risk 
of developing BPD, is able to inhibit the development of pulmonary fibrosis in an animal 
model. The beneficial effects of short-term early treatment with Dex in infants at risk of BPD 
may be due. at least in part, to antifibrotic effects. 
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General discussion 
Bronchopulmonary dysplasia (BPD) is a neonatal chronic lung disease associated with 
varying degrees of fibrosis that can develop over days to weeks after treatment for neonatal 
respiratory distress syndrome (RDS). Pulmonary fibrosis generally follows an alveolar 
inflammatory reaction. and the pathogenesis of pulmonary fibrosis is characterized by exces-
sive fibroblast proliferation (fibroproliferation) and collagen deposition (fibrogenesis). These 
processes are thought to be driven by mediators derived from the blood or produced by 
resident lung cells and/or inflammatory cells. 
Corticoisteroids are widely used in the treatment of pulmonary fibrosis as they have 
potent anti-inflammatory effects. The effects on pulmonary fibrosis and the mechanisms 
modulated by corticosteroids are largely unknown yet. 
This chapter discusses the results of the studies described in this thesis in relation to 
the present understanding of the pathogenesis of pulmonary fibrosis and BPD as well as the 
effect of corticosteroid treatment on the development of pulmonary fibrosis. 
9.1. BPD: an inadequate early but prolonged fibroproliferative 
response that may be modulated by dexamethasone treatment 
RDS is a form of acute lung injury characterized by bronchiolar and alveolar epithe-
lial damage with denudation of the basement membrane as well as endothelial damage (1-3). 
It is generally accepted that with the resolution of RDS the initial lung injury is repaired in 
an orderly manner. However. when this repair response is disordered BPD can develop (2). 
Orderly repair after lung injury involves the ntigration and proliferation of epithelial cells. 
endothelial cells and fibroblasts and is driven by a host of mediators ( 4. 5). 
Bronchoalveolar lavage (BAL) provides information on the cellular and noncellular 
components present in the alveolar space and can be used to evaluate disease activity. In 
active disease. BAL fluid from patients may contain biological/immunological markers of 
inflammation and/or active progression to fibrosis (6). 
In this thesis studies were performed in which BAL fluids. obtained at different post-
natal ages. from infants who did and did not develop BPD from RDS. were analyzed. The 
BAL procedure was performed in a standardized way as described by Grigg and previously 
used in our hospital (7. 8). The BAL fluids were analyzed for their ntitogenic activity for 
human fetal lung fibroblasts as well as for the presence of mediators known to be involved in 
repair and fibrosis development. Measurements for mitogenic activity were performed at 
least in triplicate per BAL fluid sample. Mediator levels were deterntined in duplicate in all 
the examined BAL fluid samples. Previously it was demonstrated in our hospital that there 
was a strong correlation between the concentration of proteins expressed per ml BAL fluid 
and the corrected concentration of these parameters (i.e. expressed per ml epithelial lining 
fluid) (8). Therefore. the parameters deterntined in the BAL fluid samples in our studies were 
expressed as concentration per ml BAL fluid, which is in accordance with the most recent 
ERS task force guidelines on BALin children (6). 
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In chapter 4. it was demonstrated that there was no difference in BAL fluid mitogenic 
activity for fibroblasts in the first week of life between the BPD and resolving RDS patients. 
It is therefore likely that the mitogenic activity in BAL fluid from resolving RDS is a normal 
physiological response to the initial lung injury that is needed for the restoration of the injured 
structures. Unfortunately. we have been unable to include patients ventilated because of non-
pulmonary reasons. Inclusion of such a group of patients would have learned if the mitogenic 
activity in BAL fluid was due to the disease or just a sequel of mechanical ventilation. 
However, such a group of patients would always consist of infants of longer gestation as 
almost all infants with a gestational age of less than 30 weeks have to be ventilated for 
respiratory problems. 
Acute lung injury in general is characterized by destruction of both the epithelial and 
endothelial sides of the alveolar-capillary barrier. This results in extravasation of fluid and 
cells into the interstitium and alveolar space. Once the insult has taken place. inflammatory 
cells appear in the injured site. Alveolar exudates containing fibrin fragments, fibronectin and 
other adhesive and chemotactic substances will provide a three dimensional matrix (provi-
sional matrix) for the migration of inflammatory cells. epithelial cells. endothelial cells and 
fibroblasts (9. 10). Epithelial damage and successive denudation of the basement membrane 
may promote fibroblast growth and fibroblast infiltration into the alveolar space. Under nor-
mal conditions these processes are inhibited by alveolar type-IT epithelial cells. Therefore. a 
rapid restoration of the injured alveolar epithelial barrier is thought to be crucial to prevent 
the development of pulmonary fibrosis ( 4. I 0. II). This view is supported by the observation 
that keratinocyte growth factor (KGF: a factor important in maintaining the epithelial integri-
ty) treatment prevents the development of bleomycin-induced pulmonary fibrosis in rats (12). 
As a consequence of immoderate and ongoing injury, fibroblast proliferation and 
migration into the alveolar space occurs in the pathogenesis of BPD and pulmonary fibrosis 
in general (3. 4. 13). Rapid alveolar epithelial proliferation can restore the surface layer. pre-
vent fibroblasts from entering the alveolar lumen and control their activity. The type-IT 
alveolar epithelial cell is considered as the cell regenerating the alveolar epithelium after 
injury (14). Alveolar type-I! as well as bronchiolar epithelial cell migration and proliferation 
are prominent features after lung injury (15-17). Type-IT alveolar epithelial cell proliferation 
is evident during the early reparative stages of RDS/BPD (3. 13). 
Although we did not examine it. it is likely that the BAL fluid examined in chapter 4 
exerts mitogenic activity for epithelial cells and that (mitogenic) factors present in the BAL 
fluid contribute to epithelial repair. If such is the case. it can be speculated that the mitogenic 
activity of the BAL fluid from the RDS group may be appropriate to restore the epithelial 
layer within days after injury. thereby preventing fibroblasts from entering the alveolar space 
and controlling their activity. 
In our study. the infants who developed BPD had more severe RDS (based on a 
clinical score) than patients with resolving RDS. Therefore. it is likely that the infants who 
developed BPD had more severe lung injury. The mitogenic activity in the BAL fluid in 
combination with severe ongoing lung damage in the BPD group may be inappropriate to 
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restore the epithelial barrier rapidly enough to prevent alveolar fibroblast infiltration and 
fibroproliferative progression of the disease. The view of delayed epithelial repair in the 
pathogenesis of BPD is supported by recent observations by Currie and colleagues. They 
demonstrated decreased levels of epidermal growth factor (EGF; a factor promoting ntitoge-
nesis of all epithelial cells and known to stimulate epithelial repair) on postnatal day l in 
patients developing BPD compared to patients with resolving RDS. It was concluded that this 
decreased EGF levels reflected the immaturity of the infants and predisposed to BPD (18). 
KGF is another epithelial ntitogen that is upregulated after lung injury and implicated 
in epithelial repair (17). Prelintinary data from our laboratoty indicate that KGF concentra-
tions in BAL fluid on postnatal day 2 are comparable between RDS and BPD in contrast to 
the expectation that the levels of KGF would correlate with the severity of the initial damage. 
Therefore, the KGF levels in the BPD patients may be too low to contribute to rapid 
restoration of the epithelial integrity in these patients. 
BAL fluid from adults with fibrosing lung disease has been demonstrated to contain 
increased and prolonged ntitogenic activity for lung fibroblasts compared with BAL fluid 
from controls (19. 20). Thrombin is a blood-born mediator that stimulates fibroblast pro-
liferation and collagen synthesis (21. 22), and contributes to bleomycin-induced pulmonary 
fibrosis in animals (23). Additionally. thrombin has been shown to contribute to the increased 
ntitogenic activiy of BAL fluid from fibrosing lung disease (19. 24). 
In chapter 4 we demonstrated that thrombin contributed to BAL fluid ntitogenic 
activity for fibroblasts in both RDS and BPD and that the ntitogenic activity of BPD BAL 
fluid remained stable during the first 14 postnatal days. Due to extubation of patients. we 
obtained BAL fluid samples from just two patients with resolving RDS on postnatal day 7 
and no BAL fluid samples from resolving RDS patients after postnatal day 7. Therefore. no 
conclusions can be drawn on differences in BAL fluid ntitogenic activity from postnatal day 
7 onwards between resolving RDS and BPD. Furthermore. due to the small groups of resolv-
ing RDS patients on postnatal days 4 and 7 and the small groups of BPD patients on postna-
tal days 10 and 14 the data on BAL fluid-induced fibroblast proliferation may have been 
biased. Nevertheless. the observation that BAL fluid from patients with BPD contained sig-
nificant ntitogenic activity to a postnatal age of 14 days makes it tempting to speculate about 
prolonged mitogenic activity in the lungs when BPD develops. 
Minimal ntitogenic activity has been demonstrated in BAL fluid from adults and ani-
mals without pulmonary disease (19. 24. 25). Therefore. it is reasonable to assume that the 
ntitogenic activity of BAL fluid decreases in the RDS patients with resolution of the initial 
injury. The prolonged BAL fluid ntitogenicity in the BPD group could well indicate that per-
sistent fibroproliferation may occur in the lungs from infants developing BPD and that throm-
bin contributes to this process. Infiltration of (myo )fibroblasts into the alveolar exudate (hya-
line membranes) has been described to occur within the first week after birth during BPD 
development (3. 13). A coincident infiltration of fibroblasts with the observed persistent 
mitogenic activity in the lungs may account for the observed excessive fibroproliferation and 
fibrosis in BPD. 
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When we determined thrombin activity and TAT!II levels (as a marker for thrombin 
generation) we surprisingly found them decreased in BAL fluid from BPD compared to RDS 
patients on postnatal days 2 and 4. Recently. we demonstrated that thrombin activity in BAL 
fluid from newborn surfactant depleted piglets was influenced by the type of mechanical ven-
tilation used (26). However. no correlation between the mode of mechanical ventilation and 
thrombin activity in BAL fluid was found in the infants younger than 4 days described in 
chapter 4. In a later stage. the thrombin activity increased in BAL fluid during BPD progres-
sion. reaching peak activity on day 14 comparable to that observed at postnatal days 2 and 4 
in resolving RDS. As for the data on BAL fluid-induced fibroblast proliferation the thrombin 
data may be biased due to the small groups of resolving RDS and BPD patients at later time-
points. 
Thrombin exerts multiple cellular effects important for wound healing. It promotes 
platelet aggregation. migration of inflammatory cells and the proliferation of mesenchymal 
cells. It has been demonstrated that application of thrombin and the thrombin receptor-acti-
vating peptide (TRAP) promoted wound healing. It was suggested that thrombin or TRAP 
accelerated wound healing partly via an earlier development of the proliferative phase (27). 
It may well be that alveolar thrombin generation is necessary to initiate a normal prolifera-
tive repair response for the resolution of RDS. When BPD develops. this initial response may 
be too low due to decreased alveolar thrombin generation, resulting in inadequate (too low 
and/or too slow) repair during the first postnatal days. A role for thrombin in the repair 
process in RDS is supported by the observation that treatment of infants suffering from RDS 
with antithrombin significantly prolonged the duration of mechanical ventilation and supple-
mental oxygen (28). However. when pulmonary thrombin activity is present for a prolonged 
time coinciding with ongoing lung injury as observed in BPD. it possibly contributes to the 
persistent fibroproliferation and excessive collagen deposition. 
In our study. the group of infants that developed BPD was of significantly shorter ges-
tation than the one with resolving RDS. This is in concordance with previously reported data. 
demonstrating that the most immature infants are the most likely to develop BPD (18. 29). 
We found a significant positive correlation between thrombin activity in BAL fluids at post-
natal day 2 with the gestational age of the infants. This suggests that the ability to generate 
alveolar thrombin activity is related to the relative maturity of the infant. It is indeed known 
that the coagulation system matures with increasing gestation (30-36). Recently thrombin 
activity has been described in BAL fluid from preterm lambs (gestational age: 132 d: term is 
145 d) ventilated because of RDS (37). It would be of interest to determine in such a model 
whether lambs with gestation of less than 132 d are indeed impaired in alveolar thrombin 
generation and whether they benefit from local thrombin or TRAP therapy. 
An alternative explanation for the decreased alveolar thrombin levels in the BPD 
group can be derived from data on coagulation activation as described by Brus et al. They 
demonstrated that preterm infants with RDS had increased plasma concentrations of TATIII 
on the first day after birth compared to healthy preterm infants and that these levels decreased 
witltin three days (38). Additionally. they demonstrated that infants with severe RDS had 
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increased plasma levels of TATIII compared to infants with mild/moderate RDS (39). This 
indicates that there is a positive correlation between vascular thrombin generation and the 
RDS severity. In our study. the infants who developed BPD had the most severe symptoms 
of RDS and therefore might have had increased intravascular thrombin generation (pro-
thrombin consumption). Consequently tltis may have resulted in a decreased availability of 
prothrombin to be converted into thrombin in the alveolar space. Examination of TATIII 
levels in both plasma and BAL fluid and thrombin activity in BAL fluid could reveal if there 
is an inverse correlation between vascular and pulmonary thrombin generation when BPD 
develops. 
Treatment with systemic dexamethasone (Dex) is commonly used in infants with or at 
risk of BPD. It is known to improve pulmonary function. to reduce pulmonary inflanunation 
and to facilitate weaning from the ventilator ( 40). The effect of Dex treatment on pulmonary 
fibrosis. however. is uncertain as it does not downregulate the concentrations of fibronectin 
and TGF-~ 1 in BAL fluid from preterm ventilated infants with BPD (41. 42). 
We were the first to demonstrate that BAL fluid from infants who develop BPD is 
mitogenic for human fetal lung fibroblasts (chapter 4). Increased fibroblast proliferation 
occurs in BPD and pulmonary fibrosis in general (13. 43). The data in chapter 5 are therefore 
of special interest as they show that Dex treatment of infants at risk of BPD increases the 
BAL fluid mitogenic activity for fibroblasts. 
In the study described in chapter 5 no placebo control group was included. Therefore. 
it can not be excluded that the observed increase in BAL fluid mitogenic activity is due to the 
natural course of the disease. However. comparison between data on BAL fluid mitogenic 
activity from chapter 4 with chapter 5 supports the finding that Dex treatment is responsible 
for the increase in mitogenic activity of BAL fluid. In chapter 4. BAL fluid from infants who 
acquired BPD stimulated fibroblast proliferation with 33-41% at postnatal ages of 2. 4. 7. 10 
and 14 days. In chapter 5. BAL fluid obtained from patients before Dex treatment (7-33 days 
of age) stimulated fibroblast proliferation with 35 %. thus comparable with the increased pro-
liferation described in chapter 4. After Dex treatment. BAL fluid-induced fibroblast pro-
liferation increased to 51%. exceeding all previous values as described in chapter 4. This 
observation makes it likely that it is indeed the Dex treatment that caused the increase in BAL 
fluid mitogenic activity. This is further supported by the observation that Dex treatment did 
reveal the expected anti-inflanunatory effects despite the observed increase in BAL fluid 
mitogenic activity. 
Interestingly. we noticed that from the 15 patients included in tltis study the 3 with 
decreasing mitogenic activity after Dex had a higher mitogenic activity before treatment than 
the ones with increasing mitogenic activity after Dex treatment. Although clinically all 
patients improved during Dex treatment and the ventilator settings were weaned. the data on 
mitogenic activity might suggest that possibly two types of responses to Dex treatment exist 
in infants at risk of BPD. Further studies should be performed in which more patients 
receiving Dex treatment are included. In addition to examination of the BAL fluid mitogenic 
activity. lung function tests and chest radiographs should be included at fixed time-points in 
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these studies. That could reveal whether the change in BAL fluid mitogenic activity after Dex 
treannent correlates with pulmonary function. Furthermore. although lung pathology is diffi-
cult to score from chest radiographs, especially in the case of minor changes, a correlation 
between the change in BAL fluid mitogenic activity and lung pathology (e.g. fibrosis/inter-
stitial abnormalities. emphysema) might become evident. Analyses like these could elucidate 
if there are indeed two different groups of patients at risk of BPD that respond differently to 
Dex treatment. 
In vitro studies have demonstrated that macrophages stimulated with Dex express 
increased amounts of PDGF-B mRNA. secrete increased amounts of PDGF protein. and 
stimulate fibroblast proliferation and collagen synthesis (44. 45). In concordance with this. it 
was demonstrated in chapter 5 that the increase in BAL fluid mitogenicity after Dex treat-
ment was accompanied by increased PDGF-BB concentrations in BAL fluid. Furthermore. 
by blocking the PDGF receptor system. it was demonstrated that PDGF indeed contributed 
to the BAL fluid mitogenic activity. In preliminary experiments. we found with RT -PCR that 
BAL cells expressed mRNA for both the PDGF-A and PDGF-B chain. By immunocyto-
chemical analysis we identified the alveolar macrophage as the major cell type expressing 
PDGF. It is possible that Dex treatment stimulated the alveolar macrophages to increased 
PDGF-B expression and secretion. resulting in the increased concentrations ofPDGF-BB that 
we detected in BAL fluid after this treatment. In vitro experiments. using BAL cells from 
infants at risk of BPD development. should be performed to elucidate if these cells indeed 
upregulate PDGF-B synthesis and PDGF-BB secretion upon Dex stimulation. Additionally. 
BAL cells obtained from patients before and after Dex treatment could be analyzed for 
PDGF-B mRNA expression and PDGF-BB secretion. 
Dex is known to reduce collagen synthesis by fibroblasts both in vivo and in vitro ( 46. 
47). and has been demonstrated to decrease total body collagen synthesis in infants with or at 
risk of BPD (48. 49). However. recent in vitro studies indicate that Dex stimulates collagen 
synthesis by human fetal primary lung fibroblasts (50). This makes the effect of Dex treat-
ment on lung collagen synthesis in infants at risk of BPD highly uncertain. In adults with 
ARDS it was demonstrated that methylprednisolone treatment decreased the concentrations 
of the type-! and type-III procollagen arninoterrninal propeptides (PINP and PIIINP. respec-
tively) in BAL fluid (51). We observed no differences in BAL fluid PI!INP levels before and 
after Dex. This indicates that. opposite to the reported effect on total body collagen synthe-
sis. Dex treatment does not influence lung collagen synthesis during BPD development. 
Possible effects of Dex on pulmonary collagen synthesis in our study could be 
obscured by the large variations in PIIINP levels. the small number of patients and drainage 
of PIIINP from the lung by lymph vessels. On the other hand. Meduri et al. only observed a 
significant reduction of PIIINP between 8 to 15 days after initiation of methylprednisolone in 
ARDS patients (51). We can not exclude that Dex treatment did influence pulmonary colla-
gen synthesis at later time-points after treatment in our study as the infants were extubated 
within days after treatment initiation. Due to this. BAL could not be performed anymore for 
ethical reasons. It is known. however. that Dex treatment reduces total body collagen syn-
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thesis already within three days after initiation of treatment in infants with or at risk of BPD 
( 48, 49). Therefore, it is reasonable to assume that if Dex treatment did influence pulmonary 
collagen synthesis, this should have been evident within three days of treatment. 
We suggest that the Dex regimen used in our study enhances the pulmonary fibropro-
liferation. Such increased fibroproliferation could contribute to the finding that Dex fails to 
downregulate pulmonary collagen synthesis in the lungs from infants at risk of BPD. 
Lung biopsy specimens obtained before and after initiation of Dex could reveal insight 
into the histopathological response (cell proliferation and collagen deposition) to Dex treat-
ment in infants at risk of BPD. However, studies like these are hard to perform due to ethical 
considerations. An alternative approach would be to examine lung tissue from Dex treated 
and untreated infants who died during BPD development and to determine the effect of the 
treatment on fibroblast numbers and collagen deposition. 
From the data in chapter 4 and chapter 5, it can be speculated that BPD development 
is characterized by an early inappropriate (too low and/or too slow) proliferative response to 
the initial pulmonary injury. Prolongation of this proliferative phase may contribute to the 
development of pulmonary fibrosis in BPD. This prolonged fibroproliferative response 
increases when Dex treatment is initiated after the first week of life. Therefore. initiation of 
Dex treatment after the first week of life may be no longer able to reduce the development of 
pulmonary fibrosis in the pathogenesis of BPD. Highly speculative is to suggest that initia-
tion of Dex treatment within 1-2 days after birth boosts the proliferative response in infants 
at risk of BPD, which could lead to enhanced repair, thereby preventing progression towards 
BPD. 
9.2. Matrix metalloproteinases and their inhibtors in the pathogenesis 
ofBPD 
MMP-1, TIMP-1, and TIMP-2 
Besides mechanisms resulting in increased collagen synthesis. decreased collagen 
degradation (due to decreased collagenolytic activity) is another mechanism that may con-
tribute to excessive collagen deposition. Decreased collagenolytic activity has been demon-
strated in lung tissue from adults with pulmonary fibrosis (52. 53). The fibrillar collagens 
type-! and type-III are the main types of collagen deposited in the pathogenesis of pulmonary 
fibrosis (43). MMP-1. also named (interstitial) collagenase, is able to degrade these colla-
gens. Therefore. MMP-1 expression and regulation of MMP-1 activity are of potential impor-
tance to the pathogenesis of pulmonary fibrosis. Several studies in adult human pulmonary 
fibrosis support the view that increased expression of TIMPs compared with MMP-1 results 
in a non-collagen degrading microenvironment (54-56). Evidence is accumulating indicating 
that MMP-1 may also be important in the regeneration of the injured alveolar epithelial bar-
rier after injury. comparable with the role of MMP-1 in reepithelialization after skin injury (57, 58). 
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Chapter 6 describes the immunolocalization of MMP-1, TIMP-1 and -2 during dif-
ferent developmental phases of BPD. MMP-1 localized to regenerating type-IT alveolar 
epithelial cells, which is in concordance with observations made by others in human adult 
pulmonary fibrosis (55). This observation suggests that MMP-1 expressed by these cells con-
tributes to the restoration of the alveolar epithelial barrier. This is supported by recent in vitro 
experiments demonstrating that MMP-1 contributes to alveolar type-IT epithelial cell ntigra-
tion (57). 
In the chronic phase of BPD. alveolar type-II epithelial cells revealed increased 
staining for Tll\11P-1 while MMP-1 remained comparable to the previous phases. This sug-
gests that an increase in TIMP-1 compared with MMP-1 results in reduced collagenolytic 
activity by type-II pneumocytes in the chronic phase of BPD. Additionally. fibroblasts in 
fibrotic foci during the chronic phase of BPD coexpressed MMP-1. TIMP-1. and TIMP-2. 
which may indicate decreased collagen degradation by fibroblasts. This finding is in concor-
dance with a previous report on patients with idiopathic pulmonary fibrosis that suggested 
that the co-expression of MMP-1 and TIMP-2 in fibroblasts from fibrotic foci contributed to 
progressive collagen deposition due to a decreased collagenolytic activity by these cells (55). 
From these data we conclude that decreased pulmonary collagenolytic activity may 
occur and contribute to the fibrotic changes seen in BPD. Examination of fresh lung tissue 
could reveal if there is indeed a decrease in puhnonary collagenolytic activity when BPD 
develops. In addition to this. fibroblasts could be cultured from lung tissue of BPD patients 
and analyzed for their capacity to synthesize MMP-1. TIMP-1 and TIMP-2 compared to 
control lung fibroblasts. Furtbermore. fibroblast culture supernatants could be analyzed for 
collagenolytic activity. 
MMP-2 and MMP-9 
Collectively. MMPs are able to degrade all ECM components and play key roles in 
normal physiological processes that involve ECM remodeling. such as wound healing. angio-
genesis. and development (59). The gelatinases MMP-2 and MMP-9 are secreted as latent 
(pro)enzymes that require processing to become active and are able to degrade several 
components of the basement membrane (60). 
Increased levels of MMP-2 and MMP-9 have been demonstrated in BAL fluid and 
lung tissue from adult patients with pulmonary fibrosis (55. 56. 61. 62). Furtbermore. a causal 
relationship between pulmonary fibrosis and MMP-2 and MMP-9 is suggested from studies 
in ntice where the adntinistration of an MMP inhibitor together with bleomycin prevented the 
development of pulmonary fibrosis (63). Oxygen toxicity. generally regarded as one of the 
major risk factors for BPD. resulted in increased MMP-2 and MMP-9 levels in an animal 
model of hyperoxia (64). and also oxidative stress in newborn humans was found to be 
associated with increased MMP-9 levels (65). 
Most studies on MNIP-2 and MMY-9 suggest that these enzymes contribute to lung 
damage and subsequent fibrosis. Recent evidence, however. also indicates a role for MJ\.1P-9 
in epithelial repair after injury (66-68). MMP-9 is expressed by regenerating alveolar type-II 
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epithelial cells in human pulmonary fibrosis and hyperoxia-induced lung injury in rats (55, 
64). 
Chapter 7 describes the presence of MMP-2 and MMP-9 in sequential BAL fluids 
from patients with resolving RDS and BPD development. We found that MMP-2 levels were 
comparable in BAL fluid from resolving RDS and BPD patients. Contradictory to this. 
MMP-9 levels were decreased during the first four postnatal days in BAL fluid from infants 
with subsequent BPD. In our study we determined the amount of MMP-9 in BAL fluid by 
zymography and desitometric analysis. Values for MMP-9 were related to a control collage-
nase and expressed as arbitrary units. A number of BAL fluid samples were reanalyzed by 
zymography and revealed comparable results to the first measurements. In addition to this, 
we analyzed 12 BAL fluid samples from postnatal day 2 in a commercially available MMP-
9 ELISA that detects latent MMP-9 and latent MMP-9!TIMP-l complex. A statistically sig-
nificant positive correlation (r = 0.906, p < 0.0001) was observed between the values for 
latent MMP-9 as determined by zymography and the values determined by ELISA. This 
indicates that zymography is a reliable way to determine MMP-9 levels in BAL fluid. 
When BPD developed. the MMP-9 levels increased over time and from postnatal day 
7 onwards exceeded the levels observed in resolving RDS. In accordance with the increase 
of MMP-9 in BAL fluid during BPD progression we also found that MMP-9 immunoreac-
tivity increased in lung tissue with the progression of BPD. 
BAL fluid samples from both infants with resolving RDS and infants that developed 
BPD revealed a gelatinolytic band representing a heterodimer of MMP-9 with neutrophil-
gelatinase-B-associated lipocalin (NGAL). The presence of this MMP-9/NGAL complex 
indicates that neutrophils are a source of the detected MMP-9 (69, 70). At postnatal day 2. 
particularly the NGAL/MMP-9 levels were increased when patients resolved from the initial 
RDS compared to infants that developed BPD. Measurement of this complex in BAL fluid 
may therefore be helpful to identify RDS patients who are at risk of BPD development. This 
identification can be of importance with respect to therapeutic intervention. The difference in 
NGAL/MMP-9 between resolving RDS and BPD is an interesting finding as NGAL/MMP-
9 exists exclusively in the specific granules of the neutrophil (71). 
Degranulation of specific granules in our study seems. therefore, to be associated with 
resolving RDS. It can be that the trigger required for the release of specific granules from 
neutrophils is initially present when RDS resolves but less or absent when BPD develops. 
Although we only demonstrated NGAL in association with MMP-9 in our assay, it is 
tempting to speculate that also free NGAL is released from the specific granules and present 
in increased levels in BAL fluid when RDS resolves. Free NGAL has been demonstrated to 
bind inflammatory mediators such as LTB4 and PAE and it was speculated that NGAL may 
exert a negative feedback on the inflammatory response by the binding of such inflammato-
ry mediators (71, 72). Increased levels ofLTB4 and PAF in lung effluent fluids within the first 
week of life have been shown to be associated with BPD development (73, 74). Therefore, 
the control of LTB4 and PAF activity by NGAL may control the pulmonary inflammatory 
response and contribute to RDS recovery. Decreased levels of NGAL could lead to impaired 
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regulation of the pulmonary inflammatory response and predispose to BPD. 
We observed no correlation between latent MMP-9 and the number of neutrophils in 
BAL fluid. This indicates that cell types. other than neutrophils. are likely to contribute the 
MMP-9 levels as well. We found that. besides neutrophils. also monocytes/macrophages and 
regenerating alveolar type-II epithelial cells expressed MMP-9. supporting the view that 
these cells may contribute to the MMP-9 detected in BAL fluid. 
A dramatic increase in latent MMP-9 expression has been identified within the first 24 
hours of normal healing wounds. followed by a decline at 48 hours and reaching baseline 
levels between 72 and 96 hours. Contradictory to this. it was found that in chrouic wounds 
MMP-9 remained elevated (75). Initiation of normal healing follows sequential completion 
of coagulation. inflammation, removal of damaged matrix components. cellular proliferation 
and ntigration (fibroblasts. endothelial and epithelial cells). angiogenesis. matrix synthesis. 
epithelialization and remodeling (4. 5. 76). During normal healing MMP-9 may be involved 
in the removal of the damaged ECM as well as contributing to cellular migration and angio-
genesis. The increased levels of MMP-9 in resolving RDS are likely to reflect a normal 
response to lung injury as these infants recover without pulmonary problems. Therefore. it 
can be suggested that l\1M:P-9 is involved in the repair mechanisms in the injured lung when 
RDS resolves. 
Migration and proliferation of epithelial progenitor cells are critical events in the 
regeneration of an epithelial barrier. During recovery from hyperoxia-induced lung injury the 
alveolar type-II epithelial cells have been demonstrated to secrete increased amounts of 
MMP-9 which exactly parallels peak alveolar epithelial repair in vivo and facilitates ntigra-
tion through gelatin (68. 77). An important role for MMP-9 in reepithelialization after injury 
has also been suggested from studies using bleomycin-induced lung injury and in vitro and 
ex vivo wound repair of human bronchial epithelial cells (67. 78. 79). Regarding these data it 
can be suggested that MMP-9 produced by alveolar epithelial cells and possibly other cell 
types contributes to the restoration of the alveolar epithelial bartier when RDS resolves. The 
increased MMP-9 levels in resolving RDS may. therefore. be a reflection of active epithelial 
regeneration by alveolar type-II epithelial cells that produce MMP-9 for this process. When 
BPD develops. this epithelial restoration may be delayed due to decreased MMP-9 produc-
tion resulting in impaired repair with subsequent pulmonary fibrosis. 
In addition to the effects of MMP-9 on reepithelialization after injury. MMP-9 has also 
been associated with angiogenesis and l\1:M:P-9 levels have been demonstrated to correlate 
with increases in vascularity during wound healing (80. 81). BPD is characterized by 
decreased pulmonary vascular development (82). Therefore. it is possible that the decreased 
MMP-9 levels we detected in BPD within the first four postnatal days contribute to or reflect 
the aberrant pulmonary vascular development in BPD. comparable to that suggested for 
decreased pulmonary VEGF and VEGF receptor expression in the pathogenesis of BPD (82). 
In vitro and ex vivo wound repair models could reveal if there is a difference in BAL fluid 
samples from resolving RDS and BPD to restore an injured epithelial bartier and to stimulate 
angiogenesis. Furthermore. such analyses could reveal if the MMP-9 present in the BAL fluid 
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contributes to these processes. 
EGF is a mitogen for epithelial cells that also upregulates MMP-9 secretion and 
migration of keratinocytes (83). It is possible that EGF exerts similar effects on epithelial 
cells in the lungs from preterm infants. The decreased latent MMP-9 levels in BPD during 
the first four postnatal days may therefore be due to decreased pulmonary EGF levels which 
have been shown to be associated with BPD development (18). 
Alternatively. the decreased MMP-9 levels in BPD patients within the first four post-
natal days may be due to differences in lung maturity between patients with resolving RDS 
and patients developing BPD. During lung development specific MMPs are expressed in a 
temporal manner. MMP-9 was found to be mainly expressed in the later stages of lung 
development (84 ). In our study. the patients developing BPD were of significantly shorter 
gestation than infants with resolving RDS. Although we observed no correlation between 
MMP-9 levels and gestational age! it is possible that pulmonary maturational differences 
contributed to the differences in MMP-9 in BAL fluid from the RDS and BPD group. 
When BPD developed. the MMP-9 levels in BAL fluid increased and finally exceed-
ed the levels in resolving RDS. This increase in MMP-9 may contribute to the ongoing lung 
damage in the pathogenesis of BPD. In patients with ARDS it has been demonstrated that 
increased MMP-9 levels in BAL fluid coexisted with the 7S region of type-N collagen. 
which is considered as a marker of basement membrane disruption (61). Increased levels of 
the 7S region of type-N collagen have also been demonstrated in BAL fluid from infants 
who developed BPD compared to resolving RDS. The authors suggested that oxygen metabo-
lites were involved in basement membrane degradation in the pathogenesis of BPD (85). 
However. taking our data on MMP-9 into account one can speculate that at least from post-
natal day 7. MMP-9 also contributes to the excessive basement membrane degradation in the 
pathogenesis of BPD. Studies should be undertaken to determine whether a correlation exists 
between basement membrane degradation products and the levels of MMP-9 in BAL fluid 
when BPD develops. Increased basement membrane disruption in the pathogenesis of BPD 
would allow fibroblasts to enter the alveolar lumen. This. together with the prolonged 
presence of pulmonary fibroblast mitogens as described in chapter 4. could result in 
persistent fibroblast activation with fibrosis as a consequence. 
Altogether. these findings suggest that the difference between resolving RDS and 
developing BPD may be related to the ability to raise an early adequate MMP-9 response to 
the initial pulmonary injury. Such an early MMP-9 response would be required for normal 
pulmonary restoration. However. when this MMP-9 response is delayed and finally excessive 
and prolonged it may contribute to disordered repair and extensive ECM injury. thereby 
contributing to the lung pathology as observed in BPD. 
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9.3. Post-injury short-course dexamethasone treatment inhibits pul-
monary fibrosis: a possible therapy for preventing the development 
of fibrosis in BPD 
Infants who are at risk of BPD are generally treated with a systemic course of Dex. 
Numerous different Dex regimens have been examined in preterm infants at risk for BPD. 
The outcomes of these studies on BPD incidence are inconclusive due to different patient 
populations and the different Dex regimens and concentrations used (86-91). Dex treatment 
has been shown to improve the pulmonary function and to facilitate weaning from the 
mechanical ventilator. These beneficial effects may be partly explained by the anti-inflam-
matory effects that Dex exerts in the lungs of these infants (40. 41. 92-95). In addition, 
decreased urinary excretion of hydroxyproline and decreased plasma levels of the C-terminal 
propeptide of type-! collagen and the N-terminal propeptide of type-III collagen have been 
detected after Dex treatment (48, 49). These measurements are a reflection of the whole body 
collagen synthesis and do not necessarily reflect the collagen metabolism in the lung. It has 
been demonstrated that despite an apparent anti-inflammatory effect. Dex may not influence 
pulmonary levels of fibrogenic mediators such as TGF-~1 and fibronectin in BPD (41, 42). 
suggesting that Dex may not prevent fibrosis development in BPD. In line with this it was 
reported in chapter 5 that Dex treatment. initiated between postnatal days 7 and 33. did not 
reduce the concentration PlliNP in BAL fluid. suggesting that Dex treatment started at this 
time-point does not interfere with pulmonary collagen synthesis in infants at risk of BPD. 
Recently. it was demonstrated that when Dex treatment was initiated early after birth 
in infants at risk of BPD and given for a short period. it increased the survival without BPD 
(96. 97). 
Whether such a short-course of Dex is able to interfere with pulmonary collagen 
metabolism in fibrotic lung disorders was never examined. It is. however. known that steroids 
are able to inhibit bleomycin-induced pulmonary fibrosis in animals when given prior to or 
together with bleomycin and for a prolonged period of time (98. 99). Because the bleomycin 
model has been proven to be sensitive to corticosteroids we used this model to examine if a 
short-course of Dex. initiated after fibrosis induction, was able to prevent the development of 
pulmonary fibrosis in this model as well. 
In chapter 8 we describe that a three-day course of Dex (0.5 mg/kg bw: comparable to 
what is used in infants at risk of BPD). initiated after bleomycin-induced injury/fibrosis in 
rats, inhibited excessive pulmonary collagen accumulation. Furthermore. we demonstrated 
that this inhibition of collagen accumulation was not accompanied by a decrease in BAL fluid 
levels of the profibrotic mediators TGF-~ 1 • PDGF-AB and thrombin. This indicates that the 
BAL fluid not necessarily reflects what is going on in the lung parenchyma. However. we can 
not exclude that Dex treatment reduced the expression levels of other fibrogenic mediators in 
the BAL fluid. For instance. TNF-a and IL-l expression levels are known to be downregu-
lated by corticosteroids and these cytokines are involved in the development of pulmonary 
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fibrosis after bleomycin (100-103). Up till now we have been unable to detect TNF-a and 
IL-l~ in our BAL fluids. The total lavage volume we used (12 ml) may have resulted in a 
dilution of TNF-a and IL-l~ in the BAL fluid to concentrations too low to detect by the 
assays we used. Concentrating the BAL fluids could resolve this problem. 
We noticed that Dex treatment reduced the number of proliferating cells in both 
fibrotic and normal areas of the lung parenchyma of bleomycin treated animals. We therefore 
speculate that the anti-fibrotic effect of the Dex regimen used in our study is mediated via 
pathways that may include a reduction in parenchymal cell proliferation. decreased epithelial 
apoptosis or inhibition of profibrotic mediator activity rather than reducing the levels of 
profibrotic mediators in the bronchoalveolar compartment. 
The classical model for the pathogenesis of ARDS suggested that epithelial and 
endothelial damage result in an inflammatory phase that is followed by a fibroproliferative 
phase which. if excessive, results in established fibrosis. The current hypothesis. however. is 
that fibroproliferation occurs in parallel with inflammation. It has been suggested that thera-
pies preventing the progression to established fibrosis will need to affect both proinflamma-
tory and profibrotic mechanisms (104). 
Corticosteroid treatment of ARDS has been reported to be more effective when 
administered early in the fibroproliferative phase. thus before dense acellular fibrosis with 
deranged alveolar architecture occurs. The response to therapy was found to be associated 
with pulmonary improvement and a decrease of PINP and PIIINP levels in plasma and BAL 
fluid (51, 105). From this it seems that the time at which corticosteroid therapy is initiated is 
crucial for its outcome effect to inhibit the development of fibrosis. Also for patients with 
idiopathic pulmonary fibrosis it has been suggested that corticosteroids may only be effective 
when there is a major inflammatory component associated with the disease state (I 06). 
However. it is not known whether corticosteroids establish these effects by interfering with 
inflammatory or fibrotic pathways or the cross-talk between inflammatory and fibrotic path-
ways or other mechanisms. 
The data in chapter 8 suggest that also in the bleomycin model of pulmonary fibrosis 
the fibroproliferative phase coexists with the inflammatory phase. This implicates that when 
Dex treatment is initiated early in the fibroproliferative/inflammatory phase, thus before the 
establishment of dense acellular fibrosis. it is indeed able to inhibit the development of pul-
monary fibrosis. It would be of interest to exantine whether Dex treatment initiated between 
7 and I 0 days after bleomycin exposure prevents fibrosis development in this model as well. 
This could testify the hypothesis that corticosteroid treatment is indeed more effective when 
adntinistered early in the fibroproliferative response. 
In chapter 8 we show in a rat model of pulmonary fibrosis that a three-day course of 
Dex (0.5 mglkg bw/day). initiated at an early time-point after injury at which inflammation 
and fibroproliferation are likely to occur in parallel, inhibited collagen accumulation in the 
lungs after bleomycin exposure. The data from chapter 4 suggest that fibroproliferation is 
likely to occur early in the lungs from infants that develop BPD. and that this fibroprolifera-
tion coincides with a major inflammatory component in these infants. Early initiation of a 
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short-course of Dex treatment has been demonstrated to increase survival without BPD in 
preterm infants (96, 97). However. whether such a course of Dex can inhibit pulmonary col-
lagen deposition in these infants or pulmonary fibrosis in general was not known so far. The 
data from chapter 8 suggest that the pulmonary beneficial effects of short-course early treat-
ment with Dex in infants at risk of BPD may be partly due to antifibrotic effects. An early 
short-course Dex treatment of infants at risk of developing BPD. and possibly also patients 
with other fibrosing lung diseases may therefore be useful to prevent the development of lung 
fibrosis. 
Studies could be undertaken in which infants at risk of BPD are treated with the early 
three-day course of Dex and compared with a placebo control group. BAL fluid obtained 
before and during the treatment could be analyzed for the presence of N-terrninal propeptides 
of collagen molecules and the mitogenic activity for fibroblasts as well fibrogenic and inflam-
matory mediator profile. This would reveal whether this treatment is efficient in controlling 
collagen synthesis in the lungs and whether it correlates with pulmonary improvement. 
Additionally. it could reveal whether the time-point at which Dex treatment is initiated is cru-
cial in the control of pulmonary collagen metabolism. since we described that Dex initiated 
between postnatal days 7 and 33 did not influence collagen rype-III synthesis in infants at risk 
of BPD. Alternatively. an animal model for BPD development. such as the baboon model 
described by Coalson and colleagnes. can be used (107). Such an animal model raises the 
possibility to perform biochemical and histological analyses of the lung tissue as well. A 
major point of concern, however, is that early and short-course Dex treatment in premature-
ly born infants is associated with serious side effects such as gastrointestinal perforation and 
growth retardation (91. 97). Therefore. the potential benefits on pulmonary outcome should 
be weighed against the serious potential side effects of such treatment. Studies to determine 
the minimal dose of Dex needed to inhibit the development of pulmonary fibrosis and to 
improve pulmonary function with the least side effects for infants at risk of BPD are 
therefore of prime importance. 
Concluding remarks 
I. The pathogenesis of BPD is characterized by an inadequate repair response (too low 
and/or too slow) to the initial lung injury. This is reflected by inappropriate fibroproliferation 
and decreased levels of thrombin and MMP-9 in BAL fluid at a postnatal age of 2 to 4 days. 
Subsequently. due to ongoing ECM damage to which excessive amounts of MMP~9 con-
tribute. a prolonged and disordered repair response occurs. This results in persistent 
fibroblast proliferation to which thrombin as well as other factors contribute. In addition. 
from a postnatal age of 16 days. decreased collagenolytic activity of alveolar type-IT epithe-
lial cells and fibroblasts. due to a decreased MMP-ltr!MP ratio in these cells. is likely to con-
tribute to excessive collagen accumulation in chronic BPD. The inability to raise an adequate 
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response may be related to the relative immaturity of infants that develop BPD compared to 
infants with resolving RDS. Figure I schematically depicts the time-points of BPD 
development at which fibroproliferation. thrombin. MMP-9. MMP-1 and TIMPs are present 
in the lungs and explains the possible roles of these factors in the pathogenesis of BPD. 
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RDS can either resolve or progress towards BPD. Resolving RDS is characterized by an adequate repair response. 
This consists of at least a sufficient mitogenic response that elicits cellular proliferation (epithelial and endothelial 
cells. fibrobl:l.Sts). the generation of sufficient amounts of thrombin that contributes to the mitogenic response. and 
appropriate MMP-9 production/secretion that contributes to removal of dam:lged extracellular matrix components. 
cellular migration and angiogenesis. BPD development from RDS is characterized by an inadequate repair response 
to the initial injury. Within the first week of life this is due to an insufficient mitogenic response (comparable to the 
one elicited in resolving RDS in contrast to the expectation that the mitogenic response would correlate with the 
severity of the initial damage). decrea'>ed thrombin generation and M.'l\.1P-9 production and secretion. During BPD 
progression there is ongoing injury. prolonged pulmonary mitogenic activity. an increase in pulmonary thrombin 
levels and an excessive increase in pulmonary MMP-9 levels. The increased MMP-91evels contribute to lung dam-
age. especially to the basement membrane. Persistent mitogenic activity. due to thrombin as well as other mediators. 
results in chronic fibroblast activation with sustained proliferation and collagen deposition within the lung parenchy~ 
rna :l.S a consequence. From postnatal day 16 onwards. :MMP~l (collagenolytic) activity is depressed in the lungs due 
to increased 'TII\1P expression. Together these processes contribute to fibrosis development as observed in the lungs 
from infants with BPD. 
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2. Dexamethasone treatment. initiated between postnatal days 7 and 33, reduces pul-
monary inflammation in infants at risk of BPD. However. dexamethasone treatment initiated 
beyond the age of I week is unable to reduce pulmonary collagen synthesis within 3 days. 
This is possibly due to increased fibroproliferation driven by increased pulmonary PDGF-BB 
levels after dexamethasone treatment. 
3. A three-day course of dexamethasone. initiated three days after the induction of 
bleomycin-induced pulmonary fibrosis in rats. inhibits excessive collagen accumulation in 
the lungs. Such a treatment course may be of potential therapeutic interest in preventing the 
development of pulmonary fibrosis in infants at risk of BPD. 
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Summary 
To save life. prematurely born infants with neonatal respiratory distress syndrome 
(RDS) are artificially ventilated. RDS can resolve within days after birth (uncomplicated 
RDS) or progress towards a chronic lung disease called bronchopulmonary dysplasia (BPD). 
The lung pathology of BPD is associated with varying degrees of fibrosis that develops with-
in days to weeks after mechanical ventilation treatment for RDS. The development of pul-
monary fibrosis generally follows an inflammatory phase and is characterized by an increase 
in pulmonary fibroblast numbers and increased deposition of extracellular matrix compo-
nents (especially collagen) in the lung interstitium. Numerous studies have focussed on 
inflammatory mediators in the pathogenesis of BPD. but only a few reports are available on 
the presence of fibrogenic mediators in the lungs during BPD development. 
The studies described in this thesis focussed mainly on mediators known to be 
involved in fibroproliferation (fibroblast proliferation) and fibrogenesis (collagen deposition) 
and are. therefore, of interest in understanding the pathogenesis of BPD. 
When sequential BAL fluids were examined from infants with resolving RDS and 
from infants developing BPD for their ntitogenic activity for human fetal lung fibroblasts 
(HFL-1) no differences were observed. This suggests that the mitogenic activity in the lungs 
of prematurely born infants is associated with RDS resolution and contributes to (or reflects) 
repair of the injured lung structures. The infants that developed BPD. experienced more 
severe RDS than the resolving infants. This suggests that the infants with BPD development 
had more severe lung tissue damage than infants with resolving RDS. At postnatal days 2 to 
7. the ntitogenic activity of BAL fluids was comparable between RDS and BPD. in contrast 
to the expectation that the BAL fluid mitogenic activity would correlate with the severity of 
the initial damage. Therefore. the ntitogenic activity of BAL fluid from postnatal days 2 to 7 
from infants developing BPD may be inadequate to initiate a proper repair response. 
When infants progressed to BPD. the ntitogenic activity of BAL fluid remained at the 
same level for at least 2 weeks after birth. This suggests that prolonged fibroproliferation 
occurs in the lungs of infants developing BPD. It can be postulated that an initially inadequate 
repair response followed by prolonged pulmonary fibroproliferation contributes to the 
development of the fibrosis in the lungs of these infants. The coagulation cascade serine pro-
tease thrombin was identified as an important fibroblast ntitogen in the BAL fluids. especially 
during the first four postnatal days in both resolving RDS and BPD. Furthermore, it became 
evident that from postnatal day 7 on factors other than thrombin also contributed to the 
mitogenic activity of the BAL fluid. 
Although the effect of dexamethasone (Dex) on inflammatory mediators in the lungs 
during BPD development has been intensively studied, the effect on fibrogenic mediators has 
received little attention yet. From the studies in this thesis it became evident that the current-
ly used Dex regimen to treat infants at risk of BPD increased the BAL fluid ntitogenic 
activity for lung fibroblasts. This increased BAL fluid ntitogenic activity was found to be 
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associated with an increase in the level of the fibrogenic mediator platelet-derived growth 
factor (PDGF)-BB. Additionally. Dex treatment did not reduce the BAL fluid concentrations 
of the N-terrninal propeptide of type-III collagen (PIIINP) but did reduce the interleukin 
(IL)-1~ and inflammatory cell numbers in BAL fluid. This suggests that the currently used 
Dex treatment. which is initiated after the first week of life. ntight promote fibroblast prolif-
eration despite an apparent downregulation of inflammation. Therefore. tltis treatment may 
not inhibit the development of pulmonary fibrosis in infants at risk of BPD. 
Although analysis of BAL fluid has been proven to be useful in the exantination of 
fibrotic lung disorders. additional information can be obtained from exantination of pul-
monary tissue. This is especially true since BAL fluid not always reflects what is actually 
happening within the lung parenchyma. Decreased parenchymal collagen degrading capaci-
ty has been demonstrated to be associated with pulmonary fibrosis in adult patients. This can 
be related to increased parenchymal expression of tissue inhibitors of metalloproteinases 
(TlMPs) compared with matrix metalloproteinases (MMPs). Exantination oflung tissue from 
infants that died during different phases of BDP development revealed that the chronic 
(fibrotic) phase of BPD was characterized by an increased expression of TIMP-1 in type-I! 
epithelial cells compared with the MMP-1 expression by these cells. In addition to this. 
fibroblasts in fibrotic foci expressed MMP-1 as well as TIMP-1 and TIMP-2. These data sug-
gest that decreased collagenolytic activity occurs in the lung parenchyma in the chronic phase 
ofBPD. Such a decrease in parenchymal collagenolytic activity could contribute to excessive 
collagen accumulation as observed in BPD. 
MMP-2 and MMP-9 have also been implicated with fibrosing lung disease in both 
adult humans and experimental animal models of the disease. Exantination of sequential BAL 
fluids revealed comparable MMP-2 levels at postnatal days 2 and 4 in RDS and BPD. 
MMP-9 levels. however. were decreased at these ages in BAL fluid from BPD patients com-
pared to resolving RDS. This suggests that early MMP-9 expression in BAL fluid is corre-
lated with resolving RDS. Especially the heterodimer consisting of NGAL and latent 
MMP-9 was decreased in postnatal day 2 BAL fluids from infants that developed BPD. 
Therefore. the low MMP-9 levels. particularly those of NGAL/MMP-9 at postnatal day 2. 
may help to identify RDS patients who are at risk of developing BPD. 
With the progression towards BPD a dramatic increase in MMP-9 BAL fluid level was 
observed, while MMP-2 remained relatively stable. It is suggested that this extensive increase 
of MMP-9. which is evident from postnatal day 7 onwards. contributes to the ongoing lung 
damage. especially to the basement membrane. during BPD development. Neutrophils. 
monocytes/macrophages. type-II alveolar epithelial cells and fibroblasts were identified as 
sources of MMP-9 in both resolving RDS and during BPD development. 
It has been demonstrated that short-course Dex treatment initiated between 12 and 48 
hours after birth in infants with RDS reduces the incidence of BPD. However. whether these 
beneficial effects can be attributed to an anti-fibrotic action of tltis therapy was not known. 
In tltis thesis we demonstrated that a short-course (3-days) Dex treatment. initiated three days 
after lung injury induction in rats by the anti-neoplastic agent bleomycin, was clearly able to 
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prevent excessive pulmonary collagen deposition. The observed Dex effect was established 
without a reduction in inflammatory cell numbers or levels of the fibrogenic mediators 
TGF-~1. PDGF-AB or thrombin in the BAL fluid. Short-course Dex treatment did, 
however. reduce the number of proliferating cells in normal and fibrotic lung tissue after 
bleomycin exposure. From these data we conclude that the anti-fibrotic effect ofDex is medi-
ated via pathways other than reducing the concentrations of the fibrogenic mediators 
TGF-~1. PDGF-AB and thrombin in the bronchoalveolar compartment, for instance a reduc-
tion of cell proliferation, decreased epithelial apoptosis or inhibition of tissue profibrotic 
mediator activity. 
The studies in this thesis suggest that the pathogenesis of BPD is characterized by an 
inadequate response (too low/or too slow) to the initial lung injury. This inadequate response 
leads to ongoing lung damage and persistent fibroproliferation. MMP-9. thrombin as well as 
other fibroblast mitogens are likely to contribute to these processes. In addition. increased 
expression of TIMP-1 by type-II alveolar epithelial cells relative to MMP-1 expression by 
these cells as well as co-expression of MMP-1, TIMP-1 and TIMP-2 by fibroblasts in the 
cbronic (fibrotic) phase of BPD may result in decreased parenchymal collagenolytic activity. 
This decreased collagenolytic activity favours excessive pulmonary collagen accumulation in 
the BPD lung. 
The currently used Dex treatment in infants at risk of BPD that is started after the first 
week of life may not be able to reduce the development of pulmonary fibrosis in these infants, 
possibly due to increased pulmonary fibroblast proliferation driven by increased pulmonary 
levels of PDGF-BB. In contrast. an early 3-day course of Dex may be able to inhibit the 
development of pulmonary fibrosis in BPD as this treatment regimen was proven to inhibit 
the development of bleomycin-induced lung fibrosis in rats. 
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Samenvatting voor niet-ingewijden 
K.inderen die geboren worden na een zwangerschapsduur van minder dan dertig 
weken (40 weken is normaal). zogenaamde prematuren. ontwikkelen binnen enkele minuten 
na de geboorte ademhalingsproblemen. Dit ziektebeeld wordt bet neonataal respiratoir dis-
tress syndroom genoemd (RDS). Om deze patienten in Ieven te bouden. moeten ze beademd 
worden met vaak hoge concentraties zuurstof. Een aantal van deze patienten hers~elt in de 
eerste levensweek. anderen ontwikkelen een ernstige longziekte die bronchopulmonale dys-
plasie (BPD) of cbroniscbe longziekte van de prematuriteit (CLD) genoemd wordt. De ziek-
teverscbijnselen van BPD zijn onder andere aanhoudende ademhalingsproblemen en bet 
achterblijven van de lichaamsgroei. Het merendeel van de kinderen moet langdurig (weken 
tot maanden) beademd worden en heeft nog vele maanden extra zuurstof nodig. Hoewel de 
ziekteverschijnselen verminderen gedurende de kinderjaren. blijken jong volwassenen, die 
BPD hebben gehad. bij onderzoek van het functioneren van de longen nog steeds 
afwijkingen te hebben. Deze afwijkingen kunnen een voorteken 7ijn van chronisch 
longlijden op latere leeftijd. 
Ondank.s de verbeteringen in de neonatale zorg. overlijden er nog steeds kinderen aan 
de gevolgen van BPD. Microscopisch onderzoek van de longen van overleden patienten met 
BPD Iaten een ontstekingsreactie zien. die gevolgd wordt door overmatige bindweef-
selvorming in de longen. Deze zogenaamde longfibrose heeft tot gevolg dat het functioneren 
van de longen ernstig wordt verstoord. Centraal in bet proces dat leidt tot fibrose staat de 
bindweefselcel. ook wei fibroblast genoemd. Tijdens bet ontstaan van longfibrose worden er 
bepaalde stoffen (fibrogene mecliatoren) geproduceerd door ontstekingscellen of andere 
cellen in de longen. Deze fibrogene mediatoren bebben tot gevolg dat de fibroblasten zich 
gaan vermeerderen (prolifereren) en teveel collageen gaan produceren. 
In overlevende BPD patienten kan de ontstekingsreactie. en bet ziekteproces dat leidt 
tot de bindweefselvorming, onderzocht worden door bet afnemen van een longspoelsel ofwel 
broncboalveolaire lavage (BAL). Het afnemen van een BAL is een eenvoudige procedure bij 
beademde prematuren. De BAL vloeistof kan dan onderzocbt worden op de aanwezigbeid 
van mediatoren die bijdragen aan de ontwikkeling van de longfibrose bij BPD. 
In deze studie is onderzocht of BAL vloeistof van patienten. die BPD ontwikkelen. a! 
gedurende de eerste levensweek afwijkt ten opzicbte van BAL vloeistof van patienten die 
berstellen van RDS. Uit deze analyses bleek dat de BAL vloeistof van BPD en RDS 
patienten niet verschilt in bet vermogen om fibroblasten te Iaten prolifereren. Hoewel we bet 
niet bebben kunnen analyseren. is bet aannemelijk dat met het berstel van de longen van RDS 
patienten. de activiteit in de BAL vloeistof om fibroblasten te Iaten prolifereren. afneemt. Als 
een patient BPD ontwikkelt. blijft deze activiteit gedurende de eerste twee levensweken 
echter aanwezig. Verder is aangetoond dat bet enzym thrombine voor een belangrijk deel bij-
draagt aan de het vermogen van BAL vloeistof om fibroblasten te Iaten prolifereren. Hieruit 
concluderen wij dat. in RDS patienten die berstellen. het vermogen van BAL vloeistof om 
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fibroblasten te laten prolifereren een normale reaktie is op de schade in de long en dat deze 
capaciteit mogelijk bijdraagt aan het genezingsproces. In geval van BPD ontwikkeling is deze 
reaktie in eerste instantie zwak. waardoor het herstel van de longschade niet snel genoeg gaat. 
Echter, de activiteit in de BAL vloeistof om fibroblasten te laten prolifereren, is bij BPD 
patienten gedurende langere tijd aanwezig. Dit draagt bij aan de langdurige fibroblast-
proliferatie. en uiteindelijk tot de ontwikkeling van fibrose in de longen van deze kinderen. 
Kinderen die het risico !open BPD te ontwikkelen worden na de eerste levensweek 
behandeld met een langdurige kuur met het corticosteroid dexamethason (Dex). Het is 
bekend dat Dex de ontsteking in de longen van deze patienten vennindert. Dit draagt 
waarschijnlijk in grote mate bij aan het feit dat de patienten met deze behandeling na enige 
dagen geen beademing meer nodig hebben. Of deze behandeling de vorming van fibrose in 
de longen van deze kinderen remt, is onbekend. Het bleek dat het vermogen van BAL 
vloeistof van patienten met het risico op BPD ontwikkeling om fibroblasten te Iaten pro-
lifereren, toenam binnen 1 tot 3 dagen na de start van de Dex behandeling. Dit ging gepaard 
met een verhoging van de concentratie van de fibrogene mediator platelet-derived growth 
factor (PDGF) in de BAL vloeistof. Verder bleek dat de collageen produktie in de longen niet 
belnvloed werd binnen 1 tot 3 dagen na de start van de Dex behandeling. Hieruit concluderen 
wij dat de huidige Dex behandeling, die gestart wordt n:i de eerste levensweek, de vonning 
van fibrose in de longen van kinderen, die BPD ontwikkelen, mogelijk niet remt. Dit kan het 
gevolg zijn van de verhoogde fibroblastproliferatie stimulerende activiteit in de longen na 
Dex behandeling. 
Overmatige collageen vorming in de longen hoeft niet aileen het resultaat te zijn van 
een verhoogde produktie van collageen. Normaal gesproken is er in het lichaam een balans 
tussen collageen produktie en afbraak. Als de collageen afbraak vennindert. kan dit ook over-
matige bindweefselvorming in een orgaan. zoals de long, tot gevolg hebben. 
Matrixmetalloproteinase-1 (MMP-1) is een enzym dat collageen afbreekt. De 
activiteit van :tvfl\.1P-1 wordt echter geremd door TllVIP-1 en TIIviP-2. In de longen van 
kinderen, die overleden zijn aan BPD. bleek er een sterke toename te zijn in de hoeveelheid 
TIMP-1 ten opzichte van MMP-1. Hiernit concluderen wij dat de activiteit van MMP-1 ver-
minderd is in de longen van patienten met BPD. Het gevolg hiervan is dat nieuwgevormd col-
lageen niet voldoende wordt afgebroken. met een ophoping van collageen in de longen als 
resultaat. 
Matrixmetalloproteinase-9 (MMP-9) is een enzym dat betrokken is bij wondgenezing. 
maar dat, als het in te grote hoeveelheden voorkomt, kan leiden tot weefselschade. Patienten. 
die BPD ontwikkelden, bleken tijdens de eerste vier levensdagen minder MMP-9 in de 
longen te hebben dan patienten die herstelden van RDS. Dit suggereert dat MMP-9 een rol 
speelt in het herstelproces van RDS. In geval van BPD ontwikkeling is dit herstelproces 
mogelijk verstoord door te !age concentraties MMP-9 in de longen. Bet bepalen van 
MMP-9 in de BAL vloeistof twee dagen na de geboorte kan mogelijk helpen bij het onder-
scheid maken tussen patienten met RDS die we! of geen BPD gaan ontwikkelen. 
Na de eerste levensweek was er een sterke toename in de concentratie van :tvfl\.1P-9 in 
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de longen van kinderen die BPD ontwikkelden. Deze concentratie was aanmerkelijk groter 
dan die tijdens de eerste vier levensdagen in patienten die herstelden van RDS. Dit suggereert 
dat vanaf de eerste levensweek MMP-9 weefselschade veroorzaakt in de longen van kinderen 
die BPD ontwikkelen. Dit. in samenhang met de aanwezigheid van fibrogene mediatoren. kan 
bijdragen aan de fibrosevorming in de longen van kinderen met BPD. 
Recent heeft men aangetoond dat als Dex behandeling binnen twee dagen na de 
geboorte. en slechts voor een korte peri ode. gegeven wordt. de kans op BPD ontwikkeling in 
te vroeg geboren kinderen vennindert. Hoewel deze behandeling duidelijk gunstige effecten 
heeft op de longfunctie, gaat het wel gepaard met emstige bijeffecten. zoals een vertraagde 
lichaamsgroei en darmproblemen. Het is niet bekend of deze behandeling de vorming van 
longfibrose kan remmen. 
Om te onderzoeken of een korte en vroeg gestarte Dex behandeling de vonning van 
longfibrose kan remmen, hebben wij gebruik gemaakt van een diennodel voor longfibrose. 
Het bleek dat kort (drie dagen) toedienen van Dex. gestart snel na de inductie van longschade 
(drie dagen). de vorming van longfibrose volledig remde in dit diermodel. Hieruit conclu-
deren wij dat de beschreven gunstige effecten van kortdurende, en vroege. Dex behandeling 
op de longfunctie van kinderen met risico op BPD mogelijk deels veroorzaakt wordt door een 
anti-fibrotisch effect van deze behandeling. Een dergelijke kortdurende en vroege Dex 
behandeling van kinderen met risico op BPD ontwikkeling zou daarom bruikbaar kunnen zijn 
voor het verminderen van de kans op longfibrose. Er dient echter altijd een afweging gemaakt 
te worden tussen de wellicht gunstige effecten op de longen en de bijeffecten van deze 
behandeling. 
Uit het onderzoek concluderen wij dat BPD ontwikk:eling bij te vroeg geboren 
kinderen het gevolg is van een inadequate reaktie van het lichaam op de oorspronkelijke 
schade in de longen. Deze inadequate real.'tie leidt uiteindelijk tot overmatige longschade en 
fibroblast activatie. met als gevolg verbindweefseling. De huidige toegepaste Dex behande-
ling, die start na de eerste levensweek, heeft wei een gunstig effect op de ontsteking in de 
longen. maar mogelijk geen remmend effect op de longfibrose in kinderen met risico op BPD 
ontwikkeling. Een vroege en korte behandeling met Dex. zoals door ons getest in een dier-
model voor longfibrose. zou mogelijk de verbindweefseling van de longen in kinderen met 
risico op BPD kunnen remmen. 
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Dankwoord 
Nu het boekje bijna af is. besef ik me eens temeer dat zonder de hulp van vele mensen 
dit proefschrift nooit tot stand had kunnen komen. Dit proefschrift is het resultaat van een 
samenwerking tussen vele verschillende groepen, zowel nationaal als internationaal. Het 
began als een samenwerking tussen de afdelingen Immunologie en 
Kindergeneeskunde/Neonatologie van het Erasmus MC in Rotterdam. Snel volgde er samen-
werking met de afdelingen Pathologie van het Erasmus MC, Long7iekten/Experimentele 
Immunologie en Neonatologie van het AMC in Amsterdam en het Centre for 
Cardiopulmonary Biochemistry and Respiratory Medicine. van het University College 
London, UK. Bij deze wil ik een ieder uit deze groepen die heeft bijgedragen aan dit 
proefschrift van harte bedanken. 
De afgelopen jaren heb ik met zeer vee! plezier gewerkt. Dit plezier kwam niet aileen 
voort uit het onderzoek doen. maar ook door de collega's op het lab. Daarom bedank ik al 
mijn huidige en voormalig labgenoten voor a! het plezier en de (wetenschappelijke) 
discussies van de afgelopen jaren. Een persoon wil ik in het bijzonder noemen. Gita. jij hebt 
een zeer grote bijdrage geleverd aan het tot stand komen van dit proefschrift. Je hebt altijd 
met zeer veel enthousiasme aan dit onderwerp gewerkt. Een kritische noot vanjou bij de door 
mij bedachte ultieme experimenten heb ik menigmaal gehoord en bijzonder kunnen 
waarderen. Een bet ere analist om mee sam en te werken had ik mi j Diet kunnen wensen. 
Tot slot wil ik mijn ouders, zus en vrienden bedanken voor hun belangstelling voor 
mijn werkzaamheden en de steun en hulp gedurende de afgelopen periode. 
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